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ABSTRACT
20G9 is a murine IgG that catalyses the hydrolysis of phenyl acetate to phenol and 
acetic acid. The antibody was raised to a phenyl phosphonate hapten, which was 
designed as a stable analogue of the assumed tetrahedral transition state formed 
during the hydrolysis of phenyl acetate. Site directed mutagenesis has been used to 
investigate the mechanism of the catalytic antibody 20G9. The ultimate aim of the 
research is to try to understand the important features of catalytic antibodies so that 
rational alterations can be made to improve antibody mediated catalysis.
The antibody combining site of 20G9 was modelled using the antibody modelling 
program, AbM. An attempt was made to identify potential key catalytic residues 
based upon proximity, previous kinetic characterisation of the antibody and residue 
function found in other catalytic antibodies. Residues were selected and PCR site- 
directed mutagenesis performed which succeeded in producing five mutant 
antibodies each containing single residue changes in the combining site as 
determined by sequencing. Expression was attempted in three different plasmid 
vectors of which pUC119His6mycA’Z>a was chosen. The mutant inserts were cloned 
into this vector and expression optimised. Recombinant scFv antibody was 
expressed in Escherichia coli strain TOPP2, grown at 30°C and induced for 24 
hours with ImM IPTG at 26°C. The scFv antibodies were identified by western 
blotting against the c-myc tag using the antibody 9E10 and purified by IMAC using 
a c-terminus histidine tag. Only the mutant YL96A failed to produce sufficient 
material for kinetic analysis. Kinetic characterisation of the 20G9 scFv saw similar 
activity displayed to that of the hybridoma derived 20G9. When kinetic 
characterisation was performed upon the four 20G9 scFv mutants, RH50A, RH56A 
and Yl94A were seen to be active. RH50A displayed activity comparable to the wild 
type 20G9 scFv. With RH56A and YL94A, the KM during the burst phase increased 
two-fold which may indicate involvement in binding of the substrate. No 
measurable activity was seen for the mutant YL91A indicating that a residue critical 
for activity had been eliminated. It is likely that this residue forms an acetyltyrosyl 
intermediate during the catalytic hydrolysis of phenyl acetate.
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This thesis concerns the modelling, mutagenesis, expression and characterisation of 
the antibody 20G9 and its mutants. This introduction will briefly cover the 
organisation of antibodies at a genetic and structural level. In addition it will give 
an overview of catalysis by antibodies and the methods by which they can be 
rationally and randomly engineered for expression and characterisation.
1.1 THE IMMUNE RESPONSE
Immunity is a word derived from the Latin immunitas which was given to Roman 
senators during their office tenure allowing exemption from various civic duties and 
legal prosecution. Today, immunity stills means protection but within a clinical 
context indicates protection from infectious disease. Immunity has gradually 
evolved within animals enabling them to recognise and destroy a wide variety of 
pathogens that may harm them. The immune system of mammals is currently the 
most widely understood and is increasingly manipulated by both the pharmaceutical 
and biotechnology industries for many clinical and scientific applications.
The ability to specifically recognise molecules on pathogens is key to the immune 
system. There are two tiers to the immune system:
i) natural immunity is the body’s first line of defence and is non-discriminatory in 
nature. This includes physiochemical barriers such as skin, mucus membranes and 
circulating molecules such as complement and phagocytic cells. The levels tend to 
remain static within the body and are not enhanced by repeated exposure to foreign 
bodies.
ii) acquired immunity is a defence mechanism that is induced and enhanced by 
repeated exposure to foreign particles. The predominant cell types involved in this
CHAPTER 1 INTRODUCTION
immune response are the T and B lymphocytes both of which are responsible for 
specific recognition of potential pathogens.
The B-lymphocytes possess membrane bound receptor molecules upon their surface 
but are also able to express soluble antibody molecules identical in terms of 
specificity to those bound to the membrane. Both molecule types are able to bind to 
native conformations of soluble or membrane bound antigen but only antigen bound 
to the membrane bound receptor molecules results in clonal expansion. This causes 
naive B cells, specific for that antigen, to differentiate into plasma B cells capable 
of secreting large amounts of antibody (Ab) of equal specificity. There also follows 
reduced differentiation into memory B cells. The high amounts of secreted 
antibody trigger a cascade effect, resulting in activation of the natural immune 
functions such as complement and stimulation of macrophage, natural killer cells, 
etc.
However, the B cells are not alone in the immunisation process and their expansion 
is closely linked to the T cell lymphocytes. The T cells also possess membrane 
bound receptors from the immunoglobulin superfamily whose functional role and 
genetic origins are distinct from their antibody cousins. These are T-cell receptors 
(TCR) and they recognise antigens that have been endocytosed by antigen 
presenting cells (APC’s) such as B cells and macrophage. Within the B-cell the 
internalised proteins are degraded and subsequently bind and complex with major 
histocompatibility complex class II molecules (MHC II) found within the cells 
rapidly followed by their presentation upon the surface. TCR molecules upon the 
T-cells recognise the processed antigen bound to the MHC molecule along with 
other simultaneous interactions between accessory molecules, i.e. CD4. This 
triggers T cell activation, which in turn induces or suppresses other aspects of the 
immune cascade by cytokine release, including differentiation and proliferation of 
















Figure 1.1 A widely accepted version of the interaction between the B and T cell 
lymphocytes and accessory cells. Antigen is internalised by the accessory cells, also 
named antigen presenting cells (APC), i.e. macrophage, which fragment the foreign body, 
complex its various components with MHC class II molecules and display them on the cell 
surface. The T cell binds the APC and its associated displayed complexes using its cell 
receptors and adhesion molecules and is subsequently triggered into cytokine production. 
This in turn stimulates the B cells into clonal expansion and high level expression of 




1.2.1 The Immunoglobulin Structure
An antibody molecule has two functions; to tightly bind to its epitope and to 
stimulate complement release and immune cell activation. These functions are 
combined in a single multidomain immunglobulin (Ig) molecule of which five Ig 
classes exist; IgA, IgD, IgE, IgG and IgM, each possessing different structures and 
functions. The IgG molecule is a tetrameric molecule consisting of two identical 
25kDa light chain polypeptides (VL and CL) and two identical 50kDa heavy chain 
polypeptides (VH, CH1, CH2 and CH3) linked by disulphide bonds (Figure 1.2). It 
represents 70-75% of immunoglobulin found in mammalian serum and so is by far 
the most common antibody class found in the circulation.
IgA normally accounts for 15-20% of total immunoglobulin found in human serum 
but is the principle immunoglobulin found in external secretions, i.e. saliva, tears, 
breast milk, respiratory secretion. IgA essentially has the same structure as IgG, 
two light chain molecules (VL and CL) and two heavy chain molecules (VH, CH1, 
Ch2 and CH3) but can exist as a monomer, a dimer that is held together by a J-piece 
(a 15kD polypeptide that is disulphide bonded to the Fc) and also as multimers, 
which are joined by disulphide bonding.
The overall structure of IgD is the same as IgG except that is possesses an extra 
constant domain on the heavy chain (VH, CH1, CH2, CH3 and Ch4). These 
immunoglobulins are normally present in human antisera at very low levels, < 0.2% 
with the role of this immunoglobulin poorly understood. IgE is the antibody class 
that mediates certain allergic reactions and is involved in anaphylatic shock. They 
are similar in size to IgD, possessing an extra constant domain (VH, CH1, CH2, CH3 
and Ch4) and are normally present in trace amounts within sera.
IgM is the final class of immunoglobulin and was the first to be discovered. The 
monomer of this immunoglobulin is similar in size to IgD and IgE in that it has an 
extra constant domain (VH, CH1, CH2, CH3 and Cjj4) but it exists as a pentamer in
4
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the serum. The pentameric immunoglobulin is linked by disulphide bonds on the 
CH3 and CH4 domains and also by a J-piece similar to that used to join IgA dimers. 
This antibody class is the first antibody to be produced during an immune response, 
but is soon eclipsed in concentration by IgG as the response progresses. 
Subsequently, IgG represents approximately 70% o f total immunoglobulin seen in 
human serum. This thesis concerns the engineering o f a monoclonal IgG and 
further discussion will concentrate on this class o f antibody.
The Ig molecule can be divided into several smaller function based units; the Fab 
(antigen binding fragment), which has just a single binding site and the Fc (fragment 
crystallisable) which possesses cell effector functions. In addition the Fab can be 
further divided into a Fv (variable fragment) which has no constant domains but still 






Figure 1.2 Schematic structure of an IgG molecule. The molecule is tetrameric consisting 
of two 25kDa light chains and two 50kDa chains joined together by disulphide bonds. The 
molecule can be divided into 3 main sections; Fab (antibody binding fragment), Fc 
(crystallisable fragment) and Fv (variable fragment). The Fv contains 6  CDR regions that 




The light chain is composed of two domains, VL (light variable) and CL (light 
constant), whereas the larger H chain is composed of 4 domains, VH, CH1, CH2, CH3 
(or 5 if the Ch4 domain found in IgD, IgE and IgM classes is included). The 
variable domains (V) contain the hypervariable regions that are held in place by 
conserved framework regions. The constant domains (C) are highly conserved and 
form the antiparallel p-barrel structures that are seen across all antibody classes. A 
common feature of all Ig are three conserved cysteine residues, found in the hinge 
region, which are necessary for the formation of disulphide bridges between the 
various domains and are vital for the formation of the quaternary structure [Lesk 
and Chothia, 1982].
1.2.2 The antibody combining site
Several three-dimensional structures of whole antibodies have been solved by X-ray 
crystallography [Chang et al, 1994; Lescar et al, 1993; Davies & Padlan, 1990, 
Harris et al, 1995]. In addition, structures have been solved of Fab [Braden et al, 
1994; Griest et al, 1992; Poljak, 1973] (in its natural and antigen complexed states) 
as well as the Fc [Diesenhofer, 1976]. This has allowed full structural 
characterisation of antibody molecules giving much insight into their folding. The 
VL and VH domains each contain three hypervariable loops termed complementary 
determining regions (CDR’s). The six CDRs pack together to form the antibody- 
combining site. The sequences between each CDR are termed framework regions. 
Each framework segment is a p-strand that folds with other strands to form a P- 
sandwich which, when combined with the p-sandwich of the opposing chain, forms 
a p-barrel structure.
Examining the constant and variable domains, the constant domains consist of 
seven P-strands that form two p-sheets which, joined by disulphide bridges form an 
antiparallel p-barrel. The variable domains are similar but consist of nine P-strands 
packing similarly to the constant region forming an antiparallel p-sheet. It is these 
loops joining the variable strands that are hypervariable and are denoted CDR’s 1, 2 
& 3, while the constant domain remains largely conserved. Although the CDR
6
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loops are hypervariable, the p-barrel packing of the V domain is normally 
unaffected. This stability can be exploited and CDR loops have been transplanted 
from one antibody to another with the integrity of the p-parallel barrel usually 
remaining intact. This has allowed CDR’s from a mouse antibody to be grafted 
onto framework regions of human antibodies allowing clinical use in humans 
[Riechman et al, 1988]. Occasionally, sequences differences between human and 
murine frameworks have necessitated the grafting of additional, non-CDR residues, 
to maintain the correct structure [Foote & Winter, 1992].
The specificity of the antibody combining site is mostly determined by the CDRs 
but can also be affected by the framework regions, though usually restricted to the 
outer fringes of the Fv regions [Ward et al, 1997; Winter & Foote, 1992]. A few 
residues at specific sites within the loops determine the backbone conformations of 
the six CDRs. These residues have been found to be conserved in different VL and 
VH sequences and are described as ‘key’ residues, the existence of which has 
allowed the definition of a group of homologous ‘canonical’ structures. For the 
CDRs to maintain their specific conformation, these residues must be conserved. 
The key residues that are associated with the various canonical structures can be 
used to predict any canonical class on any given antibody with the exception of the 
H3 loop [Morea et al, 1998; Al-Lazikani et al, 1997; Barre et al, 1994; Chothia, 
1989; Chothia & Lesk, 1987].
1.2.3 Antibody-Antigen Interactions
Antibodies are molecules that bind tightly to immunogenic molecules, or antigens
to which the B-cells have been exposed. Before a tight association between two
molecules can form, large entropic barriers must be overcome. Where there is loss
of free rotation of mobile elements such as side chains within the macromolecules,
there is also a loss of entropy. Contributions to overcome these barriers derive from
van der Waals interactions, hydrogen bonds and the salt bridges formed between the
antibody epitopes and its antigenic determinants upon the surface of the antigen.
These alone are insufficient to cause tight binding, and shape complementarity
between the surfaces must be sufficient to drive the association. Where this
7
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complementarity is not perfect, water molecules can assist in binding; several 
studies have shown water involvement at the interface of the two molecules [Tulip 
et al., 1992; Bhat et al., 1994] contributing up to 25% of the total binding strength 
[Corell & Mallqvist, 1997].
1.3 GENERATION OF ANTIBODY DIVERSITY
In animals, antibodies are one of the major tools used to defend the body against 
pathogens. In order to recognise the almost infinite range of pathogens to which the 
immune system will be exposed, the immune system has had to evolve to respond 
and produce an almost equally diverse repertoire of antibodies used to recognise 
and remove foreign antigens from the blood stream.
Production of antibodies is a constantly evolving process. B cells producing 
antibodies to combat an initial exposure to an antigen will not be expressing an 
identical antibody a few days later. The antibody will have evolved and developed 
an improved affinity towards the antigen and consequently will be more effective at 
lower quantities. The lower affinity antibodies produced initially are the result of a 
primary response of the naive population of lymphocytes and result in plasma and 
memory cells. The secondary response produces higher affinity antibodies and is 
due to the response using the available pool of memory cells that differentiated 
during the primary response. In between these two responses the affinity of the 
antibodies towards the antigen improves and is due to a combination of somatic 
mutation of existing antibodies and selection of antibodies with gene 
rearrangements that confer improved binding characteristics towards the antigen.
1.3.1 Immunoglobulin gene organisation and rearrangement
Unlinked gene families encode the k  and X light chains and the a, p, s, y and p 
heavy chains, with the genes for each of the chains found on separate chromosomes. 
The variable and constant segments for each chain are however proximal to one 
another [Tonegawa, 1983; Calabi & Neuberger, 1987]. The immunglobulin heavy 
gene locus is composed of 4 gene segments. The 5’ end of the gene is comprised of
CHAPTER 1 INTRODUCTION
multiple V exons followed by D (diversity) exons and J (Joining) exons. The 3’ end 
of the gene is comprised of the C (constant) segments with each segment (or exon) 
separated by non-coding DNA that is eventually discarded through gene 
rearrangement and transcription. Rearrangement of heavy chains brings the exons 
together forming a VDJC gene while in light chains a VJC gene is formed (Figure
1.3). When the various exons are spliced together, an enhancer and a promotor, 
which are distal from one another before recombination, are brought into close 
proximity triggering transcription of the gene.
If the variable chains of each of the heavy and light chains are examined, the V 
segments encode the final four residues of a peptide leader sequence and the first 95 
amino acids of the N-terminus residues that form the CDR 1, 2 and framework 
regions 1-3. In the heavy chain, the D segments and the J segments contribute to 
CDR3 and the fourth and final framework region whereas in the light chain the 
CDR3 and the fourth framework region are comprised of only the J segment (Figure
1.4). Association of these elements is thought to generate around 5.0 x 104 
sequences in the heavy chain, while there are only approximately 1.0 x 103 
sequences in the light chains due to the lack of the diversity segments (Figure 1.4). 
Consequently the CDR3 of the heavy chain has significantly more variability than 
that of the light chain CDR3. In addition, the L2 CDR is often found not to bind to 
small antigens even when all loops are found to be in contact [Tormo et a l, 1994], 





V IV 2  V3Vn D l-12 J 1-4
l l l l   IH-----llll
VI V2 V3Vn D l-2 J 3-4





VI V2 J 3.4 c
- M l -D„




V2 D2 J3 C
mRNA ------— AAA
b)
VI V2 V3Vn Jl - n
Light chain l l l l  llll
gene
Rearranged V 1V 2J2
DNA i l i i
V I V 2 J 2_ n 




mRNA  I  I------ AAA
Figure 1.3 a) immunoglobulin heavy chain germlines and their subsequent rearrangement 
into the variable regions of the V and C domains of the antibody, b) immunoglobulin light 
chain germlines and their subsequent rearrangement into the variable regions of the V and 












Figure 1.4 How the immunoglobulin genes relate to the domains of the polypeptide chains. 
The dashed boxes indicate the CDRs displaying the genes that they are formed from. The 
L3  CDR is composed of both V-J genes where as the H3 CDR is composed of V-D-J genes 
and consequently is the most variable of the hypervariable regions.
Site specific recombination is achieved using an array o f enzymes collectively 
termed recombinases that are involved in the formation o f complete variable 
regions. The enzymes are thought to recognise specific nucleotide recognition 
sequences found in the 3 ’ DNA o f each V segment and at the 5’ o f each J segment 
as well as sequences found in both sides o f each D segment (where present). The 
DNA recognition sites are conserved nucleotide heptamers or nonamers separated 
by non-conserved 12 or 23 base pair (bp) nucleotide spacers. The adjacent 
heptamers/nonamers on the V segments recognise complementary sequences on the 
J segments. However it is the 12/23bp spacers which dictate joining as a 23bp 
spacer must face a 12bp spacer on the opposing sequence and vice versa. This 
mechanism is thought to be instrumental in preventing V segments from combining 
together. Heptamer/nonamer recognition allows the formation o f DNA loop 
structures with the intervening DNA excised, followed by joining o f the cut ends. It 
is at this point where non-germline diversity is introduced into the antibody 
sequences due to imprecise restriction and ligation o f the ends, described as 
junctional diversity (heavy chain only). As a result, an identical set o f gene 
segments can result in different amino acid sequences following recombination. In 
some cases this may lead to non-functional recombinations that are out o f frame. 
This is sometimes overcome by the B cells deleting nucleotides from the non­
functional gene upstream o f the join resulting in a functional sequence. Additional 
genetic diversity is added to the immunoglobulin rearrangement by VH exchange 
[Kleinfield et al, 1986] and through N-region diversity (heavy chains only) where
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insertion of nucleotides at the V-D and D-J junctions during rearrangement of the 
heavy chain genes occurs. These nucleotide additions are referred to as N segments 
and may extend with as many as 30 nucleotides that sometimes result in a much 
extended CDR3 loop.
After immunoglobulin gene rearrangement has taken place, the B-cells expressing 
low affinity antibodies undergo a mutation and selection process termed somatic 
hypermutation [French et al., 1989; Kocks & Rajowsky, 1989]. Mutations occur at 
various positions throughout the variable regions of heavy and light chains, which 
may have an effect upon the affinity of the antibody towards its antigen. The 
diversity introduced by somatic hypermutation is estimated to increase the germ- 
line repertoire from 109 to 1030 different binding determinants [Winter & Milstein, 
1991]. Mutations are most common in the hypervariable regions and normally 
result in an increase in the affinity of an antibody, although the inverse is also true 
[Tonegawa, 1983; Wysock et al., 1990]. The higher affinity antibodies are 
subsequently selected, followed by clonal expansion of the B-cell germline. In 
reality, this huge range of generated antibodies are not produced indefinitely, 
otherwise huge amounts of antibody would be present at any one time in the 
circulation. To overcome this, memory B-cells exist which allow rapid 
upregulation, when necessary, of antibody numbers specific for a particular antigen.
1.4 EX-VIVO EXPRESSION OF ANTIBODIES AND THEIR
DERIVATIVES
1.4.1 Production of whole antibodies
Many of the antibodies that are found in blood differ from one another with regard 
to their class, isotype and in their specificity towards a given antigen. However the 
antibodies are all part of an immunoglobulin superfamily and are sufficiently 
similar in that they can all be easily isolated from blood products by similar 
methods. Blood, which has been separated from its main cellular components, 
contains this mix of antibodies and is called serum. If the antibodies within the 
serum are purified using, for example protein A, the purified antibodies are called 
polyclonal antibodies as they contain a heterologous population of antibodies which
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have different target epitopes and different binding specificities derived from 
different B cell clones.
It was not until the mid 1980’s that a homogenous population of ‘monoclonal’ 
antibodies could be produced which targeted the same antigen with identical 
specificity, possibly the most significant immunological and biotechnological event 
since the introduction of vaccines. The breakthrough in the production of 
antibodies was achieved through the use of myeloma cells. These are immortal 
tumour cells derived from antibody-secreting plasma cells and secrete high numbers 
of a single antibody and allow isolation of a single cell providing a limitless source 
of antibody, each a clone of the other. Particular myeloma clones were selected that 
retain the immortal phenotype but had lost their antibody expression. They also 
contained certain genetic features that enabled selection in a mixed population of 
myeloma cells, fused myeloma-B cell and B cells. The introduction of the antibody 
genes is achieved by cell fusion between the myeloma cells and the B cells from the 
spleen. The spleen cells that were exposed to antigen to raise specific antibodies 
are fused with the myeloma cells using polyethylene glycol that forces the cell 
membranes to blend subsequently leading to hybrid cells named hybridomas. These 
cells possess the characteristic immortality of the tumour cells but retain the 
antibody genes of the spleen cells. The cell line producing the antibody of desired 
specificity can be separated from the other cells using limit dilution and detected 
using enzyme linked immunosorbent assays (ELISA). Once selected, they can be 
cloned to establish permanent cell lines from which the monoclonal antibodies may 
be obtained. Repeated immunisation of mice with an antigen enables the isolation 
of high affinity, highly specific, monoclonal antibodies. The production of 
monoclonal antibodies by the routine procedure outlined above is a process which 
takes approximately six months, although more rapid methods of monoclonal 
antibody production have been developed such as direct immunisation of spleen cell 
culture [Stahl et al., 1995] and phage display (described in 1.4.3). At present, the 
major flaw of these non-classical methods is the absence of an effective somatic 
hypermutation stage, although artificial diversity has been introduced using phage
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antibodies by methods such as chain shuffling [Collet et al, 1992] and CDR 
randomisation [Barbas et al, 1992]
1.4.2 Expressing recombinant antibody fragments
The Fc effector functions of whole antibody are surplus to requirements if only 
specific binding of the Fab is required. Often the large size of the whole antibody 
can restrict their use in therapy due to poor tumour penetration. Although whole 
antibodies have the advantage that they are slowly depleted from circulation, they 
provide a much larger antigenic surface to which host antibodies may be raised, 
leading to undesirable immunogenic side effects. However the use of antibody 
fragments reduces or eliminates these problems and they have a considerably 
shorter half life within the body [Colcher et al, 1990]. Antibodies or antibody 
fragments have been successfully produced in bacteria, [Field et al, 1989; Mamalaki 
et al, 1993]; E. coli [Pluckthun, 1991], Bacillus subtilis [Wu et al, 1993], yeast 
[Bowdish et al, 1991], insect cells [Hasemann and Capra, 1991], mammalian cells 
[Bebbington, 1991; Gilliand et al., 1996] and plants [Owen et al, 1992; Tavladoraki 
et al, 1993; Benvennto et al, 1995]. Many laboratories express scFv, dsFv [Reiter 
& Pastan, 1998] and Fab fragments of antibodies in E. coli (Figure 1.5). However 
the associated problems of expressing eukaryotic proteins within prokaryotes has 
led to the development of eukaryotic expression hosts such as yeast and mammalian 









scFv dsFv scFv dimer scFv-0 Trimer
Figure 1.5 Schematic diagrams of antibody fragments: IgG, Fab, F(ab’)2, Fv, scFv, dsFv, 
scFv dimer and scFv-0 residue trimer. Some of the above fragments (F(ab’)2 and Fab) can 
be obtained by enzymatic digestion of whole immunoglobulins using pepsin and papain 
while others can be expressed in bacteria, yeast, mammalian cells and plant tissue although 
the antibody fragments are sometimes toxic towards the host cell.
Expression o f antibodies in prokaryotic systems has a number o f problems. For 
example, not all codons commonly found in eukaryotic genes translate well in E. 
coli. This is possibly due to variation in the levels o f specific tRNAs used in 
translation where few or no tRNAs exist for specific codons [Ikemura, 1981]. 
Consequently these codons are rarely present within E. coli genes and attempts to 
express eukaryotic genes containing these codons can present problems. Again, 
some antibody sequences appear toxic when expressed in bacteria, possibly due to 
overloading o f the cell’s transport machinery. This can result in difficulty in the 
expression o f particular antibodies and can sometimes result in bacterial cell lysis or 
in degradation o f the expressed protein [Pluckthun, 1994; Darveau et al, 1992].
The vectors used in E. coli can make an important difference to the successful 
expression o f recombinant antibodies: vector stability and promotor efficiency may 
both be critical for success [Bell, 1995]. Some vectors are unstable within E. coli,
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so that even when antibiotic markers are present the vectors can suffer large 
deletions of nucleotide sequences. Some commercially available vectors such as 
pKK233-2 have exhibited this problem. Therefore, it maybe important to transform 
and survey many vectors within E. coli in order to select a suitable and robust 
expression system for a particular antibody fragment. As mentioned previously, 
recombinant antibodies can often be toxic towards their bacterial hosts [Pluckthun, 
1994] and this, in combination with pressure on the bacterial cell to produce high 
levels of protein, can cause plasmid loss and subsequent loss of expression. It is 
critical to have a built in method of controlling expression at all times, such as via 
an inducer which can reduce the likelihood of plasmid damage or loss. However, 
the use of strong promotors to generate high expression levels can sometimes result 
in ‘leaking’ where low level expression occurs in the absence of the inducer. 
Additional controls have been developed to prevent this using inhibitors such as 
Lacl that are present in some vectors [Miller & Albertini, 1983; Fraipont et al, 
1994]. When using Lad  inhibitors, the addition of glucose can be used to suppress 
expression and this, allied with inducers, can lead to a well regulated, high level 
expression system [Tagami et al, 1995; Ishizuka et al, 1994]. Examples of 
promotors that promote strongly, yet are tightly regulated, are Piac, Ptac, ?tnc 
[Trukhan et al, 1988; Amann et al, 1988].
1.4.3 Phage display
The use of ^ -bacteriophage has allowed antibodies to be produced in vitro avoiding 
the time consuming classical method of monoclonal antibody production while 
utilising a combinatorial method which improves the specificity and affinity of the 
antibody molecule. It is the use of the polymerase chain reaction (PCR) which has 
enabled rapid reproduction of antibody gene repertoires through the use of 
degenerate oligonucleotide primers. These primers include a random nucleotide on 
‘the wobble’ while retaining the relatively conserved positions seen within the 
antibody sequences. The primers can also be designed to include restriction sites 
which allow the immunoglobuin genes to be amplified and easily transferred into 
DNA vectors [Orlandi et al, 1989; Gussow et al., 1989]. Genetic manipulation to 
fuse scFv or Fab genetic sequences with the N-terminus of phage minor coat protein 
pill or gene VIII [McCafferty et al., 1990] has allowed antibody fragments to be
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displayed on the bacteriophage surface. These correctly folded fragments are 
incorporated into the phage coat allowing binding of antigen and are termed phage- 
antibodies. The recombinant phage-antibody contains the DNA of the displayed 
antibody so that it can be ‘captured’ based on its binding properties towards an 
antigen bound to a solid surface and consequently the gene for the antibody 
isolated. The oligonucleotides generated contain the random nucleotide at ‘the 
wobble’ within the oligonucleotide primers so that the V genes of the antibody are 
amplified. The antibody gene repertoires are then amplified using PCR primers and 
subsequently cloned into the phage, creating a phage library that displays between 
106 and 109 antibodies of different specificities. Antibodies displaying the desired 
binding properties can be selected on a particular antigen while those failing to bind 
eliminated through washing [Winter et al., 1994; Griffiths et al., 1994]. A major 
benefit of this system is that human antibodies can be easily generated [Persson et 
al., 1991] avoiding the standard re-shaping protocols in order to avoid causing 
adverse immune responses [Gorman & Clark, 1990].
Phage display technology has progressed most recently with the selective infective 
phage technology (SIP). The phagemid displaying its antibody is non-infectious 
until an interaction occurs between the antibody and an antigen within the bacterial 
cell periplasmic space. This triggers cell apoptosis releasing large amounts of 
infectious phage particles [Spada et al., 1997].
1.5 BIOLOGICAL CATALYSTS
1.5.1 Bioenergetics and catalysis
Enzymes are biological catalysts that are thought to have slowly evolved over 
millions of years with many achieving a state of kinetic perfection [Fersht et al., 
1985]. Kinetic perfection exists when the catalytic turnover (kcat) of substrate to 
product by the enzyme is faster than the rate of substrate diffusion into the 
enzyme’s active site (KM). This means that the rate of catalysis is diffusion limited 
where diffusion of the substrate into the active site limits the rate or turnover of the 
enzyme (V = kcat/KM), so that it cannot be higher than 108-109 M'1 s'1. Most 
enzymes accelerate reactions are at least in the order of 106 M'1 s'1 although 
enzymes such as carbonic anhydrase, acetylcholinesterase and triosephosphate
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isomerase are between 108-109 M'1 s'1 and so are among those considered to be the 
most kinetically perfect [Albery & Knowles, 1977; Fersht, 1985]. It is important to 
understand that an enzyme is a catalyst and cannot alter the equilibrium of a 
chemical reaction but will only accelerate the attainment of equilibrium.
When a chemical reaction occurs, in order for the substrate (S) to form the product 
(P), it must pass through a transition state (Sv) that has a higher Gibbs free energy 
than either S or P. The difference in free energy between the S and is the Gibbs 
free energy of activation (AG'1'). If this value is reduced the attainment of 
equilibrium is accelerated (Figure 1.6). Enzymes stabilise the reaction transition 
state thus reducing AG'1', and consequently accelerating the attainment of 
equilibrium. With most enzyme catalysed reactions, the catalytic rate (V) varies 
with substrate concentration (S). At a fixed enzyme concentration, V is directly 
proportional to S when at small concentrations, whereas V is almost independent of 
S when at high levels and the enzyme is saturated. Based upon the Michaelis- 
Menton model [Palmer, 1995], Vmax is the resulting rate when the enzyme is fully 
saturated with substrate. The KM (the Michaelis constant) is the substrate 






Figure 1.6 Reactions are accelerated by enzymes decreasing the AG4'.and thus the reaction 
is accelerated. The kinetic profiles demonstrate catalysed and uncatalysed reactions.
Vmax
K [S] >M
Figure 1.7 The reaction velocity V is linked to substrate concentration [S] for an enzyme 
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Km is often used as a measure of affinity of the substrate for the enzyme. Therefore 
within the Michaelis-Menton model the lower the KM the stronger the affinity of 
substrate for the enzyme. The kcai is a measure of reaction turnover for the enzyme- 
substrate complex to enzyme and products as shown in equation 1.1.
ki k  j
E + S ^==^ES E + P
k .i
[k 2 =  &cat]
KThe equilibrium approximation: M ^
K  _ ( * - ! + * 2 )
The steady-state approximation: M
Equation 1.1 This equation allows the calculation o f  the affinity o f  the enzyme for the 
substrate (Km). &2 is the catalytic turnover o f  enzyme-substrate complex to enzyme and 
product. The equilibrium approximation is E + S <-» ES is only slightly disturbed by ES —> 
P, so &2 is low relative to k_\ hence Km = k .\/k \  whereas the steady-state approximation 
takes ES —> P into account.
1.5.2 Transition state versus ground state
Linus Pauling was pivotal in elucidating the fundamentals of enzymatic catalysis. 
He proposed that an enzyme binds more tightly to the transition state of a substrate 
than to the ground state [Pauling, 1948]. Antibodies are molecules that have 
evolved to bind with high affinity to stable, that is ‘ground state’, antigens. In 1969 
Jencks raised the concept of transition state stabilisation by antibodies. He 
suggested that an antibody raised to bind the transition state of a reaction could, in 
theory, catalyse a reaction in a manner analogous to that of the natural enzyme 




Initial research into catalytic antibodies met with little success for two main 
reasons, i) attempts were made to catalyse reactions that had a low background 
turnover, thus detection of trace amounts of products was difficult, ii) antibodies 
produced in the 1970’s were polyclonal so that the antibodies used would have had 
multiple specificities towards the antigen. Furthermore, within the polyclonal sera, 
catalytic antibodies were thought to exist but were only a fraction of total antibody 
present, consequently turnover levels were poor [Raso and Stollar, 1975; Burd et al, 
1977; Kohen et al., 1979]. Only the advent of monoclonal antibodies in the mid 
1980’s allowed the generation of monospecific antibodies in quantities adequate for 
definitive proof of catalysis. It was in December 1986 that two groups 
independently demonstrated that monoclonal antibodies directed towards tetrahedral 
phosphorus species could catalyse the hydrolysis of carboxylate esters and 
carbonates [Tramantono et al., 1986; Pollock et al., 1986]. One of the antibodies 
catalysed the hydrolysis of a carbonate by a factor of 102 over background. The 
other antibody catalysed the hydrolysis of a carboxylate ester at a factor of 102 over 
background with both antibodies displaying Michaelis-Menton saturation kinetics. 
To be true biological catalysts, these antibodies must display the same behaviour of 
that seen with enzymes.
1.5.3 Catalysis by antibodies
Production of catalytic antibodies has moved beyond demonstrating feasibility of 
the concept. The main question now is whether catalytic antibodies can ever 
become efficient and rapid enzymes? Since the first esterolytic antibodies there has 
been rapid development of catalytic antibodies catalysing a diverse range of 
chemical reactions; amide hydrolysis [Janda et al., 1988], Claisen rearrangement 
[Hilvert et a l, 1988], Diels-Alder reaction [Hilvert et al., 1989], DNA hydrolysis 
[Shuster et al., 1992], dis-favoured exo-Diels-Alder reaction [Gouveneur et al.,
1993] cocaine degradation [Landry et al., 1993] and peptide bond formation 
[Jacobsen & Schultz, 1994] to name but a few. A unique and potentially useful 
characteristic of certain catalytic antibodies is their enantiomeric selectivity. These 
antibodies bind to the D or L form of the substrate, depending on the chiral form of 
the transition state analogue used to raise the antibody. This stereochemical
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selection can be applied to the chiral resolution of a racemic mix of substrate, which 
potentially might be of use in producing optically pure compounds or chiral drugs, 
now required by the Food & Drug Administration (FDA) to be demonstrated prior 
to clinical trials. The catalytic antibody portfolio continues to expand but some 
recent research efforts have begun to investigate how existing antibody catalysed 
reactions can be further accelerated. This requires examination of catalytic antibody 
structures and mutagenic studies in order to elucidate the antibody mechanisms. 
Unfortunately, relatively few crystal structures of antibodies have been solved to 
date although the existing structures have provided valuable structural data on their 
mechanisms of action [Gigant et al, 1997; Wedemeyer et al, 1997; Charbonnier et 
al., 1995; Zhou et al., 1994; Flaynes et al, 1994]. Progress in determining the 
catalytic mechanisms by mutagenesis has been slowed due to the inconsistency of 
antibody fragment expression [Kipriyanov et al, 1997; Knappik & Pluckthun, 1995; 
Ulrich et al., 1995].
Catalytic antibodies generally follow Michaelis-Menton saturation kinetics. The 
values of kcat and KM and the nature of the interactions present in the combining site 
have been used to give some insight into antibody substrate complex. A study on 
polyclonal catalytic antibodies from sheep antisera showed a correlation (r = 0.87) 
between increasing kcat and KM values, thought to be indicative of destabilisation of 
antibody-substrate interactions leading to an increase in the rate of catalysis. In 
addition, a correlation (r = 0.69) between an increase of kcat/KM together with an 
increasing KM might indicate stabilisation of the transition state for the reaction 
[Gallacher, 1993].
Although catalytic antibodies have a relatively slow rate of catalysis when 
compared with enzymes they are currently the best method for producing a de novo 
protein for a specific catalytic role. Catalytic antibodies are less efficient catalysts 
than their natural enzymatic counterparts due to enzymes having slowly evolved the 
ideal environment and mechanism for the processing of its substrate. In addition, 
catalytic antibodies are more prone to product inhibition. Factors important for 
catalysis other than transition state stabilisation are also important, such as reactive
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groups, oxyanion pockets, enzymatic participation of chemical groups in a reaction, 
water free microenvironments, destabilisation of the substrate and approximation of 
reactive groups towards the substrate [Benkovic, 1996; Benkovic et al., 1990; 
Iverson et al., 1989; Houk, N., 1996].
Antibodies can bind virtually any antigen but antibodies may not have sufficient 
flexibility in their structure to provide a catalytic site for all reactions. The currently 
existing abzymes may have already reached their maximum rate of catalysis. This 
may explain why antibody catalysed reactions are several orders of magnitude 
lower than those of enzymes catalysing the same reactions. Poor understanding of 
the antibody mechanisms, poor hapten design, product inhibition and product 
clearance are all possible obstacles to the efficient and rapid catalysis by antibodies. 
Early experiments on catalytic antibody selection during screening were based on 
their strength of binding of the TSA. It is entirely possible that enzymes were not 
selected by evolution for their affinity for the substrate but upon their activity in 
catalysing a reaction. This could mean that superior catalytic antibodies are not 
necessarily those that bind the TSA tightly during the production of catalytic 
antibodies. In many instances, antibodies that bind their designed TSA have not 
exhibited any catalytic activity while other antibodies raised against the same TSA 
have. This may be due to the precise microenvironment of some antibodies being 
incompatible for catalysis, leading to too tight substrate binding or failure to release 
product [Haynes et al., 1996]. Therefore the screening method for catalytic 
antibodies should be directed towards activity rather than binding. This concept has 
been used to genetically screen for improved Claisen rearrangement antibodies, 
based on their ability to carry out a key reaction in the aromatic amino acid 
biosynthesis pathways that is vital for the survival of the mutant strain of E. coli 
used. This bacterium has a mutant gene for metabolite catalysis so that the cell 
survival is dependant upon successful production of catalytic antibodies that are 
able to efficiently catalyse the conversion of chorismate to prephenate, the 
metabolic precursor of phenylalanine and tyrosine [Tang et al., 1991]. However, 
there are few cases where this genetic screening method has been applied.
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1.5.4 Generation of antibodies towards designed haptens
A hapten is a small molecule that can act as an epitope but is incapable of eliciting
an antibody response alone. These molecules require conjugation to a carrier 
molecule to facilite their recognition by the immune system. Haptens, that were 
transition state analogues of particular reaction transition states, were conjugated to 
carrier proteins and used to induce catalytic antibodies. As suggested by their 
name, the transition state structures are unstable or transient by nature and so are 
impossible to use as haptens themselves. However, use of a transition state 
analogue is not ideal as the conformation of the transition state for most reactions is 
a ‘best guess’. The analogue molecule produced is likely to differ in conformation 
from that of the true transition state. Therefore the extent of this difference may 
dictate the success of the approach for particular reactions.
The transition state analogue haptens are conjugated to carrier proteins such as 
keyhole limpet hemocyanin (KLH) or bovine serum albumin (BSA), necessary to 
elicit an immune response. Typically, amide bonds are formed between carboxyl 
groups in the hapten and the e-amino groups of the surface lysine residues in the 
carrier proteins [Erlanger, 1980]. The spacer arm between the hapten and carrier is 
normally at least 6A in order to prevent steric interference from the carrier during 
the immunisation process [Nishima et al., 1974].
1.5.5 Antibody esterases
The first antibody catalysts produced were esterolytic antibodies [Tramantano et al, 
1986; Pollack et al, 1986]. Abyzmes that catalysed amide hydrolysis were 
produced shortly afterwards [Janda et al., 1988]. Most of the haptens designed to 
catalyse ester/amide hydrolysis mimic the tetrahedral transition state thought to 
exist during the cleavage of ester and amide bonds. The majority of the haptens 
used are phosphonates or phosphonamidates from the organophosphorous family 
(Figure 1.8) which possess a tetrahedral structure through the inclusion of a 
pentavalent phosphorus atom. Interestingly sulphur based sulphones and 
sulphonamides have been tried but with no reported success [Thomas, 1994]. An 
important feature of hapten design is that the presence of aromatic groups within the
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TSA generally leads to more successful catalytic antibody production [Thomas, 
1994], probably due to the aromatic moiety eliciting a more vigorous immune 
response. However, as indicated above, tight binding towards the TSA does not 
always indicate antibodies with efficient catalysis, highlighting the difficulties in 
screening for catalytic antibodies.
Figure 1.8 The nomenclature of organophosphorous compounds on which tetrahedral 
based transition state analogues are often based.
1.5.6 Elucidating catalytic antibody mechanisms from their crystal 
structures
An increasingly large array of kinetic data are available on existing and novel 
catalytic antibodies, while relatively little three-dimensional structural information 
exists. These data are essential for clear and rapid elucidation of the mechanisms 
involved in these antibodies [Wilson & Stanfield, 1994] and for identifying the 
residues involved in covalent or non-covalent interactions, or that simply attribute 
some catalytic function. At the time of writing, structural data exist on six catalytic 
antibodies which has allowed the elucidation of their likely mechanisms (Table 
1.1). It is important to realise that crystal structures are by nature static 
representations of the antibody structures and cannot represent their dynamic state. 
Thus, it is necessary when examining crystal structures to take account of the 
importance of flexibility in catalysis, as with enzymes.
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The antibody CNJ206 possess esterolytic activity towards a /?-nitrophenyl ester 
displaying a k ^ /k ^ t of 1.6 x 106. It has a long but shallow groove at the interface 
of the heavy and light variable chains. The residues thought to be involved are 
Tyr^O, TyrL96 and HisH35 which hydrogen bond the phosphoryl moiety of the 
TSA while the AspL55 binds the -N02 group. Hydrogen bonds are thought to form 
between the hapten and the TyrL91, TyrL49, TyrL96 Tyr^O and TyrH59 residues. 
Binding of hapten (Figure 1.9) or substrate in this antibody is thought to produce a 
dramatic shift in 11 residues of the H3 loop triggering a conformational change 
from a shallow groove to a deep pocket. [Golinelli-Pimpaneau et al., 1994; 
Charbonnier et al., 1995].
1F7
The 1F7 antibody displays chorismate mutase activity with a kcat/kuncat of 2.5 x 102. 
It was raised towards a molecule that inhibits chorismate mutase that is found in 
bacteria, fungi and plants (Figure 1.9). The chorismate mutase enzyme catalyses a 
key step in the biosynthesis of phenylalanine and tyrosine. This allowed the 
antibody to act as an in vivo catalyst for this metabolically essential reaction. The 
cells were auxotrophic mutants and so were deficient in the enzyme used for 
producing phenylalanine and tyrosine, were only able to survive if expressing the 
antibody [Tang et al, 1991]. It is thought that the antibody stabilises the same 
conformationally restricted pericyclic transition state as that occurring in the 
uncatalysed reaction. The structure of antibody 1F7 in complex with its hapten has 
been solved. The structural data allow comparison of the active site of the enzyme 
with that of the antibody, potentially providing evidence of any similarity between 
the two catalytic mechanisms. The base of the binding site appears relatively 
hydrophobic; AsnH35, TrpH47, AlaH93, PheH100b, LeuL96 and the walls consist of 
polar residues; AsnH33, AsnH50, AsnH58, ArgH95, Tyi^lOO and TyrL94. Hydrogen 
bonds are thought to form between AsnH33 and the hydroxy group of the hapten and 
between the side chain hydroxy group of the TyrL94 and the 3° carboxyl group of 
the hapten. Water molecules may form hydrogen bonds between the haptens 2° 
carboxyl group and the residues ArgH95, AspH101. However when compared with
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the original enzyme, the antibody has rotational limits upon some residues and in 
addition, fewer electrostatic interactions appear to be used to stabilise charge 
separation during catalysis. Hapten recognition is dominated by van der Waals 
contacts but many residues probably make contact with the hapten through a limited 
number of hydrogen bonds [Haynes et al., 1994].
17E8
The structure of an esterolytic catalytic antibody 17E8 bound to its hapten (Figure 
1.9) was solved at 2.5 A resolution [Zhou et al., 1994]. This antibody catalyses the 
hydrolysis of nor-leucine or L-methionine phenyl esters, with the structural and 
kinetic data supporting a hydrolytic mechanism similar to that seen in serine 
proteases. The antibody’s combining site has a Ser-His diad proximal to the 
phosphorous atom of the bound hapten which resembles the His-Ser-Asp triad that 
is seen in serine proteases. In addition the site contains a Lysine residue thought to 
stabilise oxyanion formation and a binding pocket which functions in substrate 
recognition of the norleucine/methionine side chains. Fourteen of the antibody’s 
residues are involved in binding the hapten with the phenyl ring bound in a pocket 
formed by the side chains of Tyr1^ ,  LeuL89, ArgL96, PheL98, ValH37, and TrpH47 
residues. The side chain of the hapten is contacted by 01^34, LeuL89 and TyrL91 
and its phosphonate group has electrostatic interactions with LysH93 and ArgL96 
residues. This mechanism suggests a convergence to the serine proteases family of 
catalytic structures which have evolved in some enzymes. Atomic contacts were 
seen between the Ser^95 and His^35 towards the phosphorous atom o f the TSA. 
During catalysis the pH is likely to be important as at a neutral pH, Ser1^  accepts a 
hydrogen bond from the donor TyrH97. However at pH 9.5, this hydrogen bond is 
removed and the serine residue is thought to rotate allowing nucleophilic attack 
upon the substrate carbonyl atom. The HisH35 residue accepts a proton from the 
freely rotating SerH99 residue, which allows it to form the covalent acyl 
intermediate with the substrate. The LysH97 stabilises the subsequent charge which 
builds upon the carbonyl atom. The phage display technology described earlier has 
been used to optimise binding of this catalytic antibody to its TSA resulting in 




The crystal structure of the esterase catalytic antibody 48G7 was solved with both 
the antibody complexed and uncomplexed to the hapten (Figure 1.9)[Wedemayer et 
al., 1997]. The antibody catalyses the hydrolysis of p -nitro phenyl esters and 
carbonates. Examination of the active site with and without the TSA displayed no 
significant changes due to hapten binding and has been described as “mutual fit” 
where antigen binding causes relatively minor structural changes [Webster et al.,
1994]. The hapten fits into a pre-formed pocket of approximately 10A in depth and 
shows no involvement of water molecules within the active site. The structure did 
illustrate an emerging theme seen with esterolytic antibodies where binding phenyl 
haptens (& nitro-phenyl haptens). The aryl end is buried deep into the binding 
pocket while the phosphonate and phenyl moieties are responsible for the majority 
of the antibody-hapten interactions. The complex shows that the aliphatic linker 
and carboxylic acid group is surrounded by six tyrosine residues; L32, L91, L94, L33, 
H95, H96. The phenyl ring is contacted by TyrL91 and TyrH99, the phosphorus atom 
of the hapten makes no direct contact with the antibody while its oxygen atoms 
form hydrogen bonds with ArgL96, TyrH33 and van der Waals interactions are seen 
with HisH35. Six tyrosine residues are in the active site. There has been speculation 
that antibodies containing high numbers of aromatic residues within the active sites 
can lead to n-% orbital stacking with the phenolic moieties of the hapten restricting 
product release and possibly causing product inhibition [Thomas, 1993]. However 
strict TT-Ti stacking was not observed between the phenyl moiety and aromatic 
residues within the 48G7 antibody.
D2.3
Crystal structures have been solved of the esterolytic antibody D2.3, complexed 
with a substrate analogue, transition state analogue (Figure 1.9) and with one of its 
reaction products, as well as in the unliganded form. The antibody contains an 
narrow groove in its active site but provides a deep pocket for the substrate to bind. 
A negatively charged oxyanion intermediate is formed through nucleophilic attack 
by water molecules. A tyrosine is thought to be integral in activating the ester
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substrate after which it helps stabilise the oxyanion intermediate with the help of a 
proximal asparagine residue [Gigant et al., 1997].
NPN43C9 Fv
Crystal structures are not the only structure-based method of elucidating catalytic 
antibody mechanisms. Modelling can be a rapid alternative but is a method that 
must be viewed with substantially less confidence. A model of the antibody 
NPN43C9 Fv was built and used to select residues for mutagenesis studies that 
were thought to be important in catalysis [Stewart et al, 1994]. The ArgL96 side 
chain at the base of the combining site was thought to interact with the 
phosphonamidate of the hapten (Figure 1.9). When mutated all catalytic activity 
was eliminated. Either residue HisL91 or HisH35 was thought to be a nucleophile 
involved in the formation of a covalent intermediate during catalysis.
The dielectric character of an enzyme or catalytic antibody’s catalytic 
microenvironment is also very important. Ionisation of catalytic residues is 
dependent upon their pKa, and can be an important, if not critical factor in 
determining the optimum pH for the catalytic reaction. Often the pH at which the 
reaction is to be performed will be lower than the optimum value for catalytic 
turnover. As these pH extremes can have a destructive effect on the structure of the 
antibody, a balance must be achieved.
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Figure 1.9 The transition state analogue haptens used to raise the catalytic antibodies: 
20G9, CNJ206, 48G7, 17E8, 1F7, D2.3, 43C9. All, excluding 1F7, included a 




Table 1.1 Residues observed in crystal structures and models of catalytic antibodies which 
are involved in the antibody’s catalytic mechanism. Residues numbers that coincide have 
been notated in bold *Non-estero lytic antibody
Abzymes Light chain residues Heavy chain residues
CNJ206 YU9, D^55, Y^91, Y^96 HH35, YH50, Y^59
17E8 GL34, YL36, LL89, YL91, RL96, pL vH37j Wh 47, KH93
48G7 YL32, YL33, YL91, YL94, RL96 HH35, LH95, YH96, YH99
D2.3 AL34, GL91, Yl 96 YHlOOd, W047, HH35
NPN43C9 RL96, HL91 HH35
Fv
1F7* YL94, LL96 NH33, NH35, WH47, Nh 50, Rh 58,
AH93, FHlOOb
1.5.7 The esterolytic antibody, 20G9
The antibody 20G9 was generated in 1988 against the transition state analogue 
phenylphosponate, 1 [Dufor et al., 1988] and catalyses the hydrolysis of 
phenylacetate. The TSA was coupled to the carrier protein keyhole limpet 
haemocyanin (KLH) and bovine serum albumin (BSA) at a ratio of 15:1 
(hapten/carrier). The KLH-phosphonate conjugate, buffered in lOmM phosphate 
and 150mM NaCl pH7.4, was mixed with Freunds complete adjuvant and used to 
immunise BALB/c mice over a period of months. The mouse was later sacrificed 
and its spleen cells fused with Sp2/o myeloma cells to form cell hybridomas, from 
which thirteen clones were successfully isolated which bound the 
phenylphosphonate TSA. The antibody’s substrate, phenyl acetate, spontaneously 






Figure 1.10 The phenylphosphonate hapten (1) to which the 20G9 antibody was generated. 
The possible mechanism of the hydrolysis of phenyl acetate to phenol and acetic acid via a 
tetrahedral transition state [VF].
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The 20G9 monoclonal antibody was purified by Protein A affinity chromatography 
and homogeneity confirmed by SDS-PAGE. The antibody was partly characterised 
in 1990 where its possible use as a biosensor was investigated [Blackburn et al, 
1990] but the majority of kinetic characterisation was performed by Martin et al in 
1991. This characterisation discovered two discrete kinetic rates; a pre-steady state 
burst and a steady-state phase thought to exist possibly due to product inhibition. 
The kinetic parameters were determined for the initial and steady-state velocities: 
pre-steady state kcat = 4.9±(0.5) min'1, KM = 300±(70) pM and a steady state kcat = 
4.9±(0.5) min'1, KM = 30 ±(70) pM. The pH profile for the steady state displayed an 
acid limb pK of 9.6. Tetranitromethane (TNM) was used to selectively nitrate 
active tyrosines and resulted in an almost complete loss of activity. This indicated 
tyrosine involvement in the catalytic site although their specific function(s) and 
whether this indicated the possible formation of an acyltyrosyl intermediate can 
only be a subject of speculation. It may have been that product binding of phenol to 
this intermediate was responsible for the inhibition observed.
1.5.8 A future for catalytic antibodies?
The opportunities for the application of catalytic antibodies within industry appear 
limited and it is difficult to envisage that they will be utilised within large industrial 
processes even if the rate could be improved. However a niche may exist at a 
clinical level with the activation of pro-drugs of de novo design or in destruction of 
bacterial or viral coat proteins. At an analytical level they have the potential to be 
used as novel restriction proteases using their ability as amidases. Catalytic 
antibodies have been investigated as biosensors [Blackburn et al, 1990] and so a 
possible future for abzymes may exist in micro-analytical systems with a role as a 
robust biological component when an enzyme does not exist. The additional 
benefits are due to the similar structures and properties of catalytic antibodies, 
which can allow standard immobilisation, stabilisation, calibration, storage and 
labelling procedures thus avoiding lengthy optimisation studies that would be 
necessary for different enzymes. In addition, antibodies are often found to be more
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robust than enzymes, adding flexibility with regard to reaction temperature and pH 
as well as improved short term storage.
1.6 THE AIM OF THIS THESIS
The aim of this thesis is to kinetically characterise the catalytic scFv 20G9. As 
described, the 20G9 antibody has previously undergone some biochemical and 
kinetic characterisation, discovering the burst and steady-state phases of the 
reaction. It has been speculated that tyrosine residues have a direct involvement in 
the catalytic mechanism of this antibody. This thesis aims to reinvestigate this and 
identify those residues involved in the catalysis of this antibody.
Molecular modelling will be used to identify residues that have a potential 
involvement in the mechanism. This will be carried out using AbM, an antibody 
modelling package developed in this laboratory, which allows the production of 
reasonably accurate three-dimensional structures of the antibody and its binding 
site. Residues selected as candidates for involvement within the binding site will 
primarily be selected based upon their proximity to the antibody binding site. The 
number of residues will then be narrowed down using the existing kinetic evidence 
available on 20G9 and by reference to the involvement of specific residues within 
other esterolytic antibodies. The selected residues will then be mutated in two 
stages: primary and secondary candidates for mutation, based upon their relative 
likelihood to be involved in the catalysis.
The residues selected for mutation will be mutated using PCR site-directed 
mutagenesis. Due to the low error rates seen with some polymerases during PCR, 
this is considered an easy and rapid method with which to mutate the selected 
residues. The mutated section can then be easily re-cloned into the original vector, 
or into another suitable vector for high-level expression. All mutants will be fully 
sequenced to check for polymerase errors before expression of the mutated 
antibody. The simplest way of identifying successfully cloned mutants is to express
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the antibodies using an affinity tag. This will facilitate purification of the bacterial 
expressed antibody fragment from the cell media.
The mutants will then be characterised, relative to the wild-type scFv and previous 
kinetic data from the 20G9 antibody, for kinetic activity. Changes in the steady- 
state and burst rates will be examined taking careful note of any changes to the KM 
and kcat of the steady-state and kinetic burst. Observed changes will be correlated to 
mutations introduced into the antibody, allowing greater understanding of the 
kinetic mechanism of this catalytic antibody.
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2 STANDARD MATERIALS AND METHODS
This chapter describes the general biochemical and molecular biology techniques 
used in the experiments described in this thesis. Specific methods used for 
particular experiments are detailed within that particular chapter.
2.1 MATERIALS
2.1.1 Bacterial strains used for cloning: 
Table 2.1 E. coli strains used for cloning
Strains Source Genotype Reference
XL-1 Blue Stratagene [F’::TnlO (TcR) proA+ proB+ lacFl lacZAM15] recAl Bullock, W.O. et al.
endAl gyrA96 (NalR) thi hsdR17 (r]<m|c+) supE44 relA (1987).
lac
DH5a Stratagene endAl hsdR.17 (r}cmj<c+) supE44 thi-1 recAl gyrA (NalR Hanahan, D. (1983) 
relAl A(lacZYA-argF)ui69 (<|)801acZAM15)
JM109 Promega thil rpsL endA+ sbcB15 hsdR4 supE D (lac-proAB)/F’ 
[traD36, proAB+ lacW lacZAM15]
Yanisch-Perron, C. 
et al. (1985)
2.1.2 Bacterial strains used for protein expression: 
Table 2.2 E. coli strains used for protein expression
Strains Source Genotype Reference
TOPP2
TGI
Stratagene Rif1 [F’ proAB+, TnlO (Tetr)]
G. Winter MRC sue hsd AS thiS[lac-proAB] F’ [traD36 proAB+ 
lacN lacZ AM 15
Hatt, J., et al (1992). 
Gibson, T. (1984)
2.1.3 Enzymes, chemicals and oligonucleotides
All enzymes were obtained from New England Biolabs (UK) Ltd., Hitchin, UK and 
chemicals from Sigma-Aldrich Chemical Co. Ltd., Poole, UK, Fisons Ltd., 
Loughborough, UK and BDH Ltd., Poole, UK unless stated otherwise. All 
oligonucleotides used were custom made by Perkin-Elmer Ltd., Warrington, UK.
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All were HPLC purified and supplied lyophilised. Throughout, the water was 
Millipore Q-Plus filtered water, Millipore, Watford, UK.
2.1.4 Bacterial cell culture
All cell culture materials were obtained from Difco Laboratories, Michigan, USA.
2.2 BIOCHEMICAL AND DNA MODIFICATION TECHNIQUES
2.2.1 Agarose gel electrophoresis
Nearly all sizes of DNA can be resolved using agarose gel electrophoresis by 
reducing or increasing the amount of agarose. The DNA within the gel was stained 
with ethidium bromide and visualised under long or short wave ultraviolet (UV) 
light. Gels were prepared by dissolving 1% w/v agarose (Gibco) in TBE buffer 
(89mM Tris-borate, 89mM boric acid and 2mM EDTA) and boiling in a microwave 
oven. The gel was allowed to cool to approximately 50°C at which point ethidium 
bromide was added to a concentration of 0.5pg/ml. The molten agarose was poured 
onto a horizontal gel bed that contained spacers and a well-forming comb. Once set 
the comb and spacers were removed and the gel submerged in TBE buffer. DNA 
samples were taken up into loading buffer (0.25% w/v bromophenol blue, 0.25% 
w/v xylene cyanol, 40% w/v sucrose) at a ratio of 1:5, dye:sample. Samples, lOObp 
ladder and 1Kb ladder molecular weight markers (Gibco) were loaded onto the gel 
and electrophoresed at 80V until the marker dyes had migrated sufficiently. DNA 
was visualised by fluorescence using short-wavelength ultraviolet light (UV). If the 
DNA was to be extracted then the above procedure was identical except that low 
melting point (LMP) agarose (Gibco) was used and the procedure performed at 4°C 
to prevent the gel melting. Damage to the DNA was prevented by brief 




(1 Litre) lOg Tryptone, 5g Yeast Extract, 5g NaCl 
(1 Litre) 16g Tryptone, lOg Yeast Extract, lOg NaCl 
(1 Litre) 16g Tryptone, 15g Yeast Extract, lOg NaCl
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2.2.2 Concentrating DNA by ethanol precipitation.
3M sodium acetate (CH3C02Na) pH 5.5 was added to the DNA to a concentration 
of 300mM. 2.5 volumes of absolute ethanol were added and the solution gently 
mixed and incubated overnight at -20°C. The precipitated DNA was centrifuged at
15,000 x g for 30 minutes at 4°C and the supernatant carefully removed by 
aspiration. The DNA was dried using a SpeediVac vacuum centrifuge at 500 x g 
for 30 minutes and resuspended in 5-10pl sterile water or TE buffer and stored at - 
20°C.
2.2.3 Determination of DNA concentration
5pi of the DNA solution was diluted to 1ml with water. Spectrophotometer 
readings were taken at A260 and A280. The A260 reading was measured and used to 
estimate the concentration of the DNA using the following equation:
1 A260 = 50 pg/ml double stranded DNA 
1 A260 = 33 pg/ml single stranded DNA 
The ratio (A260/A280) provided an estimation for the purity of the DNA preparation. 
A ratio of 1.8 indicated high purity. A ratio greater than 1.8 suggested RNA 
contamination while a lower figure indicated protein or solvent contamination, i.e. 
phenol.
2.2.4 Restriction enzyme digestion
Restriction digests using NEB enzymes were performed using 100-300ng DNA in a 
volume of 60pl All digests were performed in the appropriate NEB enzyme buffer 
(NEBuffer Activity Chart for Restriction Endonucleases, NEB catalogue, 96/97). 
Some NEB enzymes required the addition of BSA to a concentration of lOOpg/ml. 
Digestion of plasmid DNA required enzyme at 1 unit per 1 mg DNA whereas 
digestion of PCR extension products required 3 units per 1 mg DNA. Digestions 
were generally performed at 37°C overnight and inactivated by heating at 65-80°C 
for 15-30 minutes.
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2.2.5 Ligation of sticky and blunt ended DNA
A Fast Link ligation kit (Epicentre Technologies, Wisconsin, USA) was used to 
perform rapid ligations on sticky and blunt ended fragments. Approximately 25ng 
of digested PCR insert and 10-15ng of digested plasmid DNA were added together 
giving a ratio of 2:1 insert:plasmid. For blunt ended ligations the ratio was 
increased to 10:1 to achieve the greatest number of recombinants. 1.5pi of lOx 
ligation buffer (lOOmM NaCl, O.lmM EDTA, 0.1% v/v Triton X-100, ImM 
dithiothreitol (DTT), 50mM Tris-HCl pH 7.5) was mixed with 1.5pl of lOmM ATP.
1.0 pi of T4 DNA Ligase (2 U/pl) was added to the DNA. The reaction volume was 
made up to 15pl using sterile H20. The tubes were allowed to incubate at room 
temperature for at least 1 hour after which the reaction was stopped by heating at 
70°C for 15 minutes to inactivate the DNA ligase (Michelsen, B.K., 1995). 10% of 
the reaction mix was used directly to transform competent E. coli cells.
2.2.6 Spin-column chromatography
Spin-column chromatography was used for the removal of primers, restricted end 
fragments (<10bp), desalting and buffer exchange from small volumes (< 50pl). 
MicroSpin columns (Pharmacia Biotech Inc., St. Albans, UK) are packed with 
Sepharyl resin of various pore sizes (200,300,400) and are pre-equilibrated with TE 
buffer (pH 7.6).
The column resin is resuspended by shaking, the cap is loosened and the sealed base 
snapped off. The column was placed into a 1.5ml Eppendorf tube and centrifuged 
in a microfuge at 3,000 x g for 1 minute. If appropriate, 0.5ml of a buffer was 
placed into the column and the above spin step repeated. The column was moved 
into a fresh Eppendorf tube and the DNA solution carefully added onto the centre of 
the resin. The column was centrifuged at 3,000 x g for 2 minutes and the 
flowthrough collected.
2.2.7 DNA recovery from a low melting point (LMP) agarose gel
DNA was visualised using long wave UV light and the band carefully cut out using
a clean razor blade. The gel fragment containing the DNA was weighed to
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determine its approximate volume and melted at 65°C. lOx Agarose buffer (NEB) 
was diluted to lx concentration in the liquefied agarose, mixed and allowed to cool 
to 40°C. 1 pi of p-agarose enzyme ((1 U/ pi) NEB) was added per lOOpl 1% w/v 
agarose gel followed by incubation at 40°C for 2 hours. 3M Sodium acetate, pH 5.5 
was added to a final concentration 300mM and the mixture chilled on ice for 15 
minutes. Any undigested agarose was removed by centrifugation at 15,000 x g and 
the supernatant volume measured. 2 volumes of iso-propanol (pre-cooled at -20°C) 
were added and the mixture incubated at -20°C for at least 30 minutes. Following 
the precipitation the solution was centrifuged at 15,000 x g at 4°C for 15 minutes. 
The alcohol was carefully removed by aspiration leaving approximately 50pl 
solution to which 1ml of 70% ethanol was added. The tube was inverted 2-3 times 
and centrifuged at 15,000 x g for 5 minutes. The supernatant was removed by 
aspiration and the remaining alcohol evaporated with a short spin in a SpeediVac 
vacuum centrifuge. The pelleted DNA was resuspended in 10-15 pi of Tris-HCl pH
7.5 (TE) or sterile water.
2.2.8 Polymerase chain reaction (PCR) using Vent DNA polymerase
For high fidelity primer extensions, Vent DNA polymerase (NEB) was used which
utilises its 3’-5’ exonuclease activity for proof-reading of the extension product. 
5pl of a lOx stock of dNTPs (dATP, dCTP, dGTP, dTTP at 3mM) (Pharmacia 
Biotech), 5pl of lOx Vent polymerase buffer (lOOmM KC1, 200mM Tris-HCl pH 
8.8, lOOmM (NH4)2S04, 0.1% Triton X-100) and 0.5 pi of BSA (lOmg/ml) were 
added to 0.2ml thin-walled tubes. The tubes were placed under short-wave UV 
light for 5 minutes to eradicate any contaminating DNA. 1 pi of each 
oligonucleotide primer (50pmoles/pl), lOng of template DNA, 0.5pl of Vent DNA 
polymerase (2 U/pl) were added and the volume made up to 50pl using sterile 
Milli-Q water. A drop of mineral oil was added to the tube to cover the reaction 
and prevent evaporation. All PCR’s performed included a negative control (no 
DNA template added) and a positive control on an existing template known to give 
PCR products, allowing testing of the various parameters within the PCR such as 
buffers, enzyme and the temperature cycle.
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The thermo-cycler, model PTC-100 (Perkin-Elmer, USA) was programmed to heat 
to 94°C for 2 minutes to separate any hybridised DNA followed by cooling to the 
annealing temperature which was held for 2 minutes. For complementary 
oligonucleotides of 11-20 bases, the annealing temperature was calculated using the 
Wallace equation: Tm= 4(G + C) + 2(A + T) (Suggs et al., 1981). The calculated 
annealing temperature allowed optimal binding of the oligonucleotide primer to the 
template. This was followed by heating to an extension temperature of 72°C, 
allowing one minute per kilobase of expected extension product (excessive 
extension time lead to degradation of the extension product due to the polymerase’s 
exonuclease activity). The reaction was then heated to the denaturing temperature 
of 94°C for 2 minutes leading to separation of DNA (primers, template, products). 
The reaction was cycled back between the annealing, extension and denaturing steps 
28 times. The final step involved cooling to 72°C and maintaining this temperature 
for 1-2 minutes, which ensured that all extension products were double, stranded. 
Taq DNA polymerase was used mainly for screening exercises as the PCR products 
were not used for any cloning experiments due to risk of polymerase 
misincorporations. DNA polymerase fidelity is described in chapter 4.
2.2.9 Design of oligonucleotides
Oligonucleotide primers were designed in two steps. The first was to decide the 
function of primer (sequencing primer, PCR primer, PCR primer with base 
mismatches). The site of template binding was based primarily upon its proposed 
function (i.e. sequencing primer, introduction of restriction sites) but the following 
factors were also taken into consideration:
i) no runs of a single base (no more than 4) especially G/C rich domains.
ii) primers were at least 18 bases long to ensure good hybridisation and raise the 
stringency of the PCR.
iii) melting temperature of primer > 45°C.
The second step involved computer assessment of the designed primer using 
publicly available software (Amplify, Bill Engels 1992. University of Wisconsin). 
This allowed the primer to be checked for dimerisation against itself, partner 
primers and predict non-specific binding. This allows avoidance of ‘primer-dimers’
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where the oligonucleotide dimerise to itself or its partner primers reducing the 
amount of available primer within the reaction. The primer software also allows 
prediction of the PCR product size and highlights particular areas of non-specific 
binding providing the sequence of the DNA template is available.
If a restriction site was necessary within a desired DNA product, the section 
“Cleavage close to the end of DNA fragments (oligonucleotides)”, the reference 
appendix of the 96/97 NEB catalogue, was consulted to ensure that oligonucleotides 
were designed to produce PCR fragments that would restrict satisfactorily.
2.2.10 Automated DNA sequencing - Fluorescent DyeDeoxy terminator 
method
For automated sequencing, 300-500ng of double-stranded DNA or 30-90ng of PCR
product DNA was required. Any DNA sequenced was routinely purified by
extraction from LMP agarose gel. 3.2 pmol of HPLC purified primer was added to
a 0.2ml thin-walled tube containing the DNA and the volume made up to 12 pi with
Milli-Q water. The samples were sequenced on a 377 DNA Sequencer ABI Prism
(Perkin-Elmer) using the fluorescent dye terminator method at the Automated DNA
Sequencing Service, School of Biology and Biochemistry, Bath University. The
primer concentration was determined using the following formula:
pmol  __________ 100(A260)__________
jul (l.54nA + 0.75«C + UlnG + 0.92nT)
[n = number of A, C, G or 7]
All DNA sequences were checked against the sequence chromatograph to ensure 
that each base had been correctly identified and ‘called’ by the sequencing software.
2.2.11 Manual DNA sequencing - Sanger Coulson Protocol
Manual DNA sequencing [Sanger at al., 1977] was performed using the Sequenase
kit v.2.0 (US Biochemicals, Cleveland, USA) based upon the manufacturer’s 
modified protocol. The two sequencing plates were soaked in 5M KOH overnight, 
washed with water and polished with absolute ethanol. 1.2ml of 10% v/v acetic 
acid, 25ml of absolute ethanol, 200pl of silane A-174 adhesion promoter were
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mixed and carefully poured over the backplate. After 5 minutes the backplate was 
washed with water and polished with absolute ethanol.
Using a tissue, 5ml of dimethydichlorosilane solution was carefully wiped onto the 
surface of the notched sequencing plate. The plate was allowed to dry for 5 
minutes, rinsed off with distilled water and dried. Spacers were placed between the 
edges of the two plates and the plates taped together with extra tape at the bottom of 
the plates to ensure a good seal.
The gel matrix was prepared by mixing 25g Urea, 15ml Milli-Q water, 10ml 40% 
fo's-acrylamide (AccuGel) and 5ml lOx TBE (890mM Tris-borate, 890mM Boric 
acid, 20mM EDTA). The mixture was dissolved by warming at 37°C and 300pl 
ammonium persulphate (APS) (lOOmg/ml) added. 30pl N,N,N’,N’,- 
tetramethylethylene-diamine (TEMED) was added, the solution mixed and poured 
into the prepared plates. The reverse edge of the sequencing comb was placed into 
the notched section of the plates and bulldog clips applied at various positions over 
the plates to apply pressure to the setting gel.
lpl of 5M NaOH was added to 5pg of double stranded DNA to separate the DNA 
and the volume made up to 15 pi with water. After 5 minutes incubation at room 
temperature the DNA was passed through a MicroSpin S-200 column (Pharmacia) 
and the recovered DNA temporarily stored on ice to prevent re-annealing. 7pi of 
the DNA solution was mixed with 2pl of Reaction buffer and lpl primer 
(lOpmol/ pi). This template mixture was heated to 65°C for 5 minutes and allowed 
to cool to room temperature for 30 minutes, then stored on ice for up to 4 hours. 
Four 1.5ml Eppendorf tubes were labelled A, T, G, C. 2.5 pi of the appropriate 
ddATP, ddTTP, ddGTP, ddCTP were dispensed into the tubes respectively and the 
tubes incubated at 37°C until required. 1 pi of labelling mix was added to 4pl Milli- 
Q water and stored on ice. 0.5pl of DNA polymerase was mixed with 3.5pl of 
enzyme dilution buffer.
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lpl DTT, 2 j l x 1 of diluted labelling mix, 0.5pl a-35S dATP (1200pCi) and 2fj,l DNA 
polymerase were added to the template mixture and incubated at room temperature 
for 5 minutes. 3.5pl of this mixture was added to each of the labelled tubes and 
incubated at 37°C for 5 minutes after which 4 pi of Stop solution was added. The 
tubes were incubated at 75°C for 5 minutes before loading onto the gel.
The tape at the base of the gel was slit, the comb removed and the plate fixed into 
the sequencing apparatus. The top and bottom of the plates were immersed in TBE 
and the gel pre-warmed at 45 watts, 1700 volts for 30’, purging the gel occasionally 
to remove excess urea build-up. The toothed edge of the comb was carefully 
inserted 2mm into the gel to form the wells and sequencing samples loaded in A, C, 
G, T order. The gel was run at 45 watts, 1700 volts for 4 hours or until the lower 
sequencing dye neared the base of the gel.
The gel was removed from the sequencing apparatus and the tape removed. The 
plates were carefully prised apart and the sequencing gel attached to the back plate 
was soaked in 1 litre 10% v/v methanol, 10% v/v acetic acid for 5 minutes. The gel 
was dried onto the plate in an 80°C oven for 30 minutes after which the radio-label 
was measured using a Geiger counter to verify that the procedure had worked. In a 
darkroom, autoradiography film was applied to the dried gel and allowed 
approximately 48 hours to expose. Finally film was processed in an automatic 
autoradiography processor and the sequence read.
2.2.12 Radioactive labelling of DNA
PCR extension products were radiolabelled to observe restriction enzyme efficacy 
by the addition of [y-32P] to their 5’ termini. 10 pmoles of DNA was mixed with 2pi 
lOx polynucleotide kinase buffer (700mM Tris-HCl pH 7.6, lOOmM MgCl2, 50mM 
DTT, 20 pmoles of y-32P (>5000Ci/mole), 1 unit of T4 polynucleotide kinase (10 
U/pl) and made up to a total volume 20pl with Milli-Q water. The mixture was 
heated to 70°C for 5 minutes to separate strands, briefly chilled on ice and incubated 
at 37°C for 30 minutes. The reaction was stopped by inactivation of the enzyme at
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65°C for 20 minutes. Incorporation of radiolabel was approximately 60% that gave 
the labelled DNA an activity of between 107-108 cpm/pg.
2.2.13 SDS-PAGE Protein electrophoresis
Proteins were analysed by electrophoresis through a sodium dodecyl sulphate 
polyacrylamide matrix (SDS-PAGE). A 12% w/v resolving gel was prepared by 
mixing 4ml 30% w/v bis-acrylamide solution (ProtoGel) with 3.40ml H20 and 1.5M 
Tris-HCl pH8.8. lOOpl of 10% w/v SDS, 40pl of 25% w/v ammonium 
peroxodisulphate (AMPS) and 4ul of TEMED were mixed. 3.5ml of the mixture 
was poured into the vertical plates of the Mini-Protean II system (Bio-Rad, Herts., 
UK). 300pl of water was carefully added to ensure a smooth interface between the 
stacking and resolving gel and the gel allowed to set. A 6% w/v stacking gel was 
prepared by mixing 1.7ml 30% w/v frw-acrylamide solution with 6.7ml H20, 1.25ml 
1M Tris pH6.8, lOOpl 10% w/v SDS and 40pl 25% w/v AMPS. 10pl of TEMED 
was added and the mixture poured onto the resolving gel, a comb inserted and the 
gel allowed to set. Samples were mixed with loading solution (50mM Tris-HCl, 
pH6.8, 25% v/v glycerol, 0.1% w/v bromophenol blue, 6% w/v SDS, 4% v/v [3- 
mercaptoethanol) at a ratio of at 5:1 (sampleiloading solution). Electrophoresis was 
performed in tank buffer (250mM Tris-HCl pH 8.3, 192mM glycine, 0.1% w/v 
SDS) at 200V until the bromophenol dye passed to the bottom of the gel. Proteins 
were stained by submerging the gel in Coomassie dye solution (0.1% w/v 
Coomassie Brilliant Blue R250, 50% v/v methanol, 10% v/v acetic acid) for 2-3 
hours and destained in destain solution (10% v/v methanol, 10% v/v acetic acid) for 
1-2 hours. A silver staining kit (Bio-Rad) was used when high sensitivity was 
required, (lower detection 0.1ng/mm2), following the manufacturers instructions. 
Stained gels were wrapped in cellulose film (BIO-RAD) and dried under vacuum at 
60°C.
2.2.14 HRP Western blotting
Six pieces of 3MM filter paper (Whatmann) and one piece of Nitrocellulose 
Hybond-C membrane (Amersham, Bucks., UK) were carefully cut to the size of the
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mini-gel and soaked in 100ml transfer buffer (39mM glycine, 48mM Tris-HCl pH 
8.3, 0.037% w/v SDS, 20% v/v methanol) for 10 minutes. Three pieces of the filter 
paper were placed onto the blotting apparatus, 2117 Multiphore II Electrophoresis 
unit (LKB Bromma). The nitro-cellulose paper was placed on top of the blotting 
paper and the mini-gel onto the nitro-cellulose paper. The remaining pieces of the 
blotting paper were placed on top and any overlapping paper larger than the gel 
removed with a razor blade. Electrophoresis was performed at 80mA, 10 volts for 
30-40 minutes for one blot or at 160mA for two.
After blotting, the nitro-cellulose was removed and washed briefly in phosphate 
buffered saline (PBS) and blocked in 30ml PBS, 2% w/v non-fat dried milk 
(Marvel) for 1 hour at room temperature. The membrane was twice washed with 
30ml PBS for 3 minutes and immersed in 30ml PBS/Milk containing 0.1% v/v 
primary antibody and incubated at 4°C overnight. Excess antibody was removed by 
washing twice in 30 ml PBS, 0.05% Tween-20 for 3 minutes and twice in 30ml 
PBS for 3 minutes. 30ml PBS/Milk containing 0.1% v/v secondary antibody 
(conjugated to horse radish peroxidase HRP) was added to the membrane and 
incubated in for 40 minutes at room temperature. Finally the membrane was washed 
twice in 30ml PBS/Tween for 3 minutes followed by two 3 minute washes in 30ml 
PBS.
The antigen-antibody complex was located by immersing the membrane in 60ml 
HRP developing solution (0.3% w/v 4-chloro-l-naphthol, 8mM Tris-HCl pH 7.5, 
125mM NaCl, 0.015% v/v H20 2) and fixed in water.
45
CHAPTER 2 STANDARD MA TERIALS AND METHODS
2.3 MICROBIOLOGICAL TECHNIQUES
2.3.1 Small scale preparation of plasmid DNA
Small quantities (<5mg) of pure plasmid DNA were obtained using a Miniprep 
SNAP kit (In-Vitrogen). This plasmid DNA was of a suitable standard for reliable 
DNA sequencing. The procedure recommended by the manufacturer was followed 
exactly.
2.3.2 Medium scale preparation of plasmid DNA
Medium sized preparations (10-25mg) of plasmid DNA were obtained using the a 
Maxiprep kit. The method recommended by the manufacturers (Promega) was 
followed exactly.
2.3.3 Large scale preparation of plasmid DNA
This procedure was performed to obtain between 25-100mg of plasmid DNA. 
150ml of 2xYT containing the appropriate antibiotic and 2% w/v glucose was 
inoculated with a bacterial plaque containing the desired plasmid. The culture was 
grown at 37°C, 250 RPM overnight in a shaker incubator. The cells were harvested 
at 7,500 x g for 15 minutes and the pellet resuspended in 50ml STE (lOOmM NaCl, 
lOmM Tris-HCl pH 8.0, ImM EDTA) and centrifuged again at 7,500 x g for 15 
minutes. The pellet was resuspended in 9 ml of solution I (50mM glucose, 25mM 
Tris-HCl pH 8.0), 1ml of fresh lysozyme (lOmg/ml) and the suspension gently 
mixed for 2 minutes. 20ml of solution II (0.2N NaOH, 1% w/v SDS) was added, 
the suspension gently mixed and incubated at room temperature for 10 minutes. 
10ml of ice-cold solution III (4M potassium acetate pH 5.5, 11.5% v/v acetic acid) 
was added to the flask and the mixture inverted several times and incubated on ice 
for 10 minutes.
The lysed cells were centrifuged at 6,000 x g for 15 minutes (no brake to disturb the 
pellet). The supernatant was filtered through gauze into a clean flask. 0.6 volumes 
of isopropanol was added to the solution and left to incubate at room temperature
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for 10 minutes. The solution was centrifuged at 6,500 x g for 15 minutes at room 
temperature, the supernatant discarded and the precipitated DNA allowed to air dry. 
The pellet was resuspended in 2ml TE buffer (lOmM Tris-HCl pH 8.0, ImM 
EDTA). 2ml of 6M LiCl was added and the solution incubated on ice for 10 
minutes followed by centrifugation at 8,000 x g at 4°C for 10 minutes. The 
supernatant was decanted to a sterile tube and the DNA ethanol precipitated (2.2.x). 
The DNA pellet was resuspended in 1ml TE buffer and 10pl RNase (lOmg/ml in 
lOmM Tris-HCl pH 7.5, 15mM NaCl) was added and incubated at 37°C for one 
hour. The RNase was inactivated by incubation at 75°C for 10 minutes. The DNA 
was ethanol precipitated and resuspended in 0.5ml TE buffer.
2.3.4 Preparation of competent cells
50ml of bacterial culture was grown in LB to mid-log phase (A550 = 0.4) at 37°C in a 
shaking incubator (250 RPM). The culture was centrifuged at 3500 x g for 10 
minutes and the supernatant discarded. The cell pellet was resuspended in 5ml ice- 
cold sterile 50mM CaCl2, lOmM Tris-HCl pH 8.0 and placed on ice for 15 minutes 
to become competent. The cells were again centrifuged at 3500 x g for 5 minutes 
and the cell pellet resuspended in 15ml 50mM CaCl2, lOmM Tris-HCl (pH 8.0), 
15% (v/v) glycerol. The cells were then aliquoted in volumes of 250pl in pre­
cooled eppendorfs and then snap frozen in an acetone/dry ice bath. The cells were 
stored at -70°C.
2.3.5 Transformation of DNA by Heat Shock
A 50pl aliquot of competent cells was mixed with approximately 25ng of the DNA 
to be transformed in a pre-chilled 1.5ml Eppendorf tube. The mixture was 
incubated on ice for 30-60 minutes after which it was heated in a water bath at 42°C 
for exactly 2 minutes then chilled on ice for 2 minutes. 750ml of LB media was 
added and the cells allowed to recover for 45 minutes at 37°C. After recovery the 
cells were centrifuged at 5,000 x g and the pellet resuspended in 50pl of LB media. 
The cells were plated onto LB agarose plates containing appropriate antibiotic and 
2% w/v glucose and allowed to incubate at 37°C overnight.
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2.3.6 In-well screening for recombinant plasmids
Recombinant plasmids were identified using an Epicentre Screening Kit based upon 
the protocol of Sekar, V. (1987). This is based upon differential migration of 
supercoiled plasmids that may or may not contain an inserted fragment. Therefore 
the inserts must be of a sufficient size to allow for visual discrimination (i.e. 
>100bp). A 1% agarose gel was prepared containing sufficient wells for the 
number of colonies screened. Once the gel was prepared, 15ml of Protoplast buffer 
was added to a number of microtitre wells in accordance to the number of colonies 
screened. Each colony, at least 2-3mm in diameter, was removed using a sterile 
toothpick and vigorously mixed into the protoplast buffer in the well. When 
completed the microtitre plate was incubated at room temperature for 10 minutes to 
allow protoplast formation. While the cells were incubating, 6ml of lysis buffer 
was pipetted into an appropriate number of wells of the agarose gel. The cell 
protoplast mixture was added to the lysis filled wells and allowed to incubate for 15 
minutes. Before electrophoresing, molecular weight markers and a sample of 
supercoiled plasmid not containing any insert were loaded onto the gel. Sample 
containing the insert migrated more slowly than the control plasmid that contained 
no insert.
2.3.7 PCR screening for recombinant plasmids
If the size of the insert was insufficient or the plasmid used was not wild-type, PCR 
screening of cell plaques was used. A toothpick was used to pick E. coli plaques 
from the plate and were transferred into 20pl of sterile H20. The cells were 
incubated at 94°C for 10 minutes to lyse the cells, after which lpl was taken and 
added to the following reaction mixture: 2pl of xlO stock dNTP (300m), 2pi of lOx 
Thermopol buffer (lOOmM KC1, 200mM Tris-HCl pH 8.8, lOOmM (NH4)2S04, 
0.1% Triton X-100), 0.2pl of BSA (lOmg/ml), 12.55pl H20 and 0.25pl of Taq DNA 
polymerase (5 U/pl) were added to 0.2ml thin-walled tubes. The PCR cycle used 
was dependant of the oligonucleotide primers used for screening. 5pi of the 
reaction product was analysed on a 1% agarose gel.
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2.3.8 Maintenance of bacterial strains and plasmids
Stocks of bacterial strains and in situ plasmids were prepared for long term storage 
at -70°C by mixing 800pl of a fresh overnight culture with 200pl sterile 80% v/v 
glycerol followed by snap freezing in dry ice. Short term storage strains were 
plated out onto LB agarose plates, (containing 2% w/v glucose + antibiotic), sealed 
with Nescofilm and stored in the dark at 4°C.
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CHAPTER 3
3 MOLECULAR MODELLING OF 20G9 FV
3.1 INTRODUCTION
The aim of this thesis is to take a rational approach to altering the active site of the 
catalytic antibody 20G9 guided by a model of the combining site. Rational 
alterations are known as protein engineering. Protein engineering involves 
mutating the gene of an existing protein in an attempt to change its structure or 
function in a predictable way. To make alterations based simply upon the primary 
sequence of a given protein is hopelessly simplistic. Protein engineers have 
frequently been surprised at the range of effects upon a protein’s structure and 
function caused by a simple point mutation when the aim was to change a specific 
function or property. Protein engineering must take into account the rules of protein 
stability and the energetics of catalysis. However, the speed of structural 
elucidation is slow when compared to the relatively rapid mutagenesis experiments. 
Solving the structure of an antibody generally takes up to three years including 
expression, biochemical characterisation, purification and crystallisation. 
Ultimately the protein may not even produce crystals satisfactory for X-ray studies. 
Thus structural elucidation is the rate determining factor in the turnover of the 
protein engineering cycle [Blundell and Sternberg, 1985]. An alternative method to 
crystallography is NMR, a considerably more rapid method of structure 
determination but is currently limited by an upper molecule size limit of 
approximately 30kDa where high-resolution structural information is required. This 
has forced the rapid evolution of molecular modelling methods capable of rapidly 
producing a structure but which is still very much prediction and therefore subject 
to program design errors.
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3.1.1 Homology modelling
Predicting protein folding is difficult because of the enormous task of searching 
through all the possible conformations of a polypeptide chain to find those with the 
lowest energy. This can be reduced by taking account of sequence homology. X- 
ray crystallographic studies of protein families have demonstrated that proteins with 
homologous sequences also have similar folds. This provides the basis for 
homology modelling [Browne et al, 1969]. The first step in homology modelling 
was the alignment of known sequences for a family of proteins containing gaps in 
the sequence [Needleman and Wunsch, 1970]. Extensive alignment allowed 
structurally conserved regions (SCR’s) and variable regions (VR’s) to be assigned. 
It is thought that SCR’s are usually located in the protein core and can be predicted 
with relative confidence whereas the VR’s are generally surface located and are 
much harder to predict. Because VR regions have a poorly defined secondary 
structure they pose one of the main obstacles in predicting the folding of variable 
fragments of antibodies.
3.1.2 Modelling antibody combining sites
Padlan and Davies were the first to attempt modelling of antibody combining sites 
[Padlan et al., 1976] when relatively few antibody structures were known. 
Recognising that the SCR’s that lay within the P-sheet framework regions of 
antibody variable domains were relatively easy to model by homology, Padlan 
reasoned that the CDRs could possibly be modelled in the same way based upon 
other antibody CDR structures. This was further developed by Rees when more 
antibody structures became available [Darsley and Rees, 1985; de la Paz et al, 
1986]. In 1986 Chothia & Lesk introduced the knowledge based concept of “key” 
residues [Chothia et al., 1986] using a crystallographic database of antibodies. 
These ‘key’ conserved residues are defined by their packing, hydrogen bonding and 
ability to assume unusual 'P, § and go torsional conformations and are thought to be 
responsible for the main conformations of the hypervariable regions. This allowed 
a classification of CDRs of similar lengths into a series of “canonical” structures. 
The canonical structure approach has succeeded in modelling five of the six CDRs 
(LI, L2, L3, HI, H2). However CDR H3 doesn’t fit into a canonical class due to
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the loops greater variability in sequence, length and structure in comparison to the 
other CDRs. This is due to the fact that the H3 CDR gene sequences are situated at 
the position where the J and D segments join. In addition, the residues coded at the 
beginning of the JH genes may not even be present in the final structure. This 
variability is compounded by somatic diversity resulting in a loop that varies greatly 
in both composition and size when compared to the other five CDRs making 
prediction much more difficult but not impossible [Chothia and Lesk, 1987].
3.1.3 Antibody topology and composition
There are three shape classes which describe the overall topography of the antibody 
combining site based upon antibody x-ray crystallographic structures: i) cavity 
antibodies ii) groove antibodies iii) planar antibodies [Wang et al., 1991; Webster et 
al, 1994]. The topography type is thought to be connected to the type of antigen. 
Smaller antigens have been associated with cavity antibodies [Rini et al., 1992] and 
are buried in a hydrophobic pocket in the combining site. Larger antigens appear to 
bind over a much greater surface [Sheriff et al., 1987] forming many interactions 
and are generally associated with planar or groove antibodies. Peptides or larger 
haptens generally result in groove antibodies.
Differences between the sidechain compositions of framework and CDRs are 
commonly observed. Studies have shown [Mian et al., 1991; Padlan, 1990] that 
CDR sidechains are generally more exposed than of those in the framework and that 
there are more bifunctional residues such as His, Tyr or Asn in the CDRs. This 
contributes hydrophobic character to the loops as well as increasing their ability to 
engage in hydrogen bonding. Furthermore there is a high frequency of exposed 
hydrophobic residues. It is thought that these hydrophobic sidechains are involved 
in antigen binding whereas the charged sidechains mainly account for antigen 
specificity [Colman, 1988].
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3.2 ANTIBODY MODELLER, A COMBINED ALGORITHM
The immunoglobulin domain modelling program, AbM, uses a Combined 
Antibody Modelling Algorithm or CAMAL. The undertaking of producing an 
antibody model is approached by reducing the problem into a series of smaller 
tasks [Martin et al., 1989, Pedersen et al, 1992]. Each task can then be 
systematically tackled applying the appropriate method from a panel of options.
3.2.1 Building the framework
Antibody framework regions consist of conserved sequences that form P-barrel 
structures. The antibody model begins with the building of a framework starting 
with sequence entry by the user. This sequence is aligned against a databank of 
heavy and light chain antibody sequences of known structure. Alignment is 
achieved by inserting gaps until the sequences are all of same length. As 
framework regions of antibodies are highly conserved, alignment is usually easy. 
The program compares light and heavy chains against the sequences within the 
database. A similarity calculation is performed to find the database sequence 
that most closely matches the conserved framework regions of the target 
sequence. Gaps in the aligned sequence that are paired with conserved 
framework residues are very heavily penalised by the calculation. Finally a 
candidate framework for the model is proposed based upon the scores.
The antibody structure database used by AbM contains files of the co-ordinates 
and pre-aligned sequences of the light and heavy chains of known antibodies. 
The contents are a selection of full and pre-release Brookhaven Protein 
Databank structures solved to a high resolution. Sequences in the database have 
been pre-aligned to help maximise sequence identity and to reflect regions of 
most structural variation. In addition, it contains average co-ordinates from 
known antibody structures and are representative of the most highly conserved 
residues of the p-barrel. This “core” p-barrel is used as a template onto which 
the selected sequence is fitted.
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3.2.2 Construction of CDR loops
CDR loops of the target sequence are examined against canonical sequence 
patterns of a database. This allows assignment of a canonical class for each 
loop. Once classified the target loop is assessed for similarity towards antibody 
database loops belonging to the same class. Those loops with greatest homology 
are then used to the model the target loop. This is only applied to the three light 
chain loops, (LI, L2, L3) and the two heavy chain loops, (HI and H2) as no 
canonical classes currently exist for the H3 loop.
Any loops of CDRs LI-3 and H I-2 that do not belong to a canonical class are 
constructed using CAMAL. The build method of non-canonical loops is 
decided based upon the number of residues within it. A loop of up to three 
residues is built by conformational searching whereas loops of between four and 
seven residues are built by Coe database searching. Loops with greater than 
seven residues are built using a combination of conformational and Cot database 
searching.
Conformational and Ca database searches. Conformational searching is 
performed on loops with three or less residues, as computational time increases 
exponentially with the length of the loop. Using the conformational search 
algorithm, CONGEN [Bruccoleri and Karplus, 1987], a series of candidate 
backbone conformations are produced. CONGEN achieves this by saturation of 
available conformational space by rotation about the <|),i|/ and co torsion angles 
under restrictions based upon a form of the Ramachandran plot [Ramachandran 
et al., 1963]. This plot provides a range of torsion angles to which amino acids 
are normally restricted by a specific energy threshold. This allows elimination 
of energetically disfavoured structures and backbone torsion’s that do not exist 
naturally. Side chains are generated around all possible % angles and those 
sidechains with the lowest energy level recorded. This is repeated for each side 
chain beginning with the N-terminus residue until a constant energy level is
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reached. The energy levels of each completed loop are filtered using Eureka 
with loops of lowest energy subsequently added to the working model. Eureka 
is a force field used for energy determination [Dauber-Osgusthorpe et al., 1988] 
of peptides and proteins.
Generation of loops of between four and seven residues in length is achieved by 
searching the Ca database. This database contains Ca-Ca distances and 
backbone angles derived from protein structures in the Brookhaven Protein 
Databank. It only contains proteins with greater than 20 bonded amino-acids 
containing well defined Ca-Ca distances at resolutions of 3A or better. The 
target loops are selected upon Ca distances and have side chains added using 
CONGEN. Each candidate loop is added to the working model in turn. Five 
working models are created with each containing one of the five loops found to 
have the lowest energy. A Structurally Determining Residue (SDR) Filtering 
method [Sutcliffe, 1988] is applied to each of the working models to assess their 
resemblance to the database loops and preference of loop geometry found within 
nature.
Loops with greater than seven residues are generated using a combination of 
conformational and Ca database searching. The basic loop backgrounds are 
usually found by searching the Ca database but with reduced hits due to the 
large loop size. The basic loop backbone is positioned onto the model and the 
top 5 residues of the loop deleted and reconstructed using CONGEN. This 
allows saturation of the conformational space available to each segment by 
varying the T7 and <j> torsion angles on a grid. The resulting loop structure has its 
base residues derived from the protein structure database and those at the top 
based upon saturation of conformational space. Side chains are added using 
CONGEN and the loop screened using SDR filtering.
3.2.3 Assessment and minimisation of the model
Once a basic model has been produced there follows a process of objective 
evaluation and minimisation. No minimisation is applied during the building of
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the basic model as this requires much computational time for calculations with 
relatively little observed benefit. As the framework is directly derived from 
crystal co-ordinates it is relatively accurate and so it’s more effective to assess 
and minimise the whole model after construction. However the loop 
backgrounds, especially those constructed by non-canonical methods and the 
side chains are less accurate and so minimisation is an important in refinement 
of the model.
3.3 PRODUCING THE 20G9 MODEL
3.3.1 Sequence entry
The sequence of the light and heavy variable regions were aligned into Kabat 
[Kabat et al., 1991] format before entry into AbM (Figure 4.3). This simplified the 
manual alignment step to the displayed Fv sequences within AbM.
On execution of AbM, the algorithms described above process the sequences. The 
model of the Fv is produced in the form of a PDB (Protein Data Bank) file, which 
contains structural information of the model. It contains the sequence number of 
each atom, the atom type, the type of residue of which it is part, the sequence 
number of the residue and the x, y, z co-ordinates of the atom within the whole 
structure (Figure 3.1). These files can be displayed using software of various 
complexities, enabling the display of different image forms based upon the same 
data, i.e. RasMol (Sayle, R. GlaxoWellcome R&D, Greenford, UK), Insight 
(Biosym Technologies, San Diego, USA), MolViewer [Hartshorn, 1996] or 
MolScript [Kraulis, 1991]. The benefits of this are that various software packages 
have features useful for different tasks. Some enable the user to rapidly examine 
the structure without too great a drain on the computer processor, while others allow 
production of images suitable for publication but far too complex to allow rapid 
‘hands-on’ on-screen rotation. The details of atoms and residues contained within 
the file are important and can be easily identified within the on-screen image by 
simply pointing and clicking at the point of interest. This allows rapid 
identification of specific residues that are potentially situated within important 
positions within a structure. The numbering scheme of the residues within the PDB
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file exists as a single string and are identified with a different numbering scheme to 
that o f the Kabat alignment (Figure 3.2).
SERIAL: the atom serial number
STRING: the atom name and type
RE S I DUE: the residue name for the entry (4 characters)
SEQUENCE: the entry sequence number
X Y Z: the atomic co-ordinates
ATOM 133 C TYR 28 - 1 .6 3 0 - 1 .4 2 3 0 .8 4 7
ATOM 134 O TYR 28 - 2 .9 4 1 2 .2 1 4 - 0 .9 2 5
ATOM 135 N TYR 28 - 0 .2 8 8 - 0 .1 3 3 0 .3 2 1
Figure 3.1 Each atom within the PDB file is numbered, labelled by atom type, the residue 
name to which the atom belongs, the residue number within the protein sequence and 3 
dimensional atomic co-ordinates. These data allow the file to be displayed using different 
pieces of software which utilise various aspects of the data contained within the file all 
based upon the details and co-ordinates given.
[ L I ]
DIVMTQAAPSVIVTPGESVSISC RSSKSLLHSYGNTYLY WFLQRPGQSPQVLIY 
I I I  I I I
1 10 20 30 40 50
[L2] [L3]
RMSNLAS GVPDRFSGSGSGTAFTLRISRVEADDVGVYYC MQYLEYPYT FGGGTKLELK
I I I I I I
60 70  80 90 100  110
[HI]
EVQLHEPGAALVRPGASVMLPCRASGYSFT SFWMN WVRQRPGQGLEWIG 
I I I  I I
120 130 140 150 160
[H 2]
RIHPSDNRTRLNQKFKD KATLTVDKSSSTAYMQLISPTSEDSEVYYCAR 




Figure 3.2 Continuous residue numbering of the 20G9Fv PDB file.
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AbM successfully produced a model of 20G9 Fv and was able to base the LI, L2, L3 
and HI, H2 loops upon known canonical structures within the search database. The 
H3 cannot be based upon a canonical class and so candidate loops were constructed 
by the use of the Ca database with sidechains added using CONGEN (Table 3.1).
Table 3.1 Canonical classification of 20G9 CDRs. Canonical loops existed for five of the 
six loops. However no canonical determinants are known for CDR H3 thus this loop was 
modelled using the Ca database and sidechains added using CONGEN.
CDR Sequence CDR Length Canonical class Modelling method
LI RSSKSLLHSYGNTYLY 16 4 canonical
L2 RMSNLAS 7 1 canonical
L3 MQYLEYPYT 9 1 canonical
HI SFWMN 5 1 canonical
H2 RIHPSDNRTR 10 3 canonical
H3 EGGAY 5 NA CONGEN
3.3.2 Examination of the 20G9 Fv model
The 20G9 Fv antibody binding site appears as a long groove containing a central 
cavity into which the hapten might bind (Figures 3.3 and 3.4). Small haptens 
conjugated to a large BSA molecule are often associated with antibodies that have a 
groove for their active site. Examination of the primary sequence and the model of 
20G9 show that the light variable chain has a high number of tyrosine residues 
while the heavy variable chain possesses relatively few.
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Figure 3.3 Molscript generated space filling model of 20G9 Fv generated by AbM. This 
side view displays a clear groove running through the combining site. Hydrophilic and 
hydrophobic patches are shown on the surface as red and blue respectively.
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Figure 3.4 Molscript generated space filling model of 20G9 Fv generated by AbM. The 
view down into the binding again clearly shows the groove running through the combining 
site. Hydrophilic and hydrophobic patches are shown on the surface as red and blue 
respectively.
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3.3.3 Targeting residues for mutation
Prediction of residues critical for binding and catalysis is a difficult task and must 
be based on structural evidence from the model, information from the kinetic 
characterisation of 20G9 and also on those residues commonly found in other 
catalytic antibodies. Previous kinetic studies on 20G9 implicated tyrosine 
involvement in binding and catalysis. This was in mind on examination of the 
model. At the time of the modelling, the latest mutagenic and crystallographic 
studies demonstrated critical residues in the active sites were frequently found to be 
tyrosine and arginine, again taken into account when selecting residues. The 
purpose of the model was to identify residues within the light and heavy chain 
CDR’s or fringes (Figures 3.5 and 3.6) with particular attention paid to tyrosine and 
arginine residues proximal to the putative active site. Rotation of the wireframe 
model of 20G9 was used to gauge the relative positions of the residues with respect 
to the groove. Non-tyrosine/arginine residues with a close proximity to the active 
site were also selected. The residues were then graded primary or secondary 
mutations depending on the likelihood of involvement, in order to determine into 
which wave of mutations they would fall (Figures 3.7 and 3.8).
In total, 12 residues were identified of which six were graded primary mutations 
(PDB/Kabat numbering): R164/H50Arg, R171/H56Arg, R173/H58Arg, Y96/L91Tyr, 
Y99/L94Tyr, Y101/L96Tyr. Residues selected for secondary mutations were: 
H166/H52aHis, D169/H54Asp, Y33/L28Tyr, Y37/L32Tyr, Y39/L34Tyr, Y54/L49Tyr. 
The tyrosine and the arginine residues were selected because of their common 
involvement in abyzme catalysis, although they were not immediately proximal to 
the binding site. The histidine and aspartate residues were selected because of their 
proximity to the binding site and their generally reactive nature (Figures 3.8 and 
3.9). A degree of flexibility was used when examining the residues on the model, 
selecting residues that were within a reasonable distance of the groove centre 
(approximately 15 A), even when their orientation may not have been ideal.
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Figure 3.5 Molviewer ribbon representation of 20G9 Fv model with residues selected for 
mutagenesis studies displayed as wireframe. The residues highlighted in green are those 
thought most likely to be involved within the active site of the molecule and were selected 
for the primary round of mutagenesis studies. The remaining residues displayed in grey 
were selected for the secondary round of site-directed mutagenesis and are thought less 
likely to play an active role within the catalytic site of 20G9.
Figure 3.6 An Insight II wire frame representation of the model of 20G9 Fv which was 
generated using AbM. The view is directly down into the combining site of the antibody 
fragment. Light chain CDRs are in red and heavy chain CDRs in yellow.
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Figure 3.7 This wire frame representation of 20G9 Fv was used to examine residues 
thought likely to have a role in binding. Residues selected for site-directed mutagenesis are 
indicated: primary mutations (highlighted white), secondary mutations (highlighted 
yellow).
Figure 3.8 Insight II wire frame representation of 20G9 Fv. The closer view allows 
identification of the white primary residues (L99, L96, L101,H164, H171,H173) and the 
yellow secondary residues (L33, L37, L39, L54, H166, H169, H213). [PDB numbering 
notation with a L or H denoting heavy or light chain]. *The residues H213 and L55 were 
marked in error and should not have been highlighted.
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3.4 DISCUSSION OF THE 20G9 MODEL
3.4.1 Integrity of the 20G9 Fv model
It is likely that the 20G9 Fv model is a good representation of the actual structure as 
its sequence presented no particularly difficult problems. Five of the six CDRs 
excluding H3 were selectable as canonical structures and as a result, their 
conformations should be good. The H3 loop is always the most difficult loop to 
model since it lacks a good canonical classification. The H3 loop of 20G9 consists 
of only 5 residues, making the task of modelling the loop relatively straightforward. 
Short H3 loops are generally modelled with accuracy’s of around 1.5A RMSD, 
sufficient to guide the present study [Rees et al, 1996].
3.4.2 Selection of residues
The final step was to identify residues that were part of or proximal to the active site 
of 20G9. These would then be mutated one by one to alanine, in an attempt to 
modify or eliminate activity. This will allow us to say with a degree of confidence 
that the selected residue is critical for catalysis. Initially, consideration was given to 
mutating the tyrosine residues to phenylalanine, to preserve the ring structure and 
thus minimise structural disruption. However, if the aromatic ring present in a 
given tyrosine was playing a role in ground state binding, or in product inhibition 
due to aromatic stacking, then this may not have been eliminated. The more radical 
mutation of tyrosine to alanine was selected to avoid any aromatic stacking effects. 
These experiments are described in the next chapter.
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4 SITE-DIRECTED MUTAGENESIS OF 20G9
4.1 INTRODUCTION
To understand the functions of genes and their cognate proteins it is valuable to 
have the means to alter them in some manner so that the mutated protein can be 
compared against the original protein. Before the existence of current molecular 
biology techniques, mutants were generated by treatment of organisms (e.g. 
bacteria) with mutagenic agents or with physical stress in order to modify the DNA. 
However, such crude methods had the disadvantage that even when phenotypic 
changes were observed, one could not be sure if this was due to changes in the gene 
of interest or to some other genetic or epigenetic event. In addition, even if the 
targeted gene was altered, the nature of the change (single/multiple base changes, 
deletion/insertion of DNA, etc) would often remain unknown. Today the isolation 
and study of single genes has become routine through continual progress in 
mutagenic techniques. Previously, mutagenesis was a major task requiring many 
DNA manipulations to create or eliminate restriction sites in order to alter a gene. It 
is now relatively simple to alter a specific base in a DNA sequence and 
consequently mutagenesis has become an important basic tool in genetic 
manipulation.
4.1.1 Single oligonucleotide mutagenesis
Site-directed mutagenesis can be carried out using the single oligonucleotide 
method [Gillam et al., 1980; Zoller & Smith, 1983]. This method uses a single 
chemically synthesised oligonucleotide carrying a base mismatch towards the 
complementary sequence. The DNA sequence that is to be mutated must exist in a 
single stranded form which can be achieved using M13-based vectors or by 
denaturing double stranded into single stranded molecules. The oligonucleotide 
primes DNA synthesis and becomes incorporated into the resulting heteroduplex
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molecule with one strand for the wild-type sequence and the other coding for the 
mutant. On transformation, the heteroduplex molecule separates into a homoduplex 
molecule and the resulting plaques contain a mix of wild type and mutant plasmids. 
Often the ratio of mutants to wild type is low due to the methyl-directed mismatch 
repair system of E. coli. Bacteria attempt to repair the non-methylated DNA of the 
mutant that is paired with the complementary sequence of the wild-type thus 
preventing mutations [Kramer et al. 1984a). In order to prevent this, the host strain 
must carry the gene mutations, mutL, mutS or mutH within its genotype, which 
prevent methyl-directed repair of mismatches.
To enhance selection of plaques containing the mutant plasmid, many commercial 
methods have been developed using antibiotic selection to select mutants. The 
single primer method described above is employed by the Altered Sites II site- 
directed mutagenesis system (Promega). The system uses a vector, pALTER-1 that 
carries an inactivated ampicillin resistance gene. The gene of interest is cloned into 
the vector and the plasmid double stranded DNA on exposure to alkaline conditions 
separates into single stranded DNA. The mutagenenic oligonucleotide and 
ampicillin resistance repair oligonucleotide primers are annealed to one of the 
strands, the ‘template’. The primed template forms the mutant strand by the 
addition of DNA polymerase/DNA ligase. The double stranded construct must be 
transformed into modified E. coli bacterial strain (e.g. mutS) to prevent repair. 
Ampicillin selection allows the survival of only those bacteria transformed with the 
mutant plasmid carrying the repaired ampicillin gene. The mutated sequence is then 
restricted from the pALTER-1 vector and ligated into an appropriate expression 
vector. When using this method it is critical that the oligonucleotide carrying the 
mutant mismatch anneals and primes well against the template. The ampicillin 
gene repair oligonucleotide provided with the system normally anneals and primes 
efficiently regardless of the efficacy of other oligonucleotides. Subsequently, a 
double stranded construct with antibiotic resistance will be positively selected but 
may carry the wild type gene if the mutant oligonucleotide fails to bind to the 
template.
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4.1.2 PCR Mutagenesis
PCR is commonly used for analysis of DNA sequences but is equally useful for in 
vitro synthesis of DNA. The technique when used in a controlled manner can 
produce specific alterations within amplified DNA by the intelligent use of 
oligonucleotide primers. The 5’-end of the oligonucleotide can be designed to 
encode any sequence provided the 3’-end of the oligonucleotide contains sufficient 
complementary DNA to effectively bind the template. During the PCR 
amplification process, oligonucleotides can then be incorporated into the product 
DNA. This allows the production of chimeric DNA that carries the sequence of the 
template DNA centrally but with the designed DNA at the end(s). This allows site- 
directed mutagenesis to be rapidly and easily performed on the target DNA, [Scharf 
et al. 1986].
If mutations are desired within the centre of the DNA product, this can be achieved 
by the design and production of long primer oligonucleotides reaching into the 
middle of the fragment to be mutated. This has the drawback of high cost of 
lengthy oligonculeotides and the greater chance of the introduction of wrong 
nucleotides into the oligonucleotide during its production, (the longer the priming 
oligonucleotide, the greater the chance of PCR errors occuring). This can be 
overcome by using the overlap extension method. This allows mutations to be 
introduced in the centre of DNA fragments by designing oligonucleotides so that 
PCR amplified products overlap with other PCR amplified products. A subsequent 
reaction can be performed with the overlap priming for extension from which DNA 
polymerase creates the entire recombinant molecule (Figure 4.1), [Higuchi et al., 
1988; Ho et al., 1989). This method superseded the DNA ligase method of fusing 
together two DNA fragments and can be applied to produce specific changes, 
insertions and deletions within fragments of DNA. Mutagenesis by overlap 
extension is achieved by introducing bases changes into the oligonucleotides where 
the two PCR products overlap. It is entirely possible to introduce the base changes 
into one oligonucleotide only but this may cause a potentially difficult extension 
reaction to become impossible. Only by designing two oligonucleotides that are 
entirely complementary on the overlap and of sufficient length will the extension 
reaction become optimal (Figure 4.2). Using PCR overlap extension for
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mutagenesis represents a significant improvement over the single-oligonucleotide 
vector systems described above due mainly to its efficiency and simplicity. 
Relatively few steps are required to produce mutant inserts that can be sequenced to 
eliminate undesired mutations. Once satisfied that there are no errors (by 
sequencing the PCR product), the insert may be ligated into the vector, eliminating 
the necessity of screening for mutant constructs.
two separate PCR products
designed
sequence
5' ^  5' overlap
3’VC......................  non-productive
▼
V  ...........................................3' overlap
...........................  /  productive
Figure 4.1 Diagram of PCR overlap extension. Two separate DNA fragments can be 
combined if a sequence overlap exists between the two fragments. These overlaps will 
prime for extension of DNA when DNA polymerase is added resulting in the production of 
a single recombinant molecule. This technique can be used to introduce changes anywhere 
within a DNA sequence through the careful design of oligonucleotides.
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Figure 4.2 Site-directed mutagenesis by overlap extension. Two separate reactions are 
performed. PCR#1 contains oligonucleotide A and B and PCR#2 contains oligonucleotide 
C and D with each reaction incorporating a mutagenic oligonucleotide. Once completed, 
the PCR products are cleaned and placed into a third reaction containing the two end 
oligonucleotides (A & D) that were used in the first round of reactions. Overlap extension 
of the products occurs and the recombinant molecule is amplified using oligonucleotides A 
& D. These two oligonucleotides may be used to introduce restriction sites into the 
recombinant molecule.
69
CHAPTER 4 SITE-DIRECTED MUTA GENESIS OF 20G9
It is critical to sequence all PCR generated products as errors can be introduced 
during the PCR process. The two main factors that introduce errors are:
i) the number of PCR cycles
ii) the polymerase used.
Misincorporations early in the amplification cycle result in propagation of that error 
through subsequent cycles. This DNA would represent a significant portion of the 
final product and would probably be cloned into the vector. This problem cannot be 
eradicated but can be minimised. By adding more target template to the reaction, 
the number of cycles necessary to produce the required quantity of product is 
reduced thus reducing the opportunity for error.
The different DNA polymerases used in PCR vary in their capacity to introduce 
errors into products (Table. 4.1). The fidelity of a polymerase is directly 
proportional to its cost, with those more prone to errors found at the lower end of 
the market. For site-directed mutagenesis the highest fidelity polymerases available 
are Vent DNA polymerase (NEB) and Expand polymerase (Boehringer-Mannheim, 
Mannheim, Germany). Their low error rates are due to a 3’-5’ proof-reading 
exonuclease property. Each base is checked against the template, which ensures 
that no misincorporations are retained, but excised as detected. This results in an 
error rate of 5.7 x 10'5 compared to that of the commonly use Taq DNA polymerase 
which has a rate of 2.8 x 10'4. A common drawback with Vent polymerase is that 
PCR is highly sensitive to reaction conditions and many reactions fail to produce 
product or produce poor product due to non-specific binding resulting in heavy 
smearing. Careful design of oligonucleotides and optimisation of reaction 
conditions are necessary if a product of acceptable standard is to be produced.
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Taq DNA  
Polymerase
Error Rate(xl0'6) 57 65 8.5 <1 285
5’-3’ Polymerase + + + + +
3’-5’ Exonuclease + + + + -
Thermal stability + ++ + - +
Table 4.1 The fidelity of polymerase varies widely and is often dependent on the presence 
of proof-reading activity enabling the discovery, excision and replacement of 
misincorporated nucleotides. Relatively few polymerases are suitable for use in PCR with 
those used requiring heat stability of temperatures up to 100°C. (Figures obtained from 
Boehringer Mannheim and NEB data sheets).
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4.2 DESIGN OF OLIGONUCLEOTIDES FOR MUTAGENESIS
Mutation positions were selected using the 20G9 Fv model as a guide (Figure 4.3 & 
section 3.4.2). It was necessary to design oligonucleotides for use with PCR site- 
directed mutagenesis. This required the design of two complementary primers for 
each mutation in order to produce the upstream and downstream overlapping 
fragments for overlap extension.
v l (k)
1 10 20 24 2 7 a b c d e 2 8  34 35 40 49
I I I I I I I I I I I I I  I I




57 60 70 80 8 8  89 9 7 9 8 1 0 0  107
I I  I I I I  I I I  I
GVPDRFSG SG SG TAFTLRISRVEADDVG VYYC MQYLEYPYT FGGGTKLELK
1 10 20 3 0 3 1  3 5 3 6  40 49
I I I I I I I I I
EVQLHEPGAALVRPGASVM LPCRASGYSFT SFWMN WVRQRPGQGLEWIG
5 0 5 1  5 2 a  b  53 60 65 6 6  70 80
I I I I I I I I I  I
R I  H P SDNRTRLNQKFKD KATLTVD KSSSTAYM
8 2 a b c 8 3  90 94 95 96 100 101  102 103 112
I I I I I I I I  I I I I I  I
Q LIS P TS E D S E V Y Y C A R  E G G A Y WGQGTLVTVS
Figure 4.3 Mutation of residues based upon the 20G9 AbM model. 1° and 2° residues 
targeted for mutation are underlined. Residues are numbered using the Kabat [Kabate/ al., 
1991) numbering scheme.
The sequences of the VL and VH regions of 20G9 were entered into DNA Stryder 
vl.O (C. Merck, Dept, of Biology, Institute of Fundamental Research, Commission 
of Atomic Energy, France) and analysed for amino acid codon usage (Appendix).
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GCT was the dominant codon used for alanine residues within 20G9. Therefore the 
alanine mutants that were introduced into 20G9 used the codon GCT rather than 
GCC, GCA or GCG to maintain codon usage consistency within the gene. 
Oligonucleotides of approximately 21 nucleotides were designed to anneal at least 
nine bases on either side of the mutated codon. Each oligonucleotide was checked 
by using DNA Amplify (Bill Engels, University of Wisconsin, Genetics, Madison, 
WI 53706, USA) in order to eliminate any non-specific binding and avoid 
dimerisation of the oligonucleotides to themselves or any partner oligonucleotides. 
DNA Amplify also allowed calculation of the PCR fragment size and its probable 
intensity, which was useful in verifying the success of each PCR.
The primary mutations were designed and synthesised first. Each oligonucleotide 
was 21 nucleotides long with the codon encoding the mutated residue flanked on 
both sides by 9 bases. Each oligonucleotide primer was checked using DNA 
Amplify and checked against the pKKpelB/20G9WT construct to minimise any 
non-specific binding before their synthesis. It was found that the oligonucleotide, 
MR58A3, dimerised to itself. In order to prevent this, three bases were deleted 
from the 3’ end, and the 5’ end was increased by the addition of 5 bases. 
Oligonucleotides were custom synthesised and HPLC purified by Perkin-Elmer- 
Applied Biosystems, Warrington, UK., and were supplied lyophilised. The 
oligonucleotides were reconstituted in sterile MilliQ water and quantified 
spectrophotometrically at A260 and diluted to 50pM for use with Vent DNA 
polymerase or to lOpM if used with Taq DNA polymerase. The diluted 
oligonucleotides were aliquoted in suitable quantities and stored at -20°C. In total, 
12 oligonucleotides (Table 4.2) were produced for the primary wave of mutations. 
The primers necessary for the secondary wave of mutations were designed (Table 
4.3) but not synthesised pending the characterisation of the first series.
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y L91a Y=TAT A=GCT
MY91A5: 5’ TA TTC TAG AGC TTG CAT ACA3’ 2 0 mer T =A m 54°C
MY91A3: 5 ’ TGT ATG CAA GCT CTA GAA TA 3 ’ 2 0 mer T =± m 54°C
YL94A Y=TAT A=GCT
MY94A5 5 ’ CGT GTA CGG AGC TTC TAG ATA 3’ 2 1 mer T =A m 62°C
MY94A3 5 ’ TAT CTA GAA GCT CCG TAC ACG 3 ’ 2 1 mer T =± m 62°C
YL96A Y=TAC A=GCC
MY96A5 5 ’ TCC GAA CGT GGC CGG ATA TTC 3’ 2 1 mer T =A m 6 6 °C
MY96A3 5 ’ GAA TAT CCG GCC ACG TTC GGA3’ 2 1 mer T =A m 6 6 °C
RH50A R=AGG A=GCT
MR50A5 5 ’ AGG ATG AAT AGC GCC AAT CCA 3 ’ 2 1 mer T =A m 52°C
MR50A3 5 ’ TGG ATT GGC GCT ATT CAT CCT 3’ 2 1 mer T =A m 52°C
RH56A R=AGA A=GCT
MR56A5 5 ’ TAA CCT AGT AGC ATT ATC GGA 3 ’ 2 1 mer T =A m 48°C
MR56A3 5 ’ TCC GAT AAT GCT ACT AGG TTA 3 ’ 2 1 mer T =A m 48°C
RH58A R=AGA A=GCT
MR58A5 5 ’ CTG ATT TAA AGC AGT TCT ATT 3 ’ 2 1 mer T =± m 44°C
MR58A3 5 ’ CC GAT AAT AGA ACT GCT TTA AAT3’ 23m erT m= 48°C
Table 4.2 Primary mutation oligonucleotides designed to mutate and replace the following 
residues: rH50a? rH56a , rH58a  0f the heavy variable chain and yL91a , yL94a , 
yL96a  of the light variable chain. The naming scheme of the primer is as follows: M 
Prefix - Mutation oligonucleotide, 5 suffix = 5’ fragment, 3 suffix = 3’ fragment. The 
underlined bases represent the codons encoding the residues to be mutated. (The MR58A3 
displayed is the modified primer designed in response the dimerisation).
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d H54l D=GAC L=CTG
MD54L55’ GGA CAT CCG GAC TAT CAG GAC 3’ 21mer
MD54L35’ GTC CTG ATA CTG CGG ATG TCC 3’ 21mer
h H52a H=CAC A=GCT
MH52aA5 5’ ATC GGA AGG AGC AAT CCT GCC 3’ 21mer
MH52aA3 5’ GGC AGG ATT GCT CCT TCC GAT 3’ 21mer
YL28A Y=TAT A=GCT
MY28A5 5’ AGT GTT GCC AGC ACT ATG CAG 3’ 21mer
MY28A3 5’ CTG CAT AGT GCT GGC AAC ACT 3’ 21mer
YL32A Y=TAT A=GCT
MY32A5 5’ CCA ATA CAA AGC AGT GTT GCC 3’ 21mer
MY32A3 5’ GGC AAC ACT GCT TTG TAT TGG 3’ 21mer
YL34A Y=TAT A=GCT
MY34A5 5’ CAG GAA CCA AGC CAA TGA AGT 3’ 21mer
MY34A3 5’ ACT TAC TTG GCT TGG TTC CTG 3’ 21mer
YL49A Y=TAT A=GCT
MY49A5 5’ GGA CAT CCG AGC TAT CAG GAC 3’ 21mer
MY49A3 5’ GTC CTG ATA GCT CGG ATG TCC 3’ 21mer
Table 4.3 Secondary mutation oligonucleotides designed to mutate and replace the 
following residues: dH54l? jjH52a  of the heavy variable chain and yL28a , yL32a , 
yL34a , yL49a  0f the light variable chain.
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4.3 PRODUCTION OF OVERLAPPING PCR FRAGMENTS
Two oligonucleotides, LSI and LS2, (Appendix) were designed to bind upstream 
and downstream of the insert on the vectors pKK233-2 and pTrc99A enabling PCR 
amplification of the 20G9 insert. These oligonucleotides were used in combination 
with the mutation oligonucleotides to enable production of the overlapping 




MY96A3 H in d ll l
LSI
pelB VL LINKER VH His tag
T s i
M Y 91A 5
M Y 9 4 A 5
M Y 9 6 A 5
Figure 4.4 Mutagenesis of yL 91a, Y ^ ^ A ,  y L 96a within the L3 loop of the V l. LSI 
was used in combination with each upstream fragment oligonucleotide while LS2 was used 
in combination with each downstream fragment oligonucleotide.
76
CHAPTER 4 SITE-DIRECTED MUTA GENESIS OF 20G9
4.3.1 Materials and Methods
4.3.1.1 Production o f PCR fragments for assembly o f the mutant inserts, yL91A, 
YL94A, YL96A
5pl of Vent buffer and 5pl of the pre-mixed dNTP’s (300pM) were added to eight 
0.5ml thermo-tubes. 2pl of each 50pmol/pl oligonucleotide primer was added to 
the appropriate tube (Table 4.4) along with lpl of the template DNA 
(0.25pg/pl)(excluding the -ve control), pKKpelAVT20G9 (LiCl plasmid 
preparation) and 0.5pi of BSA (lOmg/ml). Water was added to bring the final 
volume to 49pl. 0.5pi of Vent DNA polymerase (2U/pl) was added and a drop of 
mineral oil was added to each tube. The mixtures were thermally cycled, 94°C x 1’, 
50°C x 1’, 72°C x 40 secs) x 28. After the cycle was complete, the tubes were 
removed and stored at 4°C until required.
Table 4.4 1° mutations on Vl  y L91a , y L94a ? y L96a : PCR to produce overlapping 
fragments for the 1° mutations of y L91a , y L94a ? y L96a . PCR conditions: 96°C 3 
mins., [96°C lmin., 50°C lmin, 72°C 40 secs] x 28 cycles, 72°C lmin.
(ul) 1 2 3 4 5 6 -ve +ve
Buffer 5 5 5 5 5 5 5 5
dNTP (300|iM ) 5 5 5 5 5 5 5 5
01igol(2u1) MY91A5 MY91A3 MY94A5 MY94A5 MY96A5 MY96A5 MY91A5 LSI
01igo2(2ul) LSI LS2 LSI LS2 LSI LS2 LSI LS2
DNA (0.25ug/ul) 1 1 1 1 1 1 0 1
BSA 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
(lOmg/ml)
Vent 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
(2U/ml)
MilliQ 36 36 36 36 36 36 37 36
Tot. Vol. 50 50 50 50 50 50 50 50
Each fragment was resolved by electrophoresis on a 1% LMP agarose gel and the 
fragments excised and recovered using p-agarase (see 2.2.7). Purified fragments 
were visualised on a 1% agarose to estimate their relative quantities before addition 
to the PCR overlap extension reaction.
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4.3.1.2 Production o f PCR fragments for assembly o f the mutant inserts, R^50A, 
Rh 56A and RH58A
lOpl of Vent buffer and lOpl of the pre-mixed dNTP’s (300pM) were added to 
eight 0.5ml thermo-tubes. 2pl of each 50pmol/pl oligonucleotide was added to the 
appropriate tube (Table 4.5) along with 0.25pl of the template DNA (LiCl plasmid 
preparation) (excluding the -ve control), pKKpel/WT20G9 and lpl of BSA 
(lOmg/ml). MilliQ water was added to bring the final volume to 49pl. lpl of Vent 
DNA polymerase (2U/ml) was added and a drop of mineral oil was added to each 
tube. The mixtures were thermally cycled, 94°C x 1’, 42°C x 1’, 72°C x 40 secs) x 
28. The exact details of the PCR are displayed in Table 4.5. After the cycle was 
complete, the tubes were removed and stored at 4°C until required.
Table 4.5 1° mutations on Vjj r H50a 5 r H56a , r H58a . PCR to produce overlapping 
fragments for the lo mutations R ^ O a , r H56a , r H50a . PCR conditions: 96°C 3 mins., 
[96°C lmin., 42°C lmin, 72°C 40 secs] x 28 cycles, 72°C lmin.
(ul) -ve +ve +ve (#2) 1 2 3 4 5 6
Buffer 10 10 10 10 10 10 10 1 0 10
dNTP 10 10 10 10 10 10 10 10 10
(300(iM)
Oligol (2ul) LSI LSI LSI LSI LSI LSI LS2 LS2 LS2
01igo2 (2ul) LS2 LS2 LS2 MR50A5 MR56A5 MR58A5 MR50A3 MR56A3 MR58A3
DNA 0 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
(0.25|ig/ml)
BSA 1 1 1 1 1 1 1 1 1
(lOmg/ml)
Vent 1 1 1 1 1 1 1 1 1
(2U/mI)
MilliQ 74 73.75 73.75 73.75 73.75 73.75 73.75 73.75 73.75
Tot. Vol. 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0
The PCR products were resolved by electrophoresing on a 1% LMP agarose gel. 
Each fragment was excised using longwave UV and recovered using p-agarase 
digestion, (section 2.2.7). The purified fragments were visualised and their relative 
quantities estimated by electrophoresing upon a 1% agarose against known 
quantities of 1Kb molecular weight markers, prior to their addition to the PCR 
overlap extension reaction.
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4.3.2 Results
The production o f six overlapping fragments for the subsequent overlap extension 
phase was semi-successful, producing fragments sizes o f approximately 400-600 
base pairs for the tyrosine residue mutations (Figure 4.7). However, the production 
o f six overlapping fragments for use in the arginine overlap extension stage resulted 
in only five correctly sized fragments (Figure 4.8). This PCR was repeated several 
times unsuccessfully and so consequently the fragment MH583 was unavailable for 
the overlap extension phase thus forcing the abandonment o f RH58A mutant 
production.
Figure 4.5 PCR production of overlapping fragments for the assembly of single mutation 
inserts resolved by electrophoresis on 1% agarose. 1) ~420bp ML915 fragment 2) ~580bp 
ML913 fragment 3) ~430bp ML945 fragment 4) 570bp ML943 fragment 5) ~440bp 
ML965 fragment 6) 560bp M^963 fragment, -ve: contains no template DNA, +ve: contains 
the full 20G9scFv WT construct DNA. M: lOObp ladder. [Fragment sizes as predicted by 
DNA Amplify],
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M M  1 2 3 4 5 6
Figure 4.6 PCR production of overlapping fragments for the assembly of single mutation 
inserts resolved by electrophoresis on 1% agarose, [-ve] [+ve] [+ve 2*]. 1) ~660bp 
MH5 O5 fragment 2) ~680bp M^565 fragment 3) ~690bp M^585 fragment 4) 310bp 
MH5 O3  fragment 5) ~290bp M^ 5 6 3  fragment 6 ) (285bp)oversized M^ 5 8 3  fragment. 
Markers are 1Kb and lOObp ladders. *+ve 2 - Promega kit plasmid preparation. 
[Fragment sizes are within parenthesis and were predicted using DNA Amplify].
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4.4 ASSEMBLY OF PCR FRAGMENTS
The overlapping PCR products when mixed together in PCR will extend to form a 
single fragment, in this case the 20G9 insert. Any alterations occuring in previous 
PCRs should be seen in the whole insert.
4.4.1 Materials and Methods
4.4.1.1 PCR overlap extension o f Y^91A, Y^94A and Y^96A fragments
5pl of Vent buffer and 5pi of the pre-mixed dNTP’s (300pM) were added to five
0.5ml thermo-tubes. 0.5pl of each of the 50pmol/pl oligonucleotide primers, LSI 
and LS2 were added to each tube (see Table 4.6) along with an appropriate amount 
of each of the two PCR fragments produced in 4.3.1.1 to act as assembly product. 
The -ve control excluded one PCR fragment demonstrating absence of 
contaminating template DNA). 0.5pi of BSA (lOmg/ml) and water was added to 
bring the final volume to 49pl. 0.5pl of Vent DNA polymerase was added followed 
by a single drop of mineral oil to each tube. The mixtures were thermally cycled, 
(94°C x 30 secs., 50°C x 2’, 72°C x 1’) x 28, 72°C x 1’. The exact details of the 
PCR are displayed in Table 4.6.
Table 4.6 Overlap extension of the Y91A5/3, Y91A5/3, Y91A5/3 fragments. Conditions: 
94°C 3 mins., [94°C 30 secs., 50°C 2mins., 72°C lmin.] x 28 cycles, 72°C lmin.
(ul) 1 2 3 -ve +ve
Buffer 5 5 5 5 5
dNTP (300|iM) 5 5 5 5 5
01igonucleotide#l L S I  
(0.5ul)
L S I L S I L S I L S I
01igonucleotide#2 L S 2  
(0.5ul)
L S 2 L S 2 L S 2 L S 2
Frag. #1 (ul) 91A5 (5) 94A5 (5) 96A5 (3) 91A5 (2) pKK20G9 DNA (lul)
Frag. #2 (ul) 91 A3 (5) 94A3 (5) 96A3 (5) 0 0
BSA (lOmg/ml) 0.5 0.5 0.5 0.5 0.5
Vent pol. (2U/ml) 0.5 0.5 0.5 0.5 0.5
MilliQ water 2 8 28 30 36 37
Tot. Vol. 50 50 50 50 50
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Removal of primers and PCR buffer was performed by buffer exchanging the PCR 
products into sterile water using Microspin S-200 columns followed by storage of 
the products at -20°C. Quantification of the inserts was determined at A260.
4.4.1.2 PCR overlap extension ofR^50A and R^56A fragments
The single PCR fragment for R58A was unavailable due to repeated failure of a
PCR step. The reactions for R50A and R56A were performed twice with slight
variations in the amount of template/extension material added. 5pi of Vent buffer
and 5pi of the pre-mixed dNTP’s were added to five 0.5ml thermo-tubes, lpl of
each of the 50pmol/pl oligonucleotide primers, LSI and LS2, were added to the
appropriate tube (see Table 4.7) along with an appropriate amount of the PCR
product from 4.3.1.2 as assembly product along with 0.5pl of BSA (lOOmg/ml).
Water was added to bring the final volume to 49pl. 0.5pl of Vent DNA polymerase
was added followed with a drop of mineral oil and the mixtures thermally cycled,
94°C x 30secs., 50°C x 2’, 72°C x l ’)x  28, 72°C x 1’. The exact details of the PCR
are displayed in Table 4.7. After the cycle was complete, removal of primers and
PCR buffer was performed by buffer exchanging the PCR products into sterile
water using Microspin S-200 columns, followed by storage of the products at -20°C.
Quantification of the inserts was determined at A260.
Table 4.7 Overlap extension of the RH50A 3’ & 5’ fragments and the RH56A 3’ & 5’ 
fragments. Conditions: 96°C 3 mins., [96°C 30 secs., 50°C 2mins., 72°C lmin.] x 28 
cycles, 72°C lmin. The volumes of each fragment added are included within 
parenthesises).
(u l) -ve 1 2 3 4
Buffer 5 5 5 5 5
dNTP 5 5 5 5 5
01igonucleotide#l (lul) LSI LSI LSI LSI LSI
Oligonucleotide #2 (lul)LS2 LS2 LS2 LS2 LS2
Frag. #1 (ul) 50A3 (2) 50A3 (4) 5 6A3 (5) 50A3 (2) 56A3 (3)
Frag. #2 (ul) NA 50A5 (4) 56A5 (5) 50A5 (4) 56A5 (5)
BSA 0.5 0.5 0.5 0.5 0.5
Ventpol. 0.5 0.5 0.5 0.5 0.5
MilliQ water 35 33 27 35 33
Tot. Vol. 50 50 50 50 50
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4.4.1.3 Sequencing o f mutant inserts
lOOng of each mutant insert was electrophoresed on a 1% LMP agarose gel and 
recovered from excised gel fragments using p-agarase digestion (section 2.2.6) and 
resuspended in sterile MilliQ water. The oligonucleotides Link Seq. H  and Link 
Seq. L . (Appendix) were used for sequencing mutations in the heavy and light 
variable chains respectively. 3.2 pmol of oligonucleotide was added to a 0.2ml 
thin-walled PCR tube containing the 30-90ng of PCR product and the volume made 
up to 12j l x 1 with sterile MilliQ water. Each sample was sequenced on a 377 DNA 
sequencer ABI Prism (Perkin-Elmer) (2.2.10).
4.4.2 Results
4.4.2.1 Overlap extension
Overlap extension generated PCR products of approximately 850bp (Figure 4.9). 
Fragments of this size were expected and were clear evidence that successful 
overlap extension of the previous PCR products had occurred which allow 
amplification of the whole fragment using the two end primers, LSI and LS2. The 
amount of template added to reactions 3 and 4 was estimated, based upon the 
fragment quantity after purification, to give a equimolar ratio of 1:1. This appeared 
to lead to a cleaner product than reactions 1 & 2 that were identical except for 
fragment quantity. The -ve control was missing a forward overlapping fragment 
preventing the formation of a whole insert, which subsequently would have been 
amplified by oligonucleotides LSI & LS2.
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Figure 4.7 The assembly of the mutant inserts by overlap extension that produced equal 
sized fragments of approx. 970 bases. 1) Y^91A scFv, 2) Y^94A scFv, 3) Y^96A scFv, 
4) RH50A scFv, 5) Rh 56A scFv, -ve) The -ve control lacked a forward overlapping 
fragment which prevented the formation of whole insert which subsequently would have 
been amplified by the oligonucleotides LSI & LS2. +ve) plasmid template added. M) 1Kb 
ladder molecular weight marker. The amount of template added to each reaction was 
estimated based upon the fragment quantity after purification to allow an equimolar ratio 
o f 1:1.
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4.4.3 Sequencing of the PCR products
Each PCR product of the 20G9scFv insert containing each mutation was sequenced 
to verify the inclusion of the new residue and ensure that no spurious mutations had 
occurred elsewhere within the sequence. The chromatogram verified that all 
mutations were successful (Figures 4.10 and 4.11). The sequences of each mutation 
are compared to those of the wild type sequences in Table 4.9.
Table 4.8 Comparison of the DNA sequences of the 20G9 wild type DNA those of the 
mutant DNAs produced by overlap extension mutagenesis. In each case, substitution of 2- 
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20G9 wild 
type sequence
-T G T  ATG CAA TAT CTA GAA TAT CCG TAC ACG TTC 3GA- 
l'91 L94 L96
' T  L 9 1  < 1Tyr Ala
-TG T ATG CAA GCT CTA GAA TA T-
T  L94 .  ,Tyr Ala
-TA T CTA GAA GCT CCG TAC ACG-
Tyrl%Ala
-GAA TAT CCG GCC ACG TTC GGA-
Figure 4.8 377 DNA sequencer ABI prism chromatogram of the tyrosine mutations, 
Yl 91A, Yl94A, Yl 96A sequences compared directly to the chromatogram sequence of 
the 20G9 wild type sequence.
QQ
a  *  : a  C A A a C  \ Q +  \  A
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20G9 wild 
type sequence
-TG G  A TT  GGC AGG ATT CAT CCT TCC GAT AAT AGA ACT AGG T T A - 
H50 H56
ArgH50Ala
-TG G  A T T  GGC GCT ATT CAT C C T -
a  H56 » ,Arg Ala
-T C C  GAT AAT GCT ACT AGG T T A -
Figure 4.9 377 DNA sequencer ABI prism chromatogram of the arginine mutations, 
RH50A, RH5 6 A sequences compared directly to the chromatogram sequence of the 20G9 
wild type sequence.
r c c « A  r  A < 3  C T A C > Q Q T r A . 
30 M
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4.5 DISCUSSION
4.5.1 Design of oligonucleotides for mutagenesis
The site-directed mutagenesis was successful in producing residue changes at the 
positions discussed. No spurious mutations were seen at the mutagenic site or in 
any other part of the sequence. The extension overlap mutagenesis using Vent 
DNA polymerase did not introduce any erroneous mutations that are commonly 
reported when using Taq DNA polymerase. This is almost certainly due to the high 
fidelity of the Vent DNA polymerase.
Overlapping fragments were produced by PCR for the mutants YL91A, YL94A, 
Yl96A Rh50A and RH56A. Of the PCR products for the mutant RH58A, only one of 
the two necessary fragments was of the correct size. This PCR reaction was
repeated several times but repeatedly resulted in a product of ~600 bases. This
could have been due to non-specific binding, incorrect synthesis of the MR58A3 
oligonucleotide or due to poor binding of the oligonucleotide containing the shorter 
complementary strand within its 3’ region. Consequently this mutation was 
abandoned. The mutants YL91A, YL94A, YL96A RH50A and RH56A were all 
successfully extended by PCR overlap extension to fragments of approximately 
850bp. These PCR fragments were all successfully sequenced using the primers 
Link Seq L, Link Seq H and NEB pUCl 19 sequencing primer. All confirmed that 
the planned mutation had occurred and verified that no erroneous mutations had 
been introduced elsewhere into the scFv fragment sequence by polymerase error.
Selected codons were checked against the optimal codon tables observed for 
expression in E. Coli [Ikemura, 1981]. However even if the codons used were 
inadvised, codon usage within the gene was given priority. Altering a single codon 
so that it was optimal for E. coli expression while the vast majority of surrounding 
codons could be considered poor would probably have been pointless.
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5.1 INTRODUCTION
5.1.1 Expression of scFv
The advent of the single chain antibody (scFv) [Bird et al., 1988, Huston et al., 
1988] was heralded as the solution to the antibody engineer’s problems - a molecule 
that had the ability to bind like an antibody but at one fifth of the size. Its relatively 
small size made it potentially useful for therapeutics, particularly in cancer therapy 
[King et al., 1994]. The scFv was a development of the Fv [Skerra & Pluckthun, 
1988; Field et al., 1988] in which the two variable domains are covalently joined 
using a flexible peptide linker, overcoming the problem of chain dissociation of the 
Fv at low concentrations. The scFv has been shown to fold in the same 
conformation as the variable regions of the parent antibody [Zdanov et al., 1994] 
and demonstrates similar binding affinity to that of the whole antibody [Pantoliano 
et al., 1991], However, it is now apparent that the expression of scFv in E. coli can 
be extremely difficult, regardless of the stability of the whole parent antibody. This 
is often manifested in a low level of expression in stark contrast to the high levels of 
most other recombinant proteins expressed in E. coli. This may be due to the 
presence or absence of key residues that determine scFv stability in the expression 
host, and hence whether or not it will be favourably expressed [Knappik and 
Pluckthun, 1994].
The linkers that bridge the VH and VL were engineered to span a ~35A gap between 
the carboxy terminus and amino terminus of the light and heavy chains, permitting 
correct folding but with no interference in binding. However the length and the 
sequence of the peptide linker is known to have an adverse effect on expression 
levels [Huston et al., 1991; Deonarain et al., 1997]. Most linkers are usually 
between 14-25 residues in length with the 15 residue (Gly4Ser)3 linker [Huston et 
al., 1988], currently the most commonly used. Composition is important in that 
polar residues such as serine, glutamate, aspartate can enhance solubility by
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allowing hydrogen bonding to solvent molecules, whereas the more simple glycine 
residues add flexibility to the linker preventing conformational disturbance of the 
Fv and its binding site [Argos, 1990].
There are two main methods of obtaining antibody fragments from E. coli. The first 
is to produce scFv within cytoplasmic inclusion bodies. High levels of protein can 
be expressed in the cytoplasm of E.coli where it accumulates as insoluble 
aggregates, [Huston et al., 1988] forming between 5-10% of total cell protein [Bird 
et al., 1988]. Once the cystosolic contents are extracted, the non-functional scFv 
requires in vitro folding using urea and/or guanidium hydrochloride. However, 
relatively low yields of active antibody may be obtained due incorrect folding of 
the scFv and be due to the incorrect formation of the intra-domain disulphide 
bridges [Proba et al, 1995; Buchner et al., 1992],
The second method of expression is for the cell to secrete the antibody fragment 
into the periplasmic space. The incorporation of a bacterial signal peptide, such as 
the pelB gene (pectate lysase from E. carotovora) [Kustersvan-Someren et al., 
1992] or STII [Picken et al., 1983] enables the antibody fragment to be transported 
into the periplasm. Secretion into the periplasmic, a more oxidative compartment 
than the cytoplasm, can assist folding of the scFv by the formation of the correct 
disulphide bridges [Glockshuber et al., 1990]. Correct folding generally means that 
the antibody is soluble at low levels. In addition, antibody within the periplasm is 
localised and results in a relatively easy method from which to extract the active 
scFv, with the added benefit of containing very few contaminating proteins 
compared to in the cytoplasm. However, high level expression is thought to lead to 
aggregation of scFv within the periplasmic space [Kipriyanov et al., 1994]. With 
such high levels of protein in the small periplasmic space, the formation of 
insoluble aggregates may be favoured over correct folding [Kiefhaber et al., 1991]. 
Kipriyanov et al., 1997 has found that the addition of sucrose to the growth medium 
leads to a increase in the yield of soluble scFv antibody. The sucrose is thought to 
prevent the formation of insoluble aggregates and allow soluble scFv to be passed 
into the growth supernatant from which it can be purified.
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5.1.2 Peptide tags for detection and purification
Peptide tags are useful in allowing identification of the antibody fragment and 
detection at low levels, an important feature when optimising small scale 
expression. In addition tags can be used to purify the antibody fragment from the 
cell cytoplasm, the periplasm or the culture medium.
The tag used for detection of 20G9scFv and its mutants in this thesis is the c-myc 
tag, a peptide containing the epitope of the proto-oncogene c-myc and recognised 
by the monoclonal antibody 9E10 (kindly donated by M.W. Robertson, The Scripps 
Research Inst., La Jolla, USA) [Evan et al., 1985]. The antibody can be used to 
immunoblot expressed tagged scFv. A positive blot generally indicates in-frame 
production of the protein, as the tag is at the C-terminus of the protein sequence. 
Immunoblotting is also extremely sensitive, so that low levels of protein can be 
detected. This allows protein expression on a small scale where conditions can be 
altered in order to optimise expression, with increased signal intensity indicating 
improved expression.
The second tag used on the 20G9 scFv was the histidine tag [Hochuli et al., 1988; 
Yip et al., 1989]. This consists of a short repeating sequence of histidine residues 
on the C-terminus of the protein. The imidazole rings of the histidine residues 
complex with transition metal ions such as Ni2+, Zn2+, Fe2+ and Co2+ with a high 
affinity. If these ions are immobilised onto a support then proteins with many 
histidine residues become bound to the support via the ions while other proteins 
without this affinity will elute from the support. This is the basis of immobilised 
metal affinity chromatography (IMAC) [Porath et al., 1975] (Figure 5.1). A benefit 
of IMAC is that relatively mild elution conditions only are needed to disrupt protein 
binding. Imidazole can be added to compete for metal coordination sites displacing 
the protein or strong chelators such as EDTA that strip the support of its metal ions 
can be used. A further method involves lowering the pH resulting in protonation of 
the histidine residues causing release of the bound protein.
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Figure 5.1 Interaction between a histidine tag and Ni-NTA resin (Qiagen). The basis of 
IMAC purification is that the imidazole rings of the histidine co-ordinate with the metal 
ions on the support which enable the tagged protein to bind while un-tagged proteins pass 
through during the washing pre-elution phase (picture reproduced from Qiagen literature).
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5.1.3 A survey of suitable expression vectors: problems and solutions
5.1.3.1 pKK233-2
The esterolytic antibody 20G9 was cloned and assembled by PCR into the scFv 
format [Smith et al., 1993]. The light and heavy variable chains were joined with 
the 14 residue peptide linker (EGKSSGSGSESKVD) in the unconventional (but 
unimportant) order o f VL-VH [Whitlow & Filpula, 1991]. The scFv also included a 
C-terminal histidine tag o f five residues in length. The antibody fragment was 
cloned into the expression vector pKK233-2 (Clontech Laboratories Inc., Palo Alto, 
USA; distributors for Pharmacia Biotech) which was the form in which it was 














Figure 5.2 20G9 scFv was cloned into the vector pKK233-2 and the construct named 
pKK233/20G9scFv. A single base in the restriction siteTVcoI was deleted disabling the site 
and start codon within it, allowing the ATG codon of pelB to initiate ‘in frame’ translation.
The restriction sites into which the scFv was cloned were Ncol/Hindlll, the first and 
last restriction sites within the multiple cloning site (MCS) o f pKK233-2. The Ncol 
restriction site, CCATGG, encodes an ATG codon which initiates protein 
translation, a deliberate feature of this vector. If  translation initiates at this Ncol 
start codon instead of the start codon o f the the pelB signal peptide then the scFv is 
expressed ‘out o f frame’. This was prevented by a single base deletion o f G from 
the ATG codon allowing translation to initiate at the ATG codon o f the pelB  signal 
peptide [Smith, 1994].
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The pKK233/20G9scFv construct was supplied in the E. coli strain XL-1 Blue as a 
stab culture. Glycerol stocks of the culture were prepared and stored at -70°C along 
with plasmid preparations of the construct that were stored at -20°C and -70°C. An 
!IGEN expression protocol for scFv expression was used, growing the cells in 2xYT 
containing lOOpg/ml ampicillin and 15pg/ml tetracycline. The culture was grown 
at 30°C to an A600 of 1.5 followed by induction with lmM IPTG at 26°C for 3 hours 
from which protein was obtained through periplasmic lysis. However expression 
levels fell and poor yields were improved by changing to the E.coli strain TG-1, but 
again fell after initial success. The pKK233-2 vector was later withdrawn by 
Pharmacia Biotech almost certainly due to plasmid instability [Bell, 1994; Elliot, 
1994], later known to have been a relatively common phenomenon when using this 
vector. A replacement vector, pTrc99A, was donated by Pharmacia Biotech.
5.1.3.2 pTrc99A
The prokaryotic expression vector pTrc99A (Pharmacia Biotech) was the succesor 
to the vector pKK233-2. pTrc99A (Figure 5.3) holds several improvements over its 
predecessor. It includes a laclq gene encoding the lac promotor repressor protein 
allowing strong repression before induction preventing pre-induction ‘leakage’ and 
a trc promotor, a hybrid of the trp and tac promotors and a stronger promoter than 
the lac and tac inducible promotors. The vector had also been designed with the 
promotor, the ribosome binding site (RBS) and the MCS in quick succession. The 
optimal positioning of these sites with respect to the start of the cloned gene is 
known to be a factor that strongly influences expression. The restriction site Ncol is 
the first site within the MCS and encodes an ATG codon eliminating the need for a 
start codon within any insert.
The pelB leader sequence upstream of the 20G9scFv gene encodes a start codon for 
translation initiation for ‘in-frame’ expression of the antibody fragment. To clone 
the 20G9 scFv gene into pTrc99A, the Ncol site must be used but the pelB start 
codon is a single base downstream of the start codon within the Ncol site. If the 
restriction site ATG codon is left intact, translation of the scFv is out of frame. 
Deletion of the bases between the two ATG codons can eliminate the restriction site
'IGEN International Ltd. are a biotech company based in Rockville, Maryland, USA that had a
commercial interest in the early catalytic antibodies.
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but may introduce alterations into the periplasmic leader sequence which is critical 
for functional secretion. Deletion o f at least a single base o f the Ncol ATG codon 
would be necessary to shift initiation o f translation to the pelB ATG codon and 
allow expression o f 20G9 scFv.
AG G AAACAGACC ATG  G AA T T C  GAG CTC GGT ACC CGG GGA TCC TC TA G A  G TCG AC CTGC AG GC ATG CA AG CTT
P t r c  --------------- ------------------------------  ---- --------------------------------------------------------------
N c o l E c o R I  S a c l  Kpnl Smal BamH I K b a l  S a i l  P s t I  S p h l  H i n d l l l









Figure 5.3 The expression vector pTrc99A uses the Ptrc promotor, a hybrid of the trp and 
tac promotors. The lacV\ repressor gene helps reduce uninduced expression. The 
restriction site Ncol is the first site within the MCS encoding an ATG codon eliminating the 
necessity for an ATG codon on a potential insert.
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5.1.3.3 p U C ll 9His 6mycXba
The vector pUC119His6mycXba [Griffiths et al., 1994] (kindly donated by G. 
Winter, MRC, Cambridge, UK) is derived from the pUC119 vector [Vieira and 
Messing, 1987] and contains four restriction sites o f which the Hindlll site is closest 
to the promoter (Figure 5.4). Downstream of the Notl site is a c-myc and His6  tag 
that can be used for detection and purification. The vector promotor is lac and the 
vector confers ampicillin resistance. 20G9 scFv did not encode these restriction 
sites and so engineering of the scFv DNA was necessary to introduce the relevant 
restriction sites. The penta-His tail o f 20G9 scFv required removal by PCR due to 
the existence o f the myc and histidine tags in the vector.
EcoKt
G AAC AA AA AC TCA TC TC A G A A G A G G A TC TG A A T G G G G C C G C A C A T C A C C A TC A TC A C C A TTA A T A A  G AATTC  
E Q K L I S E E D L N G A A H H H H H H *  *
c-m yc tag  H is6 tag
Xba  I
Hindlll Xhol N otl
AAGCTT CTAGAATCGCCATTAGCGATGT CTCGAG TCTGGCAGAG GCGGCCGC A
Hindlll X ba l Xh9l Notl EcoK\
pUC 119 \ -------   1------ H ---------\ p ' J C I I 9
m yc His6
i)
Hind m  Xba i
, Xho j




Figure 5.4 i) sequence of the pUCl 19HisMycXba multiple cloning site, ii) the vector 
pUCl 19His6mycXba uses the lac promotor and includes the c-myc and a hexa-histidine tag 
downstream of the MCS. The vector confers ampicillin resistance to the cell.
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5.2 CLONING INTO THE VECTOR: PTRC99A
5.2.1 Methods
The Ncol restriction site of pKK233/20G9scFv was previously disabled by a single 
deletion. Therefore it was first necessary to re-engineer the site into 20G9scFv 
enabling it to be easily restricted and ligated into the pTrc99A vector. Disabling the 
ATG codon within the Ncol restriction site after construction required that the site 
was restricted using Ncol followed by exposure to mung-bean nuclease, specifically 
degrading single-stranded DNA (ie.. sticky-ends of restricted DNA). However it 
was important to remove only the single stranded DNA as further degradation of 
proximal DNA would have resulted in the deletion of the ATG codon of the pelB 
leader sequence, which was critical for successful expression. Only EndA' E. coli 
strains, i.e. XL-1 Blue or DH5a, were used due to reduced nuclease activity on the 
DNA preparations.
5.2.1.1 Engineering the Ncol restriction site into 20G9scFv by PCR
lpl of pKK233/20G9scFv plasmid (LiCl plasmid preparation, 250ng/ml) was
mixed with 5pl Vent buffer, 5pl of mixed dNTPs and 0.5pl BSA (lOOug/ml). 0.5pl 
of the oligonucleotide primers NCOITRC (lOOng/ul) and LS2 (lOOng/ul) 
(Appendix) were added and the volume raised to 49.5pl with water. Finally 0.5pi 
of Vent DNA polymerase (2U/ul) was added followed by a drop of mineral oil 
(2.2.8). The control was water substituted for DNA. Each reaction was thermally 
cycled (94°C x 1 ’, 55°C x 1’, 72°C x 1’) x 28, 72°C x 1 ’ and the PCR product passed 
through a MicroSpin S-200 column (Pharmacia Biotech) to buffer exchange and 
remove primers (2.2.5).
5.2.1.2 Restriction o f 20G9 scFv and the vector pTrc99A
A restriction enzyme digestion (2.2.4) was performed on lOpl (200ng/pX) of the 
PCR product and 0.5pl (200ng/ml) of the vector pTrc99A. 2pi of NEBuffer 2 and 
0.5pl of Ncol (lOU/pl) and Hindlll (20U/pl) were added to both and each volume 
taken to 20pl. Three controls were included where only a single or no restriction 
enzyme was added. The reactions were incubated at 37°C overnight followed by
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heat inactivation. The DNA samples were each run on a LMP agarose gel and the 
restricted insert and digested vector removed and recovered using p-agarase 
digestion (2.2.6) and quantified by UV at A280.
5.2.1.3 Ligation o f 20G9 scFv into the vector pTrc99A
4pl of the restricted 20G9scFv insert and 1 pi of the restricted pTrc99A vector were 
mixed with lpl of ligation buffer, 0.5 T4 DNA ligase (20U/pl) and the volume 
taken to lOpl with water. The ligation control substituted water for the insert. The 
ligation reaction was incubated at 16°C overnight followed by heat inactivation and 
buffer exchanged in MicroSpin columns (2.2.6). The ligations were transformed 
into E.coli strain TGI and DNA minipreps (2.3.1) prepared from subsequent 
colonies.
5.2.1.4 Exonuclease reduction o f pTrcpel/WT20G9 usingMung-Bean nuclease
A restriction enzyme digestion (2.2.4) was performed on 3pi (200ng/pl) of the
pTrcpel/WT20G9 construct to which 2pl of NEBuffer 2 and lpl of Ncol (lOU/pl) 
where added. The volume was taken to 20pl and incubated at 37°C overnight 
followed by heat inactivation. The control was substitution of restriction enzyme 
by water. Restricted construct was buffer exchanged in a MicroSpin column 
(Pharmacia Biotech). Mung-Bean nuclease (lOU/pl) (NEB) was diluted 1:9 in the 
supplied mung-bean nuclease buffer (NEB) (-0.6U per lpg DNA). In duplicate, 
2pl of the restricted pTrcpel/WT20G9 construct (500ng/pl) were mixed with 0.6pl 
of nuclease, 2.5pl of lOx buffer and the volume taken to 25pl with water. The 
control was water substituted for nuclease. The reactions were heated at 30°C for 
10 and 30 minutes and inactivated by the addition of 0.01% SDS. The DNA was 
recovered by ethanol precipitation at -20°C overnight and resuspended in 5pl of 
Millipore water. 2pl of each were run on 1% agarose to verify that the DNA 
remained essentially intact.
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5.2.1.5 Blunt-end ligation o f the pTrcpel/WT20G9 construct 
1  j j .1  of the blunt-ended pTrcpel/WT20G9 construct and the nuclease negative
controls were mixed with lpl of ligation buffer (NEB), 0.5 T4 DNA ligase
(20U/pl)(NEB) and the volume taken to lOpl with water. The ligation reaction was
incubated at 16°C overnight followed by heat inactivation. The ligation reactions
were buffer exchanged in MicroSpin columns (2.2.6) and transformed into E. coli
strain TGI. 5 colonies from each of the two plates were selected which possessed
the putative Ncol've pTrcpel/WT20G9 construct and DNA minipreps performed
(2.3.1). 2pl of each DNA miniprep was restricted with 0.5pi Ncol to screen for
constructs containing disabled Ncol sites. Those failing to restrict were sequenced
to enable examination of the disabled site and its surrounding DNA.
5.2.2 Results
5.2.2.1 Cloning 20G9 scFv into thepTrc Expression Vector
The PCR produced inserts of approximately 850bp in length which were restricted
with Ncol and Hindlll along with the pTrc99A vector and purified and buffer 
exchanged. After ligation, transformation of the constructs produced several 
hundreds of plaques of which 10 were PCR screened for the 20G9 insert from 
which 9 were found to be positive.
5.2.2.2 Disabling the Ncol site o f the pTrcpel/WT20G9
The two positive clones after restriction and exposure to mung-bean nuclease had 
approximately the expected length. The blunt ended linear plasmid was ligated and 
transformation of the ligation mix produced approximately 150 colonies. Of the 10 
selected 50% failed to digest when exposed to the restriction enzyme Ncol which 
was indicative of a disabled site (Figure 5.5).
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1 2 3 4 5 6  7 8  9 10 11 12 13 14
Figure 5.5 Screening for Ncol disabled construct. 1) +ve restriction control 2) -ve 
restriction control 3) M.Wt. Marker 4) M.Wt. Marker. Lanes 5-14 contain selected 
constructs of which 5, 7, 10, 11 and 13 fail to restrict withAfcoI which indicated that this 
restriction site had been successfully disabled.
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NcoT TTTCACACAGGAAACAGACCATGGATGAAATACCTATTGCCTACGGCA
05 : TTTCA-----------------------------CATGGATGAAATACCTATTGCCTACGGCA
10 : T T T C AC AC AGGAAAC AGACCATG--------------------------------- CCTACGGCA
13  : TTTCA-----------------------------CATGGATGAAATACCTATTGCCTACGGCA
Figure 5.6 The flanking DNA sequences of the disabled Ncol site of three nucleased 
pTrcpel/WT20G9 constructs. Construct 5 and 13 both deleted 3’-5’ disrupting the site but 
leaving the ATG codon of the site intact. Construct 10 a disabled Ncol but also had many 
bases of the pelB leader sequence deleted.
Sequencing of three of the constructs allowed examination of the nuclease-treated 
region (Figure 5.6). It was found that the nuclease degraded the single-stranded 
DNA but repeatedly degraded double-stranded DNA also. In the above examples 
the ATG codon of the Ncol site was either left intact or the nuclease degraded the 
pelB leader sequence. The example shown was the best of four attempts that 
included different conditions (20°C, 30°C and 5, 10 and 30 minutes). However, 
these resulted in either a single nuclease digestion or resulted in large deletions of 
the scFv gene. Only after lengthy repeated failures involving restriction, nuclease 
digestion, blunt-end ligation, screening and sequencing, was the experiment 
abandoned and a decision taken to attempt cloning into a new vector, 
pUCl 19His 6mycXba.
5.3 CLONING INTO THE VECTOR: pUCl 19His6mycXba
5.3.1 Methods
5.3.1.1 Engineering the Hindlll and Notl restriction sites into 20G9scFv
Two oligonucleotide primers were designed (HINDFOR & NOTBACK, Appendix)
that introduce a Hindlll and Notl restriction site 5’and 3’ respectively of 20G9scFv. 
lpl of pKK233/20G9scFv plasmid was mixed with 5pi Vent buffer, 5pl of mixed 
dNTPs and 0.5pl BSA (lOOug/ml). 0.5pl of the oligonucleotide primers HINDFOR
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and NOTBACK were added and the volume taken to 49.5pl with water. Finally 
0.5pl of Vent DNA polymerase was added followed by a drop of mineral oil (2.2.8). 
Controls were used by substituting DNA for water. The mixture was thermally 
cycled (94°C x 1’, 50°C x V, 72°C x 1’) x 28 and the PCR product passed through a 
MicroSpin column to buffer exchange and remove primers (2.2.5).
5.3.1.2 Cloning the 20G9scFv insert into pUCl 19His6mycXba
A restriction enzyme digestion (2.2.4) was performed upon lOpl (200ng/pl) of the
PCR product and 0.5pi (200ng/ml) of the vector pUC119His6mycXba. 2pi of 
NEBuffer 3 and 0.5pi of Notl (lOU/pl) and Hindlll (20U/pl) were added to the 
vector and 1.5pi of Notl and Hindlll added to the insert and the volumes taken to 
20pl with water. Three controls were included where only a single enzyme or no 
restriction enzyme was added to the vector. The reactions were incubated at 37°C 
overnight followed by heat inactivation. The DNA samples were each run on a 
LMP agarose gel and the restricted insert and vector recovered using p-agarase 
digestion (2.2.6) and quantified by UV at A280.
5.3.1.3 Verification o f insert digestion
Insertion of the restricted 20G9scFv into the restricted pUCl l9Yl\s6mycXba vector 
proved difficult. In order to verify that the PCR insert was digesting with the 
restriction enzymes the 5’ termini of the insert were labelled with 32P (2.2.11) and 
the insert restricted with Hindlll and Notl to confirm that the ends of the PCR 
fragment had been removed.
12pl of the restricted 20G9scFv insert and 3pl of the restricted pUC 119His6mycXba 
vector were mixed with lpl of ligation buffer, 0.5 T4 DNA ligase (20U/pl) and the 
volume taken to lOpl with water. A ligation control was water substituted for 
insert. The ligation reactions were incubated at 16°C overnight followed by heat 
inactivation and buffer exchange in MicroSpin columns (Pharmacia Biotech.) 
(2.2.6). Each ligation mixture was transformed (2.3.5) into the E.coli strain XL-1
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Blue and the transformed cells plated onto LB plates (2% (w/v) glucose, lOOpg/ml 
ampicillin, 15pg/ml tetracycline) and incubated overnight at 37°C. Subsequently, 
15 colonies of at least 2mm diameter were picked from the plate and screened for 
recombinant plasmid using protoplast screening (2.3.6).
5.3.1.4 Small scale expression o f scFv
Two freshly transformed plaques were used to inoculate 250ml flasks containing 
50ml of XL media and appropriate antibiotics. The cultures were then incubated at 
30°C with shaking at 250RPM until reaching a density of A600 1.5-2.0. The cells 
were then induced with ImM IPTG and incubated at 26°C with shaking at 250RPM 
for the specified time. The cells were harvested at 6000 x g using a Sepatech 
Megafuge 1.0 benchtop centrifuge (Heraeus, Brentwood, UK). The pellets were 
resuspended in 10 ml of osmotic shock buffer (30mM Tris/HCl pH 8.0, 20% (w/v) 
sucrose, ImM EDTA), incubated at room temperature with shaking for 10 minutes 
and pelleted at 6000 x g, (10ml buffer was added per 50ml of culture). The 
supernatant was discarded and the pellet resuspend in 20ml of 5mM MgS04 and 
incubated at 4°C with shaking for 10 minutes. Finally the lysed cells were spun at 
8500 x g and the supernatant lysate collected. Any large particulates were removed 
from the lysate by passing through a 0.45pM filter (Millipore). All lysates were 
then concentrated in a Centricon-10 (Amicon) to a final volume of 0.5ml. The 
concentrated lysates were loaded onto a 12% SDS-PAGE gel and examined for 
scFv with Coomasie blue stain or by Western blotting targetted to the myc tag.
5.3.1.5 Western Blotting o f the tagged 20G9 scFv
15pi of each of the two concentrated cell lysates were loaded onto 12% SDS-PAGE 
(2.2.13) along with the positive control of Fab possessing a myc tag and low 
molecular weight rainbow markers (Amersham International, Amersham, UK). The 
gel was blotted onto nitrocellulose membrane (2.2.14) and after blocking with 
reconstituted powdered milk the membrane was incubated with the primary 
monoclonal antibody, 9E10 (donated by M. Robertson, The Scripps Research 
Institute, La Jolla, USA) overnight at 4°C. The membrane was washed and
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incubated for 2 hours at room temperature with the secondary polyclonal antibody, 
horse radish peroxidase (HRP) conjugated to goat anti-mouse antibody. The 
antigen-antibody complex was located by immersion of the membrane in 
developing solution (2.2.14), fixed in water, dried and stored in darkness to prevent 
fading.
5.3.1.6 Sequencing o f the constructs
Constructs positively located by Western blotting were sequenced (2.2.10) to verify 
that no PCR induced mutations had been introduced to the scFv. Two sequencing 
primers were used (Appendix): LACB which annealed to the construct upstream of 
the insert allowing sequencing of the pelB, VL and linker, LSH annealed to the 
20G9scFv linker sequence and allowed sequencing of the VH and myc and His tags.
5.3.2 Results
5.3.2.1 Cloning 20G9 scFv intopUCll9His6mycXba
A PCR product of approximately 850bp in size was obtained, as determined by the 
molecular weight ladders which corresponded with the values calculated using 
DNA Amplify. The insert and vector were digested with Hindlll and Notl (Figure 
5.7), with digestion of the 20G9scFv insert verified by radiolabelling the ends of the 
insert followed by its restriction (Figure 5.8).
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Figure 5.7 Restriction of the pUC119His6mycXba vector and the 20G9scFv insert by 
Hindlll and Notl enzymes. 1) unrestricted vector 2) Notl restriction of vector 3) Hindlll 
restriction of vector 4) Notl/Hindlll double restriction of vector 5) NotUHindlll double 
restriction of insert 6 ) unrestricted insert.
UN SD SD DD
Figure 5.8 The 20G9scFv insert ends were radiolabelled with 32p and digested with Notl 
and Hindlll. (1) no restriction (2) Hindlll only (3) Notl only (4) double digestion with 
Hindlll and Notl. This verifies restriction of the inserts when the levels are too low to 
visualise by UV on agarose gels.
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5.3.2.2 Protoplast screening fo r  the pUC-20G9-His6myc construct 
Two recombinants were identified from the 15 plaques screened (Figure 5.9).
5.3.2.3 Expression and Western blot detection o f 20G9scFv
20G9scFv was detected in the cell lysate by Western blotting with 9E10 (Figure
5.10). The scFv was approximately 31.5kDa in size determined by the molecular 
weight markers. In addition the approximate mass of the protein was calculated 
based upon the average molecular weight of amino acids.
5.3.2.4 Sequencing o f  the constructs
SNAP mini-preps prepared from the two positive expressors denoted pUC-20G9- 
His6myc [H] and [10] were sequenced with LACB and LSH (Appendix) and 
revealed no mutation of either sequence (the full DNA sequence for pUC-20G9- 
His6myc is shown in Appendix).




Figure 5.9 Protoplast screening for recombinants after ligation of wild type 20G9scFv into 
the vector pUC119His6wiycA7>a. WT control (wild-type vector without insert) 1-7) 
Screened plaques. M - 1Kb ladder. 2 and 4 display recombinants which are of a higher 
molecular weight than the WT control. The second row (not displayed) contained no 
recombinants.
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Figure 5.10 12% SDS-PAGE gel of cell lysate of the constructs pUC-20G9- His6myc [H] 
and [10] analysed by Western blotting with the antibody 9E10. Protein of 31.5kDa in size 
possessing the Myc-tag is detected for both constructs.
5.4 EXPRESSION AND PURIFICATION OF 20G9 SCFV
Once cloned into the final expression vector the conditions for the expression of 
20G9 scFv were optimised. There exist typical expression conditions for scFvs, 
although some factors can favour increased expression levels for particular 
antibodies. A factor common to many expression protocols are the temperatures 
during the growth (30°C) and induction (26°C) phases [Somerville et al., 1994; 
Skerra and Pluckthun, 1991], adherence to which have been shown to improve 
yields o f functional protein. However, many other variables can also have dramatic 
affects on yields: the media volume within the conical flask, the amount o f IPTG 
inducer added, the length o f induction in addition to the culture media and bacterial 
strains used. The two most commonly used culture medias are LB and 2xYT, the 
latter simply twice as concentrated as the first. However, Griffiths et al., 1994 
demonstrated that increasing the relative levels o f yeast extract to tryptone 
improved the levels o f scFv expression. This novel growth media was named XL 
media (15g trypton, 15g yeast extract, lOg NaCl for 1L) and was used in the 
expression o f 20G9scFv and its mutants. E. coli strains used for expression of 
20G9scFv were TG-1 and TOPP2.
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5.4.1 Expression and purification methods
5.4.1.1 Optimisation o f the 20G9scFv expression
Several small scale expressions (15ml XL media containing appropriate antibiotics) 
were performed and examined the bacterial expression strain, the induction time 
and the necessity of protease inhibition in downstream processing. The E.coli 
strains TGI and TOPP2 were compared during induction times of 1, 3, 5, 8 and 24 
hours. The effect of the protease inhibitor PMSF was also assessed.
5.4.1.2 Large scale expression o f scFv
A freshly transformed colony was used to inoculate a starter culture of 20ml of XL 
media containing appropriate antibiotic. The culture was incubated at 30°C in a 
shaker incubator (250 RPM) until A600 = 0.8. From this culture, 1 ml was used to 
inoculate a 2L flask containing 500ml XL media containing appropriate antibiotic. 
The culture was allowed to incubated at 30°C in the shaker incubator overnight. 
Fresh antibiotic and IPTG was added to a final concentration of ImM and the 
incubator temperature reduced to 26°C and the culture allowed to induce for 24 
hours. Cells were harvested by centrifugation at 5,000 x g for 15 minutes at room 
temperature and the pellet resuspended in osmotic shock buffer (30mM Tris/HCl 
pH 8.0, 20% sucrose, ImM EDTA). 1ml of buffer was added per 5ml culture, 
followed by incubation at room temperature with vigorous shaking for 10 minutes. 
The solution was centrifuged at 8,000 x g for 10 minutes at 4°C after which the 
supernatant was discarded. The pellet was resuspended in ice cold 5mM MgS04 by 
adding an amount equal to that of the osmotic shock buffer. The mixture was 
incubated at 4°C with vigorous shaking followed by centrifugation at 8,000 x g for 
10 minutes at 4°C. The supernatant lysate was decanted and filtered through 
0.45pM filters (Millipore) and stored at 5°C.
5.4.1.3 N '-terminal His- Tag purification
300pl of Ni2+ charged NTA-resin slurry (Qiagen) was added to 100ml of filtered 
cell lysate and incubated with shaking at 4°C for 1 hour. The resin was allowed to 
settle for 30 minutes and carefully decanted into a 5ml Econo-column (Bio-Rad,
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Hemel Hempstead, UK). Any remaining resin was retrieved by gentle 
centrifugation (50 x g) of the lysate from which the resin was recovered and added 
to the column. The resin was washed with wash buffer (50mM NaP04 pH 8.0, 
300mM NaCl, 20mM imidazole) using a peristaltic pump until the A260 of the 
breakthrough was identical to the wash buffer (approx. 250ml). The column was 
connected to a Biologic LP low pressure chromatography system (Bio-Rad) and the 
scFv eluted from the column by an Imidazole gradient using the elution buffer 
(50mM NaP04 pH 8.0, 300mM NaCl, 250mM imidazole) with the correct peak 
collected in 1ml aliquots. The absorbance of each aliquot was measured at A280 in 
order to verify the location of scFv and the aliquots pooled appropriately. The scFv 
was concentrated and buffer exchanged with assay buffer (lOmM Tris pH 8.8, 
140mM NaCl) in a Centricon-10 membrane filter (Amicon). The concentration of 
the protein was measured using a BCA protein assay kit (Pierce) and diluted to 
approximately 250pg/ml with assay buffer. If the scFv preparation was not used 
immediately, it was snap frozen using an acetone and dry ice bath and stored at - 
70°C until futher use.
5.5 RESULTS
5.5.1 Small scale expression and purification
5.5.1.1 Optimising the expression and secretion conditions
ImM IPTG was found to be optimal for induction of 20G9scFv. E.coli strain
TOPP2 led to increased yields of scFv in comparison to E.coli strain TG-1. 
Increased yields of periplasmically secreted scFv were seen after 3 and 24 hours 
induction at 26°C. The level of scFv within the cell supernatant was highest after 24 
hours while the addition of PMSF appeared to have no observable effect (Figures 
5.11-5.14).
5.5.1.2 N ’-terminal His-Tag purification
Periplasmic lysate and the cell supernatant both contained 20G9scFv. The scFv 
was easily purified from the periplasmic lysate by batch binding with Ni2+ charged 
NTA-resin (Figure 5.15) but it was not possible to purify the scFv from large 
volumes of cell supernatant.
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Figure 5.11 Comparison of 3hr vs 24hr IPTG induction periods with 20G9scFv expression 
in E.coli strains TOPP2 and TGI. The addition of PMSF protease inhibitor was assessed in 
the same study. +/- = with/withoutPMSF. 1) TOPP2, 3hr, - 2) TOPP2, 3hr, + 3) TOPP2, 
24hr, - 4) TOPP2, 24hr, + 5) TGI, 3hr, - 6) TGI, 3hr, + 7) TGI, 24hr, - 8) TGI, 24hr, +. 
The IMAC purified protein was resolved by 12% SDS-PAGE and stained with Coomasie 
blue.
+ve +ve-2 1 2 3 4 5 6 7 8
KDa-----------------  — -------------------------------------------------------------
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Figure 5.12 Comparison of 3hr vs 24hr IPTG induction periods of 20G9scFv expression 
in E.coli strains TOPP2 and TGI and identified by Western blotting with 9E10. The 
addition of PMSF protease inhibitor was assessed in the same study. +/- = 
with/withoutPMSF. 1) TOPP2, 3hr, - 2) TOPP2, 3hr, + 3) TOPP2, 24hr, - 4) TOPP2, 
24hr, + 5) TGI, 3hr, - 6) TGI, 3hr, + 7) TGI, 24hr, - 8) TGI, 24hr, +. The IMAC purified 
protein was resolved by 12% SDS-PAGE and stained with Coomasie blue.
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Figure 5.13 Optimisation of induction time (hours) at 26°C for periplasmic secretion of 
20G9scFv-WT in E.coli strain TOPP2. Each cell lysate was resolved on 12% SDS-PAGE 
and analysed by Western blotting using 9E10 anti-myc tag antiserum. 1) 2hr 2) 3hr 3) 5hr 
4) 8hr 5) 24hr [+ve: myc-tagged Fab].
+ve 1 2 3 4 5
kDar -------------------------------------------------------
Figure 5.14 Optimisation of induction time (hours) at 26°C for secretion of 20G9scFv- 
WT into the supernatant from E.coli strain TOPP2. Each supernatant was first 
concentrated by membrane centrifugation and resolved on 12% SDS-PAGE. Analysis was 
by Western blotting using 9E10 anti-myc tag antiserum. [+ve: myc-tagged Fab], 1) 2hr 2) 
3hr 3) 5hr 4) 8hr 5) 24hr.
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Figure 5.15 Gradient IMAC purified 20G9scFv resolved by 12% SDS-PAGE and 
visualised by staining with Coomasie blue R-250.
5.5.2 Cloning, expression and purification methods to produce scFv 
mutants.
5.5.2.1 Cloning o f  the 20G9scFv mutants,
RH56A, into the vector pU C l 19His6mycXba.
The oligonucleotide primers HINDFOR & NOTBACK, (Appendix) were used to 
introduce the Hindlll and Notl restriction sites 5’and 3’ respectively onto the 20G9 
mutant PCR products, lp l  o f PCR product for YL91A, YL96A, RH50A, RH56A and 
3 pi o f  the YL94A PCR product were mixed with 5 pi Vent buffer, 5 pi o f mixed 
dNTPs and 0.5pl BSA (lOOug/ml). 0.5pl o f the oligonucleotide primers HINDFOR 
and NOTBACK were added and the volume taken to 49.5pl with water. Finally 
0.5pl o f Vent DNA polymerase was added followed by a drop o f mineral oil (2.2.8). 
The negative control was water substituted for template DNA and the positive
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control was pKK233/20G9scFv added as the template. The mixture was thermally
cycled (94°C x 30 secs., 50°C x 2’, 72°C x 1’) x 28 and the PCR products passed
through a MicroSpin column (Pharmacia Biotech) to buffer exchange and remove
the primers (2.2.6). A restriction enzyme digestion (2.2.4) was performed on 45pl
(200ng/ml) of the PCR product and 1 OjllI (400ng/ml) o f the vector
pUC119His6mycXba. 6pl of NEBuffer 3 and 2pi of Notl (lOU/pl) and Hindlll
(20U/pl) were added to the PCR products and lpl of Notl and Hindlll to the
pUCl\9Yl\s6mycXba and the volumes taken to 60pl with water. The reactions were
incubated at 37°C overnight followed by heat inactivation. The DNA samples were
each run on a LMP agarose gel and the restricted mutant inserts and vector
recovered using P-agarase digestion (2.2.7) and quantified by UV at A280.
The restricted inserts and vector were ligated using a Fast-Link ligation kit 
%
(Epicentre Technologies, Cambridge, UK) (2.2.5). 0.5pl of restricted vector
(lOU/pl) and 7pl of each of the restricted inserts were mixed with 1.5pl of Fast-link 
ligation buffer (lOx) and 1.5pl ATP solution(lOmM). lpl of the T4 DNA ligase (2 
U/pl) was added, the volume taken to 15pi with water and the reaction incubated at 
room temperature for 1 hour and heat inactivated at 70°C for 15 minutes. 2.5pl of 
each ligation mixture was transformed into E.coli strain XL-1 Blue and plated onto 
LB media containing 2%(w/v) glucose, ampicillin (lOOpg/ml), tetracycline 
(15pg/ml) and incubated in darkness at 37°C overnight. 10 colonies were selected 
from each plate, except that containing YL94A where only 5 colonies were selected, 
and screened for recombinant plasmid using protoplast screening (2.3.6). A DNA 
SNAP mini-prep (2.3.1) was performed on the two colonies that screened positive 
for the mutants and the plasmid preparations sequenced (2.2.10).
5.5.2.2 Expression and purification o f the 20G9scFv mutants
Each mutant scFv was first expressed on a small scale based on the method in
section 5.2.1.2 and myc-tagged antibody fragments were immunodetected using the
antibody 9E10 (2.2.14). Positively detected mutant scFvs were expressed on a large
scale (5.4.1.2), IMAC purified (5.4.1.3), snap frozen and stored at -70°C if not used
immediately.
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5.5.3 Results
5.5.3.1 Cloning o f  the 2 0G9scFv mutants, Y^91A, Y^94A, Y^96A, R^50A,
R^56A, into the vector pU C l 19His6mycXba.
All the mutants YL91A, YL94A, YL96A RH50A and RH56A that had been 
successfully extended by PCR overlap extension in section 4.4.2.1 had Hindlll and 
Notl restriction sites introducted by PCR. The inserts were successfully restricted 
(Figure 5.16 & 5.17) and ligated into the pUC119His6mycYZ>a vector. All 10 
colonies were positive for the constructs pUC-YL9 1 A-His6myc, pUC-RH50A- 
His6myc and pUC-RH56A-His6myc while 7 out o f 10 were positive for the pUC- 
YL96A-His6myc constructs (Figures 5.18 & 5.19). Two from five colonies were 
positive for the pUC-YL94A-His6myc construct. Sequencing o f one o f each o f the 
mutant constructs showed no PCR induced errors by Vent polymerase.
Figure 5.16 PCR products and the pUC119His6mycXba vector after restriction with the 
Hindlll and Notl enzymes: M) 1 Kb ladder 1) YL91A 2) YL96A 3) RH5 OA 4) 
RH5 6 A 5) restricted pUC 119His6mycXba. Each insert had the restriction sites Hindlll and 
Notl introduced by PCR. However the PCR involving the Y^94A mutant gave a low yield 
of product and was repeated separately (see below).
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Figure 5.17 The PCR product of the YL9 4 A mutant after an additional round of PCR 1) 1 
Kb ladder 2) -ve control 3) Y^91A 4) +ve control.
WT 1 2 3 4 5 6 7 8 9  10
M WT  1 2 3 4 5 6 7 8 9  10
Figure 5.18 Protoplast screening for the YL9 IA & Y^96A constructs based upon 
increased molecular weight. Top row: WT- pUC119His6m>>cY&a vector, 1-10) YL9 IA 
protoplast screens. All +ve. Bottom row: WT - pUCl 19His6mycXba vector 1-10) Y^96A 
protoplast screens. (5,9 & 11 -ve only).
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Figure 5.19 Protoplast screening for the R.H5 0 A & R.H5 6 A constructs based upon 
increased molecular weight. Top row: WT- pUC119His6mycAfor vector, 1-10) R.H5 0 A 
protoplast screens. All +ve. Bottom row: WT - pUC 119Yi\s6mycXba vector 1-10) 
R.H5 6 A protoplast screens. All +ve.
5.5.3.2 Expression and purification o f the 20G9scFv mutants
Cell lysates from each small-scale expression o f the mutants were Western blotted,
using the 9E10 antibody (Figures 5.21 & 5.22). Large scale expressions were
performed and each scFv IMAC purified (Figure 5.20 & 5.23). However, the
YL96A scFv mutant expressed at a level that was only just detectable using Western
blotting. Despite several attempts, insufficient protein was obtained for kinetic
characterisation.
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Figure 5.20 12% SDS-PAGE resolution of expressed and purified scFv antibody
fragments. 1) 20G9WT scFv (230jng/ml) 2) 20G9-RH50A s c F v  (220pg/ml) 3) 20G9-
yL91A sc F v  (235pg/ml) 4) 20G9-RH56A scFv (I60pg/ml) 5) 20G9-YL96A scFv
(<20pg/ml). M - Rainbow marker (low M.Wt).
kDa





Figure 5.21 Coomassie blue stained 12% SDS-PAGE of 20G9 scFv-WT and mutant cell 
lysates and eluate. 1) mutant RH50A 2) mutant YL91A 3) mutant YL96A 4) 20G9scFv- 
WT^l 5) 2 0 G 9 s c F v - W T ^ 2  6 ) 20G9scFv-WT eluate. [+ve: myc-tagged Fab] [-ve: WT 
plasmid].
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Figure 5.22 Western blot using 9E10 anti-myc tag antisera applied to a 12% SDS-PAGE 
of 20G9 scFv-WT and mutant cell lysates and eluate, identical to the above Coomasie blue 
stained gel. 1) mutant R.H50a 2) mutant yL 91a 3) mutant yL 96a  4) 20G9scFv-WT#l 5) 
2 0 G 9 s c F v - W T # 2  6 ) 20G9scFv-WT eluate. [+ve: myc-tagged Fab] [-ve: WT plasmid].
Figure 5.23 12% SDS-PAGE resolution of expressed and purified scFv antibody. 1) 
2 0 G9 -YL9 4 a  scFv (225pg/ml). M - Rainbow marker (low M.Wt).
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5.6 EXPRESSION OF 20G9S<CFV: CONCLUSIONS
The 20G9scFv construct, cloned into the Pharmacia vector pKK233-2 by IGEN Inc. 
(USA) had major problems with expression. Initial expression of the 20G9scFv 
antibody was in batch culture using; the E. coli strain XL-1 Blue but was barely 
detectable on Coomasie blue staining;. Other bacterial strains were explored and the 
E. coli strain TGI was selected selected since it produced higher levels of 
20G9scFv. However, levels of expression in TGI fell over time to the point where 
expression ceased. Even cells freshly transformed with construct or cells taken 
from the initial glycerol stocks failed to reverse the loss of expression. Other 
reports of instability of this vector wrere later confirmed by Pharmacia. A decision 
was taken to clone into a replacement vector donated by Pharmacia, for which the 
problem of vector instability had been resolved.
The pTrc99A vector was the “improved” successor to pKK233-2 but its use led to 
other problems. The pKK233/WT20G9scFv construct included a disabled Ncol 
restriction site, preventing direct restriction and ligation of the 20G9scFv gene into 
pTrc99A. It was first necessary to introduce an Ncol restriction site using PCR. 
However, successful restriction and cloning of the PCR product into the pTrc99A 
vector introduced a new problem. The Ncol restriction site encoded an ATG start 
codon adjacent to the normal ATG start codon located in the pelB leader sequence 
of 20G9scFv. Transcription of this construct led to out-of-frame expression of 
20G9scFv and required disabling, as seen in the construct, pKK233/TW20G9scFv. 
The numerous attempts made to delete several of the Ncol bases using mung bean 
nuclease either resulted in insufficient deletion to disable the Ncol site or deletion of 
large amounts of DNA. Eventually the decision was taken to abandon pTrc99A in 
favour of a vector from an academic source with some history of success.
The vector pUC119His6mycXba, donated from Dr. Greg Winter’s group, had 
successfully been used for scFv expression. This vector contained a hexa-histidine 
tag for purification and a c-myc tag for identification. This required removal of the
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penta-histidine tag present on the 20G9scFv gene. This was achieved during 
introduction of the required Notl and Hindlll sites using PCR. However, restriction 
and ligation of the PCR product into the vector proved problematic with repeated 
failure to produce constructs. Digestion of the 32P labelled PCR product confirmed 
that product digestion was occurring. Persistant PCR led to a construct that was 
verified by sequencing to be free of any mutations. Small scale expression (50ml) 
was attempted and successful expression of the wild type 20G9scFv was seen using 
Western blotting towards the myc tag. This was followed by scale up and 
optimisation of expression.
A parallel attempt to clone 20G9scFv into the vector p4xH was performed while 
cloning into pUC119His6mycA&a. p4xH is a chimaeric Fab expression vector 
supplied by Professor Peter Schultz’s group (UCSF) and in which strong expression 
had been observed. The VH and VL were both successfully cloned into this vector, 
but was halted after successful expression in pUCl 19His6MycA&a.
Expression of the antibody construct in pUC119His6mycA’&a was first optimised and 
then followed by scale up of expression to produce antibody in quantities sufficient 
for purification. Optimisation was monitored using the myc tag that allows 
detection of antibody from small-scale expressions. Stronger expression was 
clearly observed using the E. coli strain TOPP2 over TGI. The length of induction 
was important; strong expression into the periplasmic space was seen at 3 and 24 
hours, whereas expression into the supernatant was only seen after 24 hours. No 
improvements were observed with the use of protease inhibitors. Purification of 
scFv from the periplasm and supernatant was attempted using Ni2+ chelating 
columns. However, scFv in sufficient quantities was only successfully purified 
from the periplasm. No scFv was purifiable from the supernatant. This may have 
been due to the presence of ions within the spent media interfering with the ability 
of the nickel to chelate the antibody fragments. Subsequent large scale expressions 
used a 3 hour induction followed by recovery of scFv from the periplasm.
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ScFv from the large-scale batches were captured using batch binding. This is where 
Ni2+ chelate resin is added direct to the vessel containing the periplasmic 
preparation. This method increases the chances of reaching binding equilibrium 
which is less likely than simply running the scFv through resin packed into a short 
column. The initial method of elution involved washing in 50mM NaP04 pH 8.0, 
300mM NaCl, 20mM Imidazole, followed by elution of scFv using 0.5M EDTA or 
250mM Imidazole added in a single step. However, the scFv produced from this 
method required further purification. When gel filtration or ion exchange were 
attempted a large proportion of the antibody was lost, probably due to the relatively 
low starting levels of antibody in each preparation. Consequently a different 
approach was required. After the antibody had been batch bound to the Ni2+, the 
resin was collected into a column and connected to an FPLC system, allowing the 
use of an imidazole gradient for elution. This allowed far greater control and 
consequently production of high purity scFv suitable for kinetic studies.
When a reliable method of expression and purification had been established, each 
mutant construct was cloned into the pUC119His6mycAZ>a vector. The levels of 
expression of each mutant varied quite widely, 20G9WT scFv being the highest, 
followed by 20G9-RH50A, 20G9-YL9]A, 20G9-RH56A and 20G9-YL94A. The mutant 
20G9-YL96A failed to express in quantities sufficient for purification, resulting in 
abandonment of this construct for kinetic characterisation.
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6 KINETIC CHARACTERISATION OF FOUR
MUTANTS OF 20G9 SINGLE CHAIN FV
6.1 INTRODUCTION
For catalytic antibodies, relatively high levels of antibody are required for kinetic 
characterisation since their turnover rates are normally much lower than those of 
enzymes. When using such relatively large amounts of protein it is important to 
establish that the observed catalysis is due to the antibody and not a contaminant, 
necessitating purification steps which, in themselves, cause some loss of protein.
The 20G9 antibody was first produced in 1988 [Durfor et al, 1988] and catalyses 
the hydrolysis of the ester, phenyl acetate, resulting in the formation of two 
products, phenol and acetic acid. Phenyl acetate undergoes hydrolysis in aqueous 
solution and is thought to pass through a tetrahedral transition state during its 
breakdown. To generate the murine antibody response, a stable analogue of the 
proposed transition state thought to approximately mimic its geometry and bond 
lengths was synthesised (Figure 6.1). The transition state mimic, phenyl 
phosphonate, was conjugated to keyhole limpet hemocyanin (KLH) and used to 
immunise BALB/c mice. 20G9 IgG was one of several catalytic antibodies 
produced from the resulting hybridoma cells. The antibody was purified from the 
hybridoma ascites fluid using protein A affinity chromatography. This was the 
material used for the original kinetic characterisation of the wild type antibody 
[Martin et al, 1991a].
Kinetic measurements can be made spectrophotometrically if the extinction 
coefficient of one of the reactant or product species is known. For 20G9, the phenol 
produced can be followed at 270nm and its rate of production used to calculate the 
reaction rate. The substrate, phenyl acetate, spontaneously hydrolyses with a
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measurable rate, so it was important to use a dual-beam spectrophotometer to allow 
subtraction of the background reaction. During catalysis of phenyl acetate by 20G9, 
an unusual profile is seen where the reaction slows dramatically after a few 
turnovers. The initial rate is described as the burst rate and following that the 
steady-state rate. This two-phase profile is possibly due to product inhibition by 
phenol, supported by the observation that the addition of phenol eliminates the burst 
[Martin et al, 1991a].
As discussed in chapter 1, preliminary kinetic evidence supported the involvement 
of tyrosine residues within the active site of 20G9 [Martin et al, 1991a]. These 
observations, in part, led to the decision to mutate some of the CDR tyrosine 
residues. Previous kinetic characterisation of the 20G9 intact IgG determined KM’s 
of 300 pM and 36 pM and kcat’s of 4.9 min'1 and 0.54 min'1 for the burst and steady- 
state rates respectively, [Martin et al, 1991a]. The calculated acceleration of 
reaction over background (kuncat = 4.9 x 10"4 min'1) gave a value of kcat/kuncat = 1.0 x 
104 min'1 for the burst phase and 1.1 x 103 min'1 for the steady-state phase.
The relatively low rates of reactions catalysed by catalytic antibodies make it 
important to establish that the observed activity can be attributed to the antibody. 
For 20G9, this was attempted by the following:
i) observation of the distinctive burst/steady-state reaction profile for 20G9 due to 
product inhibition by phenol. Contaminating enzymes are likely to have a single 
linear profile. The burst phase of 20G9 can be eliminated by the addition of phenol.
ii) rates approximate to those previously observed during kinetic characterisation of 
20G9.
iii) addition of the transition state analogue to the reaction. The antibody that was 
raised against the TSA has high affinity towards it, thus the TSA should inhibit 
catalysis.
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Figure 6.1 The 20G9 antibody catalysed hydrolysis of phenyl acetate [1] producing phenol 
[3] and acetic acid [4]. The presumed transition state [2] is shown on which the design of 
the transition state analogue (TSA) [5] was based.
The aim of this chapter to determine if the activities of 20G9 mutant scFvs have 
been altered by the specific residue changes. The burst and steady-state rates of the 
whole antibody had been previously characterised, allowing a degree of comparison 
to be made between the scFv antibody and the whole IgG. The mutant kinetics may 
allow a model to be proposed in which the function of particular residues within the 
abzyme’s binding site can be attributed a specific role.
6.2 MATERIALS
6.2.1 Preparation of phenyl acetate
Phenyl acetate (Sigma-Aldrich) was stored at 4°C and sealed with parafilm to 
exclude entry of water vapour. A 50mM solution of phenyl acetate and 250mM 
dimethyl sulfoxide (DMSO), (Sigma-Aldrich) was first prepared. Phenyl acetate 
(F.W. 136.15; density 1.073) exists as a liquid at 7.88M. 317.2pl of phenyl acetate 
was mixed with 900pl of DMSO and made to a total volume of 50ml with MilliQ 
water. This was shaken by hand initially and then mixed by inversion at 4°C for 1 
hour until completely homogenous. 0.5ml of the 50mM solution was taken and 
diluted to 5ml with MilliQ water with a resulting substrate concentration of 5mM.
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The 5mM phenyl acetate solution was stored on ice while in use and discarded at 
the end of the day.
6.2.2 Antibody preparation
20G9 wild type and mutant scFv antibodies were concentrated in Centricon-10 
concentrators (Amicon) and their concentrations measured using a BCA protein 
assay kit (Pierce). The antibodies were all diluted with catalytic assay buffer to give 
approximate concentrations of 200-250 pg/ml. The scFv antibodies were dispensed 
into 60pl aliquots in 0.5ml eppendorfs and snap frozen in dry ice and acetone and 
stored at -70°C until used. Only freshly thawed aliquots were used for each kinetic 
study with all antibody aliquots held on ice during the studies.
6.2.3 Dual-beam Spectrophotomer
A 3B dual-beam spectrophotometer (Perkin-Elmer) was used to collect kinetic data 
from the assays. The instrument was driven by Perkin-Elmer software. Assay data 
were stored on disk for statistical analysis using Grafit v3.01 (Erithacus Software 
Ltd.).
6.3 METHODS
6.3.1 Determination of the background hydrolysis (kuncat) of phenyl acetate
Catalytic assay buffer and two 0.5ml optically matched quartz cuvettes were
allowed to equilibrate at 25°C in a water bath. Up to 500pl of catalytic assay buffer 
(lOmM Tris-HCl pH 8.8, 140mM NaCl) was added to the reference and sample 
cuvettes. Readings were taken over a range of phenyl acetate concentrations 0-5000 
pM. The 5mM phenyl acetate solution was throughly mixed before addition to the 
cuvette to ensure complete homogeneity. Absorbance at A270 was measured at 5 
second intervals over a period of 25 minutes. Zero substrate measurements 
confirmed the correct functioning of the dual beam spectrophotometer and 
eliminated drift. Regular checking of the substrate k^^  ensured that the prepared 
substrate was consistent between assays.
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6.3.2 Catalytic assays on 20G9 wild-type scFv and its mutants
The catalytic assay buffer and the 0.5ml cuvettes were allowed to warm to 25°C in a
water bath. Appropriate volumes of pre-warmed assay buffer were added to the 
reference and sample cuvettes. Each scFv antibody was added to the sample 
cuvette, inverted and allowed 30 seconds to equilibrate in the buffer. Phenyl acetate 
was then added to the cuvettes, mixed by inversion and read at A270 over a period of 
up to 25 minutes at 5 second intervals. Assays were performed over a range of 
phenyl acetate concentrations (100, 200, 300, 400, 500, 600 pM). An assay was 
repeated into which 12.5pM phenol (Sigma-Aldrich) was added the the sample and 
reference cuvettes to allow observation of any changes to the reaction profile 
through product inhibition.
6.4 RESULTS
6.4.1 Background hydrolysis of phenyl acetate
No increase in absorbance was seen when both cuvettes contained only assay buffer 
or when equal quantities of phenyl acetate were added to both cuvettes. This
verified correct functioning of the dual-beam spectrophotometer. When the
concentration of phenyl acetate was increased the absorbance increased in direct 
proportion (Table 6.1). V (pMmin1), the rate of hydrolysis, was calculated using an 
extinction coefficient of As270 = 1425 M'1 cm'1 for phenyl acetate. Linear regression 
was performed on a plot of V (pMmin'1) against [S] (pM) (Figure 6.2). The 
gradient of the line (y = ax + b) gave a gradient of 5.6 x 10-4 m in1 which equates to 
the k^caf
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Table 6.1 First order hydrolysis of phenyl acetate. Increasing substrate concentration (pM) 
resulted in a proportional increase in rate (V) of phenol production. The slope of the linear 
regression is taken as the kuncat.
Phenyl acetate (pM) V (pM m in'1)
0 0 . 0
1 0 0 0 . 2 1 2
2 0 0 0.297
400 0.410
800 0.552
1 0 0 0 0.764
1 2 0 0 0.850
1600 1.146





1000 2000 3000 4000
Figure 6.2 V (pM m in'l) vs [S] (pM) from the spontaneous hydrolysis of phenyl acetate. 
Linear regression performed on the data gave a gradient of 5.6 x 10' 4 m in'1.
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6.4.2 Determination of the K^, Vmax and kcat of 20G9 wild type scFv
Six assays were performed on 20G9 wild-type scFv (0.5 lpM  per assay) and all
displayed a visible burst and steady-state phase. The gradients (A270 sec'1) for each 
of the experiments were calculated for the burst phase (0-320 seconds) and steady- 
state phase (320-1495 seconds) by linear regression for each substrate 
concentration. The gradient values (A270 s '1) were divided by the extinction 
coefficient (Ae) for phenyl acetate at pH 8 . 8  (1425 M ' 1 cm '1) to convert the slope to a 
rate value (V pM min'1) (Table 6.2).
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The rate (V) was plotted against the phenyl acetate concentration [S] used in each 
assay (Table 6.2) and a simplex curve fitted to the data from which the KM and Vmax 
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Burst phase Steady-state
The kcat for the catalytic antibody was calculated using the Vmax 
concentration using the formula kcat = Vmax/[Ab0].
and the antibody
Table 6.2 Linear regression was applied to the 20G9 wild-type scFv data points of the 
burst and steady-state phases from which the gradient (A2 7 0  sec 'l) was calculated. The 
extinction coefficient of phenyl acetate [A8 2 7 0  = 1425 M"1 cm 'l] was used to convert the 
gradient to V (pM min"l) [V=slope/Ae].
Burst Steady-state









CHAPTER 6 KINETIC CHARA CTERISA TION OF FOUR MUTANTS OF 20G9 SINGLE CHAIN FV
A burst and post-burst phase was seen on all the assays performed. The 
characteristic burst and steady-state profile seen with the hybridoma derived 20G9 
and its elimination by the addition o f 12.5pM phenol to the assay was reproduced 
with 20G9 scFv (Figure 6.3), and suggested that the hybridoma derived 20G9 and 
the 20G9 scFv were behaving in a comparable manner.
0.012
|  0.006-
0 500 1000 1500
Figure 6.3 Kinetic profile of 20G9scFv at a phenyl acetate concentration of 300uM. The 
lower profile is from an assay to which 12.5uM phenol has been added.
The values obtained for the Michaelis constant, KM and the catalytic constant, kcat, 
for the 20G9 scFv wild-type during the burst phase were 193±31 pM, and 
1.37±0.07 min ' 1 and are comparable to the values previously obtained for the 
hybridoma derived 20G9 antibody (KM = 300 pM and kcat = 4.9). The KM and kcat 
values obtained for 20G9 scFv wild-type during the steady-state phase were 63±18 
pM and 0.56±0.08 min ' 1 respectively, again similar to the values obtained for the 
hybridoma derived 20G9 antibody (KM=24.4 pM and kcax=0.54 m in'1) (Table 6.3). 
The acceleration (kcat/kuncat) o f the hydrolytic reaction by 20G9 wild-type scFv over 
background (kuncat = 5.9 x 10'4 m in'1) is 2.3 x 103 for the burst and 9.5 x 102 for the 
steady-state.
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Table 6.3 The catalytic and binding properties of the 20G9 scFv compared to those of the 









20G9 scFv Burst 0.699±0.040 1.37±0.07 193±31 7.1 x 103
Steady-state 0.288±0.04 0.56 ±0.08 63±18 8.9 x 103
20G9 IgG Burst - 4.9 300 1.6 xlO4
Steady-state - 0.54 24.4 2.2 x 104
When the data of the scFv and hybridoma derived antibody are compared, the 
catalytic and binding properties are relatively similar. However, the hybridoma 
derived antibody clearly has a higher catalytic turnover during the burst phase 
compared to that of the scFv, while the KM of the scFv is lower. During the steady- 
state phase, the reverse is true with the scFv displaying slightly weaker binding to 
the substrate but having a marginally higher catalytic turnover when compared to 
the hybridoma derived antibody. The differences may be due to the greater stability 
of the whole IgG when compared to that of a scFv. The IgG may provide a superior 
environment for the transition state of the hydrolytic reaction through the structural 
stability of the Fv region, but in turn may have a reduced affinity towards the 
substrate or ground state. In contrast, scFv may have a higher affinity for the 
substrate or ground state due to its greater flexibility, possibly due to the absence of 
the constant regions. The disadvantage of any additional flexibility in the scFv is 
that it may reduce the effectiveness of catalysis. During the steady-state phase, the 
differences between the catalytic and binding properties of the hybridoma derived 
antibody and the scFv are negligible. The product inhibition by phenol may act by 
reducing the effects that any structural differences have upon binding and catalysis 
through steric hinderance within the active site of the 20G9 IgG and 20G9 scFv.
6.4.3 Determination of the KM, Vmax and kcat of the 20G9 scFv mutants, 
Rh50A, Rh56A, Yl 91 A, Yl94A
Six assays were performed upon each of the 20G9 scFv mutants Rh50A, Rh56A, 
Yl91A and YL94A at scFv concentrations as close a possible to those used in the 
20G9 scFv wild-type catalytic assays (0.48, 0.35, 0.51 and 0.49pM respectively) to
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ensure comparability o f the assays thus allowing any differences to be attributed to 
their binding and catalytic properties. Each mutant displayed a burst and steady- 
state phase. As for the wild-type scFv, the slope for each assay (A270 sec'1) was 
taken for the burst phase over 0-320 seconds and for the steady-state phase over 
320-1495 seconds. The slope was calculated for each phase using linear regression 
and the gradient values (A270 s '1) divided by the phenyl acetate extinction coefficient 
(Ae) (1425 M '1 c m 1) converting the slope to V pM m in'1.
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Kinetic profiles for the 20G9 mutant scFv RH50A at phenyl acetate concentrations 
o f lOOpM, 200pM, 300pM, 400pM, 500pM & 600pM.
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Kinetic profiles for the 20G9 mutant scFv RH56A at phenyl acetate concentrations 
o f lOOpM, 200pM, 300pM, 400pM, 500pM & 600pM.
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Kinetic profiles for the 20G9 mutant scFv YL94A at phenyl acetate concentrations 
o f lOOpM, 200pM, 300pM, 400pM, 500pM & 600pM.
Elimination o f the characteristic burst and steady-state profile through the addition 
o f 12.5pM phenol was repeated with each mutant.
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Figure 6.4 Kinetic profile of the 20G9 scFv mutant RH5 0 A, RH5 6 A, Y^94A at a phenyl 
acetate concentration of 400pM with and without the addition of 12.5pM Phenol to the 
reaction.
Each mutant saw the burst phase o f the profile eliminated on the addition of 
12.5pM phenol to the assay. However, it was observed that the characteristic 
burst/steady-state profile observed for 20G9 wild-type and for the 20G9 RH50A 
scFv mutant were less pronounced in RH56A and YL94A mutant scFvs (Figure 6.4).
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Table 6.4 Linear regression was applied to the six kinetic profiles for each mutant scFv, 
R.H5 0 A, R.H5 6 A, YL9 IA, YL9 4 A, which allowed the gradient for the burst and steady- 
state phases to be calculated based upon the A2 7 0  sec'l. The extinction coefficient of 
phenyl acetate [AS2 7 0  = 1425 M“1 cm 'l] was used to convert the gradient (A2 7 0  sec_l) to 
a rate, V (pM min'l), [V=slope/AE], for each of the substrate concentrations used. ND - 
No activity observed.



















0 0.000 0.000 0.000 0.000 NA NA 0.000 0.000
100 0.250 0.186 0.158 0.095 NA NA 0.173 0.138
200 0.340 0.190 0.203 0.146 NA NA 0.297 0.210
300 0.397 0.227 0.295 0.180 NA NA 0.326 0.224
400 0.496 0.227 0.291 0.184 NA NA 0.350 0.222
500 0.510 0.249 0.335 0.182 NA NA 0.425 0.271
600 0.484 0.282 0.340 0.176 NA NA 0.401 0.275
The rate (V) was plotted against the phenyl acetate concentration (S) used in each 
assay (Table 6.4) and a simplex curve fitted to the data from which the KM and Vmax 
were calculated to 95% confidence intervals. The kcat for the catalytic antibody was 
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The values obtained by the Simplex curve fit for the the Michaelis constant, KM and 
the catalytic constant, kcat o f 20G9 RH50A scFv mutant were 173±40 pM and 
kcax=1.25±0.11 m in'1. The KM and kcat values obtained for the steady-state phase 
were 71 ±27 pM and 0.59±0.04 m in'1 respectively. The acceleration (kcat/kuncat) o f the
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hydrolytic reaction by the mutant scFv is by a factor o f = 2.1 x 103 for the burst and 
1.0 x 103 for the steady-state.










0 . 1 2 -




0 . 0 2 -
6000 200 400
R^56A scFv Burst Steady-state
For the burst phase, the KM and kcat o f 20G9 RH56A scFv mutant was 213±48 pM 
and kcax=1.33±0.11 m in'1 respectively. The KM and kcat values obtained for the 
steady-state phase were 113±32 pM and 0.64±0.04 m in'1 respectively, an 
acceleration over the background reaction o f 2.25 x 103 for the burst and 1.1 x 103 
for the steady-state.
6 .4 .3 .3  Yl 9 4 A sc F v
0.3
The Km and kcat o f the YL94A mutant for the burst phase was 199145 pM and 
kcax= l. 1210.08 m in'1 respectively. The KM and kcat values for the steady-state phase 
were 134132 pM and 0.6710.05 m in'1 respectively, an acceleration over the 
background reaction o f 1.9 x 103 for the burst and 1.1 x 103 for the steady-state.
s s
Y^94A scFv Burst Steady-state
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6 .4 .3 .4  Yl 9 1 A scF v
A number of assays were performed on the mutant YL91A antibody upon several 
occasions but no measurable activity was detected. The mutant expressed well 
(Figures 5.20 and 5.22) and were easily picked up by Western blotting. During the 
assays, the concentration of scFv added to the assay was increased up to 0.9pM in 
an attempt to demonstrate activity, yet no activity was observed.
Table 6.5 Comparison of the catalytic and binding properties of the 20G9 scFv mutants 
and wild-type. NA indicates that no activity was observed.








20G9-W Burst 0.699±0.040 1.37±0.07 193±31 7.1 x 103
Steady-state 0.288±0.04 0.56 ±0.08 63±18 8.9 x 103
Rh50A Burst 0.600±0.051 1.25±0.11 173±40 7.2 x 103
Steady-state 0.286±0.022 0.59±0.04 71 ±27 8.3 x 103
RH56A Burst 0.466±0.040 1.33±0.12 213±48 6.2 x 103
Steady-state 0.226±0.017 0.64+0.04 113±32 5.7 x 103
YL94A Burst 0.553±0.046 1.12±0.08 199±45 5.6 x 103
Steady-state 0.329±0.023 0.67±0.05 134±32 5.0 x 103
YL91A Burst NA NA NA -
Steady-state NA NA NA -
6.4.4 Mutated residues and their effect upon activity
A model of the key residues within the 20G9 active site can be built based upon the:
i) activity seen with each mutant ii) the 20G9 Fv AbM model iii) kinetic studies 
upon the 20G9 hybridoma derived antibody iv) residues used in other esterolytic 
antibodies. The change in activity seen by mutating the arginine H50 residue to 
alanine is negligible (Table 6.5) and so it is extremely unlikely to play a significant 
role in the catalysis of the phenyl acetate substrate despite its proximity to the 
putative 20G9 active site. Arginine residues have been shown to form hydrogen 
bonds with substrates of other catalytic antibodies, such as in 48G7 [Wedemayer et
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al, 1997], but there is no kinetic evidence to support its involvement in the active 
site of 20G9.
Table 6.6 The percentage increase/decrease in Km  & for each mutant with respect to 
the 20G9WT scFv.
Steady-state Burst
Km |c^cat Km \r-^ cat
Rh50A +13% +5% -10% -9%
Rh56A +80% +14% +10% -3%
Yl94A +112% +2-% +3% -18%
Yl91A Not Determined -100% Not Determined -100%
However mutation of the the arginine residue at H56 to alanine resulted in an 80% 
increase in the value of KM during the steady-state phase, indicating the affinity of 
the substrate for the mutant had been reduced, although no significant change in 
catalytic turnover was seen (Table 6.6). The burst KM and kcat were largely 
unaffected. Based upon this evidence it is possible that the arginine residue at H56 
is involved in the binding of the substrate, phenyl acetate. It was observed from the 
20G9 model that the arginine residue is within the active site groove of the 
antibody, although the orientation of the side chain in the model oriented away from 
the active site (Figure 6.5). However, if the orientation is changed, the side chain 
could face into the groove stabilising the oxygen atoms of the substrate by H- 
bonding. A similar stabilisation has been seen in the 48G7 catalytic antibody. This 
stabilising affect might become redundant after the formation of the reaction 
product, phenol, which itself appears to assist in the binding of the substrate to 
20G9 during the steady-state phase.
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Arg56
\ra56
Figure 6.5 Side and topview of the 20G9 Fv model of 20G9Fv displaying the five residues 
that were mutated (RH50a , r H56a , yL91 a , y L94a , y L96A & y L91a ).
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A similar affect is seen in the YL94A mutant with an increase of 112% in the 
steady-state KM value, again indicating a significant reduction in the affinity of the 
mutant antibody fragment towards phenyl acetate (Table 6.6). As with the RH56A 
mutant, the steady-state phase kcat and the burst KM and kcat are comparable to the 
those seen in the 20G9 WT scFv during the burst and steady-state phases. This 
would indicate that the tyrosine residue is involved in binding to the substrate. This 
may be through 7c-stacking of its aromatic ring with the phenol group of phenyl 
acetate. However, after several catalytic turnovers, multiple phenols, formed as 
reaction products, may become involved in 7i-stacking with the tyrosine side 
chain(s), hence enhancing binding of the substrate to the active site. This would 
account for the increased KM value seen between YL94A and the 20G9 WT. The 
comparable kcat values seen during the burst phase and the steady-state phase would 
indicate that tyrosine at L94 has no involvement in the transition state. Interestingly, 
Tyr94L residue is also found in the active site of the catalytic antibody 48G7, 
oriented towards the carbonyl atom of the substrate. Thus, ArgH56 and Tyr94L may 
both play an important role in binding phenyl acetate within the antibody’s active 
site groove.
The most dramatic change in kinetic activity was observed with the YL91A mutant 
scFv. No catalytic activity was observed with this mutant indicating that this 
residue has a critical role in the active site of the 20G9 catalytic antibody. This is 
supported by the model in which the which the Tyr91L residue is seen deep in the 
active site groove of 20G9, although the model orientation may be incorrect. 
However, the previous kinetic studies on the hybridoma derived 20G9 IgG showed 
that a tyrosine was pivotal through the formation of an acetyltyrosyl intermediate 
[Martin et al, 1991a]. This is further reinforced by the crystal structure of 48G7 that 
shows contact of this same residue with the nitrophenyl ring of the substrate [Patten 
et al, 1996]. These arguments are consistent for the Tyr91L role in the catalysis of 
phenyl acetate by 20G9.
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From the foregoing, a possible mechanism for 20G9 is that the phenol ring of 
phenyl acetate is buried in the binding site and is stabilised by the Tyr94L sidechain. 
Other surrounding tyrosine residues (e.g. Tyr96L) may also be involved. Arg56H may 
H-bond to oxygen atoms on the substrate and is correctly oriented to do so, unlike 
Arg50H. Hydrolysis at the exposed carbonyl carbon (8+) occurs possibly due to 
attack by water or by the Tyr91L phenolate releasing a phenol molecule. Where an 
acyl intermediate with Tyr91L is formed, this is followed by further hydroxy attack 
by water resulting in the formation of acetic acid. However, the phenol product 
does not immediately disperse, possibly due to 7i-stacking of the phenol with the 
aromatic rings of the surrounding tyrosines. This acts to stabilise subsequent entry 
of phenyl acetate molecules into the active site but slows catalysis by steric 
hindrance or possibly due to slight orientation changes in the positioning of the 
substrate (Figure 6.6).
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The aim of this thesis was to attempt to kinetically characterise the catalytic 
antibody 20G9, partly based upon the previous biochemical and kinetic 
characterisation but by producing mutants guided by a model of the antibody. This 
allowed an attempt to be made to identify those residues in the active site of 20G9 
that may have had a role in the antibody’s esterase activity.
The 20G9 Fv model
AbM, the antibody modelling package, produced a three-dimensional structure of 
the antibody Fv and its binding site. All loops excluding H3 were canonical. H3 
consisting of only five residues, was modelled by an ab initio method. The small 
size of H3 gave reason to believe that the final model was an accurate representation 
of the 20G9 Fv. In addition to the model, previous characterisation had implicated 
tyrosine residues in the catalytic mechanism of the antibody. This, along with 
evidence of tyrosine and arginine involvement in other esterolytic antibodies, led to 
a particular focus on these residue types located within the distinctive groove seen 
in the model of 20G9.
The orientation of the residues within the active site caused the most concern. A 
decision had to be taken based on whether the orientation of the residues within the 
model were accurate. The modelling of side chains is possibly the most 
difficult task for a modelling procedure to perform correctly. Therefore it was 
decided that provided the Ca atom positions of the candidate residue types were 
within a cut-off distance of the groove (~ 15A), then the side chain would be 
included.
For practical purposes, residues selected for mutation were split into two groups 
with those thought most likely to be involved mutated first. The first group
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consisted of three heavy chain arginine residues and three light chain tyrosine 
residues. The second included four light chain tyrosine residues, a heavy chain 
histidine residue and a heavy chain aspartate residue.
Mutagenesis studies
For the mutation of the selected residues, there was a choice between using a kit 
based on single oligonucleotide mutagenesis or simply using PCR site-directed 
mutagenesis. The latter method has previously tended to be overlooked due to the 
relatively high probability of introducing base mutations into the DNA sequence 
through the polymerase. However, the arrival of high fidelity DNA polymerases, 
such as Vent DNA polymerase, has reduced this risk due to their low error rates. 
One major advantage of PCR mutagenesis over single oligonucleotide mutagenesis 
is that the degree of control over the DNA is much higher. The use of bacteria in 
producing the mutant DNA is also eliminated, simplifying mutagenesis.
When working with PCR, it is crucial to optimise the design of the priming 
oligonucleotides. When designed poorly, they may anneal non-specifically to 
template DNA, to other oligonucleotides within the reaction, or to themselves. This 
can have the effect of producing multiple bands of PCR product, smearing, or 
reduction of reaction efficiency due to the loss of available oligonucleotides within 
the reaction, sometimes to the point where no product can be seen. In this study, 
oligonucleotides were computer checked for binding towards the DNA vectors 
used, the 20G9 gene, and for dimerisation towards partner oligonucleotides or 
themselves. As a result, almost all PCR reactions performed were successful in 
producing strong and clean product bands. However, this design process was not 
foolproof. During the design of the priming oligonucleotides for the mutation of 
Rh58, the first forward oligonucleotide design for this mutant (MR58A3) was 
predicted to dimerise with itself and was subsequently redesigned. However, this 
oligonucleotide, although apparently satisfactory in design, repeatedly gave an 
unexpected PCR product size and so this mutant was eventually abandoned.
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All of the final PCR products containing the mutated bases within the 20G9 gene 
were fully sequenced to verify that no polymerase related errors had been 
introduced before the mutated gene was ligated into the DNA vector. No errors 
were seen, validating this method as a robust, simple and effective way of 
introducing specific mutations into a gene.
Expression o f 20G9 scFv
The problems encountered with expression of 20G9 scFv are not uncommon in this 
field. It was very unfortunate that the instability of the vector pKK233-2 could not 
have been predicted, since a good deal of time was wasted. The vector, 
pUCl\9H\s6mycXba, from a non-commercial source was available and had been 
fully characterised through its extensive use in scFv expression. Obtaining this 
vector allowed the project to progress after several failures such as with the 
pTrc99A vector.
Even when using a reliable vector, expression of recombinant antibody molecules 
and antibody fragments can be difficult. Currently it is impossible to predict 
whether an antibody will easily express in E. coli, and this is especially true for 
antibody fragments. ScFv’s may be particularly difficult to express when compared 
to whole antibodies or Fab fragments. The groups of Thomas Scanlan and Peter 
Schultz saw greatly improved expression of their antibody fragments when 
expressing them as chimeric Fab fragments through the p4xH vector instead of as 
scFvs. The reason for this is unclear, but may be due to the influence of the 
constant regions on folding of the antibody fragments molecules during expression, 
reducing aggregation due to poor folding or misfolded molecules.
When ligating the PCR inserts into the pUC 119His6mycXba vector, a novel method 
was used for screening vectors for a PCR insert. Protoplast screening was used 
based on the differential migration of supercoiled plasmids which had taken up an 
inserted fragment. This was a rapid method of determining whether ligation had 
been successful by taking plaques from an agar plate, and digesting the bacterial 
cell wall resulting in a bacterial protoplast. The addition of a lysis buffer
144
CHAPTER 7 DISCUSSION
osmotically shocked the cell, spilling the cytoplasm containing the plasmid. The 
plasmid, when compared to a plasmid containing no insert, revealed whether 
successful ligation had been achieved with the whole was used to establish the 
successful ligation of 20G9 Fv and its 5 mutants into the pUC119His6/wycA^a vector.
20G9 scFv and its mutants were successfully expressed using the 
pUC119His6mycXba vector, although their levels varied even though only a single 
residue change was present on each mutant. This resulted in the failure to express 
any of the YL96A scFv mutant. The presence of the myc tag on the antibody 
fragments allowed small scale expression to be easily followed using Western 
blotting, while the hexa-histidine tag allowed relatively simple and effective 
purification of the scFvs.
20G9 scFv kinetic studies
Limited kinetic data were produced from each mutant although they were sufficient 
to allow calculation of kcat and KM. An approximate antibody concentration of 
0.5pM was used in each kinetic reaction although it was not possible to determine 
the exact amount of active or correctly folded scFv added to each assay by active- 
site titration due to the degradation of the transition state analogue, phenyl 
phosphonate. Proton NMR and phosphorus NMR (400Mhz) analysis, fast atom 
bombardment mass spectrometry and infrared spectrometry performed on the 
transition state analogue in the Department of Chemistry at the University of Bath 
showed that the transition state analogue had decomposed. This was possibly due 
to hydrolysis by water vapour over its long period of storage (synthesised in 1988 at 
IGEN Inc. USA). The kinetic behaviour of the wild type scFv was essentially the 
same as for 20G9. The elimination of the burst phase in the scFv kinetic profile, 
seen in the hybridoma derived 20G9 antibody (Figure 6.4) was also good evidence 
of the integrity of the active site of the scFv. The kinetic data for the mutants has 
allowed a tentative reaction mechanism to be proposed.
During the kinetic studies, differences the background rate of phenyl acetate 
hydrolysis were observed with a calculated k^^  of 5.6 x 10-4 min-l. The kmC!Lt
145
CHAPTER 7 DISCUSSION
determined during the characterisation of 20G9 IgG had a rate of 4.9 x 10'4 min'1 
[Martin et al, 1991; Blackburn et al, 1991]. It is not clear why this slight difference 
in rate was observed, but is possibly due to experimental error during measurement.
The 20G9 catalytic mechanism
Stabilisation of the substrate phenyl ring by the aromatic groups (TyrL94 and 
possibly TyrL96) is an attractive suggestion for the 20G9 mechanism. Arg1156 is in a 
position where is can stabilise the oxygen(s) of the substrate molecule, as seen in 
other esterolytic antibodies. Whether the orientation of the Tyr9^  phenolate is 
correct for interaction with the 8+ charge upon the phenyl acetate carbonyl carbon is 
unknown but is also possible. This residue when mutated led to elimination of all 
activity. Previously obtained kinetic data suggested the formation of a tyrosylacetyl 
intermediate. This has been seen in antibody 48G7 with the same tyrosine (YL91), 
lending further support to this hypothesis. These arguments provide strong 
circumstantial evidence that L91 tyrosine forms a catalytic acyl intermediate.
Future work upon 20G9
Future studies could see completion of the single residue mutants proposed in this 
thesis. However, only X-ray crystallographic studies of 20G9 will allow thorough 
characterisation of the 20G9 active site and verify if the 20G9 Fv model generated 
by AbM is correct.
This project was badly affected by the problems encountered with expression of 
recombinant scFv antibody, although similar expression difficulties have been 
widely reported [Kipriyanov et al, 1997]. Not withstanding these problems, an 
attempt was made to understand the mechanism of this catalytic antibody based on 
a mutagenesis study guided by a 3-D model of 20G9. The project was successful 





Length: 37mer Tm: 54°C
Forward oligonucleotide which is used to introduce the Hindlll restriction site. Can 
be used in combination with M-5 oligonucleotides to produce a forward overlap.
NotIback2: 5’-GAAGGAAAAAAGCGGCCGCTGCAGAGACAGTGACCAGAGT-3’
Length: 40mer Tm: 68°C
Backward oligonucleotide used to introduce the Notl restriction site. Can also be 
used in combination with M-3 oligonucleotides to produce a reverse overlap.
Link Seq. H: 5’-GAGGGTAAATCCTCAGG-3’
Length: 17mer Tm: 52 °C
Forward oligonucleotide that anneals to the linker sequence of 20G9 scFv allowing 
sequencing of the VH region of 20G9.
Link Seq. L: 5’-TTTGGATTCGGAGCCAG-3’
Length: 17mer Tm: 52 °C
Reverse oligonucleotide that anneals to the linker sequence of 20G9 scFv allowing 
sequencing of the VL region of 20G9.
LSI: 5’-CGGCTCGTATAATGTGTGGAAT-3’
Length: 22mer Tm: 68°C
Forward oligonucleotide that anneals to the vectors pKK233-2, pTrc99A upstream 
of the insert allowing PCR amplification and sequencing.
LS2: 5’-ACCGCTTCTGCGTTCTGATTT-3’
Length: 21mer Tm: 62°C
Reverse oligonucleotide that anneals to the vectors pKK233-2, pTrc99A 
downstream of the insert allowing PCR amplification and sequencing.
MY91A5: 5 ’-TATTCTAGAGCTTGCATACA-3’
Length: 20mer Tm: 54°C
MY91A3: 5 ’-TGTATGCAAGCTCTAGAATA-3’
Length: 20mer Tm: 54°C
MY94A5 5’-CGTGTACGGAGCTTCTAGATA-3’
Length: 21mer Tm: 62°C
MY94A3 5’-TATCTAGAAGCTCCGTACACG-3’
Length: 21mer Tm: 62°C
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MY96A5 5 ’-TCCGAACGTGGCCGGATATTC-3’
Length: 21mer Tm: 66°C
MY96A3 5 ’-GAATATCCGGCCACGTTCGGA-3’
Length: 21mer Tm: 66°C
MR50A5 5’-AGGATGAATAGCGCCAATCCA-3’
Length: 21mer Tm: 52°C
MR50A3 5,-TGGATTGGCGCTATTCATCCT-3,
Length: 21mer Tm: 52°C
MR56A5 5 ’-TAACCTAGTAGCATTATCGGA-3 ’
Length: 21mer Tm: 48°C
MR56A3 5 ’-TCCGATAATGCTACTAGGTTA-3’
Length: 21mer Tm: 48°C
MR58A5 5’-CTGATTTAAAGCAGTTCTATT-3’
Length: 21mer Tm: 44°C
MR58A3 5 ’-CCGATAATAGAACTGCTTTAAAT-3’
Length: 23mer Tm: 48°C
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pelB20G9His5 scFv nucleotide sequence
M K Y L L P T A A A G L L L  
AT G A AA  TAC CT A TTG CCT ACG GCA GCC GCT GGA TTG T T A TTG 
10 20 30 40
L A A Q P A M A D I V M T Q  
CT A GCT GCC CAA CCA GCG AT G GCC GAT AT T  GTG AT G ACT  CAG 
50 60 70 80
A A P S V I V T P G E S V S  
GCT GCA CCC TCT GTG AT T  GTC ACT  CCT GGA GAG TCA GT A TCC 
90 100 110  120
I S C R S S K S L L H S Y G  
AT C TCC TGC AGG TCT AGT AAG AGT CTC CTG CAT AGT TAT  GGC 
130  140  150 160
N T Y L Y W F L Q R P G Q S  
AAC ACT  TAC TTG TAT TGG TTC CTG CAG AGG CCA GGC CAG TCT 
170  180  190  2 0 0  210
P Q V L I Y R M S N L A S G  
CCT CAG GTC CTG A T A  TAT  CGG AT G TCC AAC CTT GCC T CA GGA 
2 2 0  230  2 4 0  2 5 0
V P D R F S G S G S G T A F  
GTC CCA GAC AGG TTC AGT GGC AGT GGG T CA GGA ACT  GCT TTC 
2 6 0  2 7 0  2 9 0  300
T L R I S R V E A D D V G V  
ACA CTG AGA AT C AGT AGA GTG GAG GCT GAC GAT GTG GGT GTT 
310  320  330  340
Y Y C M Q Y L E Y P Y T F G  
TAT  TAC TGT AT G CAA TAT  CTA GAA TAT  CCG TAC ACG TTC GGA 
350  360  370  380
G G T K L E L K E G K S S G  
GGG GGG ACC AAG CTG GAG CTG A A A  GAG GGT A A A  TCC T CA GGA 
3 90  400  410  420  430
S G S E S K V D E V Q L H E  
TCT GGC TCC GAA TCC A A A  GTC GAC GAG GTG CAG CTG CAC GAG 
440  450  460  470
P G A A L V R P H A S V M L  
CCT GGG GCT GCA CTG GTA AGG CCT GGA GCT T CA GTG ATG CTG 
480  490  500  510
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p C R A S G Y S F T S F W M
c c c TGC AGG GCT TCT GGC TAC TCC TTC ACC AGC TTC TGG ATG
520 530 540 550
N W V R Q R P G Q G L E W I
AAC TGG GTG AGG CAG AGG CCT GGA CAA GGC CTT GAG TGG ATT
560 570 580 590
G R I H P S D N R T R L N Q
GGC AGG ATT CAT CCT TCC GAT AAT AGA ACT AGG TTA AAT CAG
600 610 6i20 630 640
K F K D K A T L T V D K S S
AAG TTC AAG GAC AAG GCC ACA TTG ACT GTA GAC AAA TCC TCC
650 660 670 680
S T A Y M Q L I S P T S E D
AGC ACA GCC TAC ATG CAA CTC ATC AGT CCG ACC TCT GAG GAC
690 700 710 720
S E V Y Y C A R E G G A Y W
TCT GAG GTC TAT TAC TGT GCA AGA GAG GGC GGG GCT TAC TGG
730 740 750 760
H Q H T L V T V S A H H H H
GGC CAA GGG ACT CTG GTC ACT GTC TCT GCA CAC CAT CAC CAT
770 780 790 800
j-j *  *





M K Y L L P T A A A G L L L  
ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTG 
10 20 30 40
L A A Q P A M A D I V M T Q  
CTA GCT GCC CAA CCA GCG ATG GCC GAT ATT GTG ATG ACT CAG 
50 60 70 80
A A P S V I V T P G E S V S  
GCT GCA CCC TCT GTG ATT GTC ACT CCT GGA GAG TCA GTA TCC 
90 100 110  120
I S C R S S K S L L H S Y G  
ATC TCC TGC AGG TCT AGT AAG AGT CTC CTG CAT AGT TAT GGC 
130  140 150  160
N T Y L Y W F L Q R P G Q S  
AAC ACT TAC TTG TAT TGG TTC CTG CAG AGG CCA GGC CAG TCT 
170  180 190  2 0 0  210
P Q V L I Y R M S N L A S G  
CCT CAG GTC CTG ATA TAT CGG ATG TCC AAC CTT GCC TCA GGA 
2 2 0  2 3 0  2 4 0  250
V P D R F S G S G S G T A F  
GTC CCA GAC AGG TTC AGT GGC AGT GGG TCA GGA ACT GCT TTC 
260  270  290  300
T L R I  S R V E A D D V G V  
ACA CTG AGA ATC AGT AGA GTG GAG GCT GAC GAT GTG GGT GTT 
310  320 330  340
Y Y C M Q Y L E Y P Y T F G  
TAT TAC TGT ATG CAA TAT CTA GAA TAT CCG TAC ACG TTC GGA 
350  360  370  380
G G T K L E L K E G K S S G  
GGG GGG ACC AAG CTG GAG CTG AAA GAG GGT AAA TCC TCA GGA 
390  400  410  420  430
S G S E S K V D E V Q L H E  
TCT GGC TCC GAA TCC AAA GTC GAC GAG GTG CAG CTG CAC GAG 
440  450 460  470
P G A A L V R P H A S V M L  
CCT GGG GCT GCA CTG GTA AGG CCT GGA GCT TCA GTG ATG CTG 
480  490  500  510
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p C R A S G Y S F T S F W
c c c TGC AGG GCT TCT GGC TAC TCC TTC ACC AGC TTC TGG
520 530 540 550
N W V R Q R P G Q G L E W
AAC TGG GTG AGG CAG AGG CCT GGA CAA GGC CTT GAG TGG
560 570 580 590
G R I H P S D N R T R L N
GGC AGG ATT CAT CCT TCC GAT AAT AGA ACT AGG TTA AAT
600 610 620 630
K F K D K A T L T V D K S
AAG TTC AAG GAC AAG GCC ACA TTG ACT GTA GAC AAA TCC
650 660 670 6!
S T A Y M Q L I S P T S E
AGC ACA GCC TAC ATG CAA CTC ATC AGT CCG ACC TCT GAG
690 700 710 720
S E V Y Y C A R E G G A Y
TCT GAG GTC TAT TAC TGT GCA AGA GAG GGC GGG GCT TAC
730 74 0 750 760
H Q H T L V T V S A
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